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Clinical practice should be based on the best available evidence. Ideally such 
evidence is obtained through rigorously conducted, purpose-designed clinical studies 
such as randomised controlled trials and prospective cohort studies. However 
gathering information in this way requires a massive effort, can be prohibitively 
expensive, is time consuming, and may not always be ethical or practicable. When 
answers are needed urgently and purpose-designed prospective studies are not 
feasible, retrospective healthcare data may offer the best evidence there is. But can 
we rely on analysis with such data to give us meaningful answers?  
The current thesis studies this question through analysis with repeated psychological 
symptom screening data that were routinely collected from over 20,000 outpatients 
who attended selected oncology clinics in Scotland. Linked to patients’ oncology 
records these data offer a unique opportunity to study the progress of distress 
symptoms on an unprecedented scale in this population. However, the limitations to 
such routinely collected observational healthcare data are many. We approach the 
analysis within a missing data context and develop a Bayesian model in WinBUGS 
to estimate the posterior predictive distribution for the incomplete longitudinal 
response and covariate data under both Missing At Random and Missing Not At 
Random mechanisms and use this model to generate multiply imputed datasets for 
further frequentist analysis.  
Additional to the routinely collected screening data we also present a purpose-
designed, prospective cohort study of distress symptoms in the same cancer 
outpatient population. This study collected distress outcome scores from enrolled 
patients at regular intervals and with very little missing data. Consequently it 
contained many of the features that were lacking in the routinely collected screening 
data and provided a useful contrast, offering an insight into how the screening data 
might have been were it not for the limitations. We evaluate the extent to which it 
was possible to reproduce the clinical study results with the analysis of the 
observational screening data.  
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Lastly, using the modelling strategy previously developed we analyse the abundant 
screening data to estimate the prevalence of depression in a cancer outpatient 
population and the associations with demographic and clinical characteristics, 
thereby addressing important clinical research questions that have not been 
adequately studied elsewhere. The thesis concludes that analysis with observational 
healthcare data can potentially be advanced considerably with the use of flexible and 







The work presented in this thesis seeks to determine if routinely collected clinical 
data can be used to address research questions that would ordinarily be addressed 
using purpose-designed clinical studies which are typically expensive and time 
consuming to conduct. The thesis utilises data from two sources; the first being a 
prospective clinical study investigating the persistence of psychological distress in 
cancer patients, titled the Persistence of Distress Study (the POD Study), while the 
second source comprises routinely collected data from a depression screening service 
which ran in selected oncology outpatient clinics in Scotland, UK, from 2008 to 
2011. The depression screening database contained records on over 20,000 patients 
with repeated psychological symptoms data. Patients’ clinical and demographic 
information from the Scottish National Cancer Registry were linked to their 
symptoms screening data and prepared in anonymised form by NHS Scotland 
Information Services Division. 
 
Study 1: Screening patients for distress in a hospital clinic setting 
Within a couple of weeks of the clinic visit the depression screening service routinely 
contacted patients who had scored greater than or equal to 15 on the HADS to give 
them a structured interview for depression. However, a concern was that the hospital 
environment in which the HAD scores were obtained might have added to patients’ 
feelings of stress and could as a consequence have artificially inflated the HAD 
scores, requiring more patients than necessary to be followed up in the subsequent 
telephone depression interview. In order to examine whether the HADS scores from 
the clinic overestimated patients’ distress levels, we followed up 218 patients who 
had scored high on the HADS in clinic and asked them to complete the HADS one 
week later over the telephone at home. We found that 72.5% (95% CI: 66.6 to 
78.4%) of patients remained high scorers on the follow-up assessment, and the mean 
score at follow-up was 1.74 (95% CI: 1.09 to 2.39) units lower than the scores 
obtained in clinic. The chapter focusses on estimation of the regression to the mean 
effect (a statistical artefact of the sampling technique) and concludes that this 
accounted for most of the drop in scores between the two assessments. The study 
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further concludes that measuring distress on self-rated paper questionnaires in clinic 
is a reasonably reliable method for identifying patients with symptoms of distress. 
 
Study II: A purpose-designed study to investigate the persistence of distress in 
cancer outpatients 
People living with a cancer diagnosis are at increased risk of psychological distress, 
with some presenting as clinically depressed and requiring treatment. Little is known 
however about symptoms of significant psychological distress in people who do not 
meet the criteria for major depression. The POD Study aimed to investigate the 
persistence of distress over a seven month period among this population and to 
identify characteristics that were predictive of persistent distress. This was a 
prospective, purpose-designed clinical study of 325 cancer patients who had been 
identified by the depression screening service as presenting with symptoms of 
significant distress (Hospital Anxiety and Depression Scale (HADS) total score ≥ 15) 
at a clinic appointment. Enrolled participants were asked to complete the HADS over 
the telephone at regular intervals over a seven months period. Results suggested that 
a significant proportion of patients (37%; 95% CI: 31.4 to 42.5%) remained 
distressed after seven months, and that distress status one month after the initial 
clinic visit was a strong predictor of its persistence. 
 
Study III: Analysis of the routinely collected screening data to address the aims of 
the POD Study 
The large, routinely collected data from the depression screening service were 
analysed to determine the possibility of addressing the same research questions posed 
by the POD Study. We identified cases in the screening database who had scored 15 
or more on the HADS at a clinic visit (the qualifying visit) and included in the 
analysis any available HADS data from subsequent clinic visits over the following 
seven months. To match the structure of data collection in the POD Study, the data 
were categorised into time windows. Patients’ HADS scores could only be observed 
on their attendance at clinic appointments, and the amount of observed data was 
therefore linked to the frequency with which patients attended clinics. The screening 
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data were analysed using missing data methods coupled with flexible statistical 
modelling techniques using WinBUGS.  
 
The estimated distress prevalence fell to just below 50% after the qualifying clinic 
visit and remained there with little variation thereafter. The patterns of change over 
time in the distress prevalence and mean distress scores were very similar over time 
in both the screening data and in the POD study, but the prevalence estimates were 
somewhat higher in the screening data. The two analyses agreed that there were no 
associations of persistent distress at seven months with gender, age and cancer type, 
and that distress status at one month after the qualifying visit was a strong predictor 
of persistence. There were no directly contradicting results arising from the two 
analyses. In the light of the limitations of the screening data the findings from the 
two datasets were remarkably similar. 
 
Study IV: Analysis of the screening data to address a novel research question 
In a final application of the screening data we aimed to estimate the prevalence of 
depression among the five most common cancer types and to identify demographic 
and clinical characteristics associated with depression. We followed a modelling 
strategy similar to that previously developed for analysis of the incomplete screening 
data and found prevalence rates of 13.1% (95% CI: 11.9 to 14.2%) in lung cancer 
patients; 10.9% (95% CI: 9.8 to 12.1%) in gynaecological cancers; 9.3% (95% CI: 
8.7 to 10.0%) in breast cancer patients; 7.0% (95% CI: 6.1 to 8.0%) in gastro 
intestinal cancers and 5.6% (95% CI: 4.5 to 6.7%) in the almost exclusively male 
genitourinary cancer patients. We found that female gender, deprivation and young 
age were strongly associated with depression. 
 
Conclusion 
Our work demonstrates that original research with observational healthcare data is 
possible, with a good understanding of the clinical context, the background and the 
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Clinical practice should be based on the best available evidence. Ideally, such 
evidence is obtained from rigorous, purpose-designed clinical studies such as 
randomised controlled trials and prospective cohort studies. But gathering 
information in this way requires a massive effort, can be prohibitively expensive and 
is very time consuming. Controlled experiments are not always practicable or ethical, 
and sometimes answers are just needed quickly. For example, after the Lancet 
publication of the now discredited study which suggested a link between the MMR 
vaccine and autism (Wakefield et al., 1998) many parents opted not to have their 
children immunised, and answers were urgently needed to avoid putting children’s 
health at risk. Establishing long-term links between exposure and outcomes can be 
notoriously difficult, and often retrospective healthcare data offer the best evidence 
there is. Thanks to the now widely computerised, networked data entry and storage 
systems in the health sector, observational healthcare data are routinely collected and 
stored as part of normal clinical practice. But can we rely on analysis with such data 
to give us meaningful answers? 
 
1.1 Context 
A recent special issue of Statistical Methods in Medical Research focussed on 
effectiveness and safety research with observational healthcare data. There are some 
considerable advantages of using observational healthcare data for research. 
Overhage & Overhage (2013) note that such data allow interventions and conditions 
to be studied that would not be economically feasible to evaluate in randomised 
controlled trials. Further, analysis with observational healthcare data often involves 
much, much larger samples, but at a fraction of the cost.  Purpose-designed research 
studies, such as trials, typically use strict inclusion and exclusion criteria for patient 
involvement, and patients have to agree to participate. This means that the patient 
samples studied tend to be more homogenous. Consequently, findings may have 
greater generalizability when based on observational healthcare data. Such data also 
allow healthcare practices and treatments to be studied as they are delivered and can 
therefore provide better insight into real world clinical practice. In the same issue 




they may provide the best evidence available for the study of rare safety events 
associated with medical products already on the market, and Le et al. (2013) propose 
a semi-automated method for rapidly evaluating safety signals using multiple 
longitudinal healthcare databases. 
 
Of course, there are also many limitations to observational healthcare data. Overhage 
& Overhage (2013) review in broad terms the central limitations and consider the 
advantages and disadvantages of using administrative claims data (mostly relevant to 
the US) and data from clinical systems including electronic medical records. The 
paper lists several major challenges: Claims data may contain intentional 
inaccuracies introduced through efforts to maximise reimbursement. Patients may 
receive health care that is not logged anywhere. Absence of evidence of diagnostic 
tests, symptoms and treatments etc. could mean that such events did not occur, or 
that they were not recorded. Clinical systems are dynamic in the sense that certain 
events may have been routinely logged for a while, but then dropped from the logs 
later on. It may equally be the case that certain clinical events occurred routinely for 
a while before being stopped. Often there is no indication in the data itself about such 
procedural changes. 
 
These authors also note that routine data are incomplete in the sense that data are 
typically collected when patients have an appointment, e.g. to have diagnostic tests 
performed, or when some other clinical procedure or check-up is needed, rather than 
on any regular basis. Routine data are almost invariably subject to missingness and 
may not therefore reliably contain the information needed for certain analyses. 
Second, certain scenarios or meanings may not be immediately clear from the 
available data so that one must rely on a combination of data to understand the 
meaning. For example, the authors note that: “observational data consist primarily 
of transactions that occur during the care of a patient which means that there is 
rarely data about when a patient stopped taking medications or when a condition 
was resolved.” 
 
Another important issue is that the populations included in observational data vary 




obtained. The samples may not therefore be representative of the target population of 
interest. Observational healthcare data are biased in a way that controlled 
experiments are not since patients and their doctors choose the timing, the type and 
intensity of the care received. In conclusion the authors emphasise the importance of 
paying close attention to the detailed characteristics of the data.  
 
Yet another article in the same issue focusses on data linkage methods for ensuring 
data quality. The paper by Li X & Chen (2013) reviews such methods and suggests 
that probabilistic matching methods using latent class models which have been 
applied to diagnostic testing can be translated and applied in record linkage. The 
paper concludes that more research is needed to evaluate the performance of various 
matching approaches and that there are tremendous opportunities for statisticians to 
collaborate with medical informaticians and computer scientists to progress research 
and practice in the field. Li L et al. (2013) provide a review of Inverse Probability 
Weighting methods and place this in the context of analysis with secondary 
healthcare databases for medical research, and Danaei et al. (2013) present a 
comprehensive analysis using observational data to investigate the effect on the risk 
of coronary heart disease of initiating treatment with statins. The general idea is to 
emulate a hypothetical randomised trial by imposing similar inclusion criteria on the 
analysis sample as would have been appropriate for eligibility in a trial. The 
emulated trial then proceeds by comparing events in patients who subsequently 
initiate treatment with events in those who do not. Assuming that all important 
confounders are known and have been measured, a valid effect estimate can be 
obtained by adjusting for all confounders in the final analysis. The paper concludes 
that the analysis yielded surprisingly promising findings and that meaningful analysis 
of observational data can be achieved with the right combination of high quality data, 
good subject-matter knowledge, and appropriate statistical methodology. 
 
1.2 Motivation for the present study 
Analysis with routinely collected, observational healthcare data is clearly an 
important and topical area of research. We had access to repeated psychological 




attended selected oncology clinics in Scotland, UK. Patients attending for 
appointments were approached in the clinic waiting area by a symptom monitoring 
and screening service managed by our group, Psychological Medicine Research at 
the University of Edinburgh. The screening service asked patients to complete a 
questionnaire which enquired about physical and psychological symptoms. The 
questionnaire answers were used to help the oncologists address issues that were of 
concern to the patients, and also to identify patients with major depression who were 
eligible for enrolment in the SMaRT oncology-2 and 3 trials (Walker, Cassidy & 
Sharpe, 2009a, 2009b). However we wondered if these routinely collected data might 
also offer a unique opportunity to study the progress of distress symptoms on an 
unprecedented scale in this population. Clearly the limitations were many, so how 
could we make the most of these data?    
 
Separate from the depression trials Psychological Medicine Research also conducted 
a purpose-designed, prospective cohort study into the persistence of distress 
symptoms in the same cancer outpatient population. The Persistence Of Distress 
Study (PODS) collected distress outcome scores from enrolled patients at regular 
intervals with very little missing data and consequently contained many of the 
features that were lacking in the routinely collected screening data. Perhaps PODS 
could act as a useful contrast to the screening data, a sort of gold-standard offering an 
insight into what the screening dataset might have looked like were it not for its 
limitations. Would we be able to reproduce the results obtained with PODS through 
secondary analysis with the observational screening data? Clinical cohort studies 
have limitations of their own. Could there even be advantages to the abundant but 
highly irregular screening data that might actually outweigh those of the purpose-
designed, but much smaller clinical study?  
 
These were the specific circumstances which motivated the project. Anchored in 
these concrete data and questions the work described in this thesis aims to investigate 






Chapter 2 outlines some early and exploratory work before placing the problem in a 
missing data context. Relevant methods for handling missing data are further 
reviewed in Chapter 3. The focus is returned to the routinely collected symptom data 
in Chapter 4. The chapter considers the intra-patient correlation between repeated 
distress measurements and examines the extent to which patient selection criteria 
employed in the POD Study (and routinely by the depression screening service to 
identify patients that are likely to be depressed) induce regression to the mean in 
subsequent outcomes. The POD Study and its findings are the subject of Chapter 5. 
Bayesian modelling with incomplete data is introduced in Chapter 6. The chapter 
provides an account of exploratory work with different modelling approaches in 
WinBUGS to analyse incomplete data that are simulated under known missingness 
processes using the SAS software. In Chapter 7 we construct a dataset from the 
routinely collected symptom data that mimics the POD Study data structure. We then 
develop a Bayesian model in WinBUGS to estimate the posterior predictive 
distribution for the incomplete longitudinal response data and covariates under both 
Missing At Random (MAR) and Missing Not At Random (MNAR) mechanisms and 
use this model to generate multiply imputed datasets for further analysis. The 
findings are compared with those from the prospective POD Study. Finally in 
Chapter 8 we follow a similar modelling strategy using the observational screening 
data to address clinical research questions that have not been adequately studied 
elsewhere. The present research project is summarised in Chapter 9. We reflect on 





This chapter is introduced with an overview of an early review of the literature on 
analysis with routinely collected patient health outcomes. This was not the result of a 
formal systematic review and should not be seen as providing an exhaustive account 
of the available literature on the subject. Rather it serves to define the topic by 
providing an impression of the breadth of this, and to put into context the current 
project. The project is then placed within a missing data context, and lastly we 
describe Rubin’s taxonomy for classifying mechanisms for missing data. 
 
2.1 Review of the background 
Routinely collected patient health outcomes include physiological measurements, 
psychological symptoms and self-reported functional scores, quality of life 
measurements, patients’ satisfaction with care etc. Collecting such patient outcomes 
has numerous purposes that can broadly be divided into two categories. Firstly, at the 
patient level, individual responses may be used for the screening or monitoring of 
outcomes in individual patients. The routine collection of general health outcomes 
from patients also facilitates communication about the patient within medical teams, 
as well as directly with the patient, thereby promoting patient-centred care 
(Greenhalgh, 2009). Secondly, at the group level, the aggregate data from all patients 
may be used as a means of measuring the quality of a clinical service, assessing the 
effect of an intervention on patient outcomes or to research other epidemiological 
questions.  
 
Rose & Bezjak (2009) consider the logistics of collecting patient reported outcomes 
in a clinical setting and draw attention to a number of factors that are necessary for 
the successful collection of useful data. The authors emphasise the importance of 
having routine procedures in place to minimise data that are incomplete or biased 
towards more compliant patients. Analyses based on routinely collected outcomes 
should be interpreted with caution. Davies & Crombie (1997) provide a detailed 
account of the pitfalls in interpreting such outcomes. Contrary to controlled 
experiments where patients are allocated at random to interventions and test 




outcomes. Patients are not sampled with a specific research question in mind, and the 
sampled patients may not be representative of the research target population.  
 
Systematic non-response in routine medical outcomes can produce data that are 
biased for example towards more treatment compliant patients, or patients with 
particular demographic or health characteristics. The limitations are exacerbated 
when considering routine data for longitudinal research. For convenience, patient 
outcomes are sometimes collected immediately before a patient’s clinical 
appointment. As a result, patients’ outcome measurements are inseparably linked 
with the event of having a clinic visit. The frequency of clinic visits (and therefore 
the amount of observed data) can vary between patients depending on the health state 
and, if in treatment, the treatment stage of the patient. A cross-sectional analysis of 
outcome data might focus on data from the first visit from each patient, thereby 
ensuring that all sampled patients contribute equally to the analysis. In a longitudinal 
analysis, the frequency with which data are observed (and therefore the amount of 
data observed from each patient) may have a direct bearing on the value of the 
outcomes. Routinely collected longitudinal healthcare data might be valuable but 
simple analysis strategies are unlikely to suffice.  
 
The analysis of routinely collected outcome data in healthcare is a broad topic. 
Analysis of outcomes have been used (and misused) by policy makers and healthcare 
managers as a tool for monitoring targets and managing the performance of clinical 
staff (Epstein, 1990; Blisker & Goldner, 2002; Lilford et al., 2004). With the increase 
in electronic databases used for storing patients’ medical records there has been a 
growing interest in the reuse of data extracted directly from medical notes for clinical 
research (Curcin et al., 2010; Rosenbloom et al., 2012). A recent publication in the 
Lancet studying child maltreatment across six different countries used longitudinal 
analysis of routine healthcare data to investigate the scale of the problem and trends 
over time (Gilbert et al., 2012). However despite growing interest in analysis with 
such data relatively little methodological work has been published on the topic. 
There are a few published studies on the use and analysis methods of routinely 




Macdonald, 2002). Interrupted Time-Series analysis of routine longitudinal 
healthcare data has been proposed as a pragmatic alternative to expensive and time-
consuming randomised controlled trials in places and situations where such trials are 
not feasible, for example to evaluate changes in health policy in developing countries 
(Lagarde, 2012). However, time-series analysis is best suited to the modelling of 
many correlated data points from a single (or very few) series such as is commonly 
observed in economics. These data structures are less common in clinical studies 
which are typically concerned with many independent units (usually patients), each 
contributing with only a few correlated measurements. We found a number of other 
studies on broadly related topics. Sithole & Jones (2003) use GP prescription data to 
fit a Bayesian repeated measures model for detecting differences in GP prescribing 
habits following an educational intervention. Their data are complete at every time 
point and the paper does not consider some central limitations to routinely observed 
data. Hogan & Lancaster (2004) use the example of an observational HIV natural 
history study to compare instrumental variables (IV) methods, typically used in 
social sciences and econometrics for drawing causal inferences in the presence of 
potential unobserved confounders, with the epidemiologic approach of inverse 
probability weighting. McDonald et al. (2009) report on a population-based record-
linkage study of mortality rates in people with Hepatitis C in Scotland based on 
national databases. The focus of this study is predominantly on data linkage rather 
than statistical modelling. Finally, He et al. (2010) use multiple imputation to 
complete a centralised cancer care outcomes survey dataset with considerable 
missingness on multiple variables for subsequent multi-objective analysis by external 
investigators.  
 
2.2 Choosing an angle 
There are many different ways of handling irregular spacing in the analysis of 
longitudinal data. We considered some alternative approaches in exploratory work. 
Lowess curves and various other plots were produced to summarise the distress 
scores from the observational symptom screening data in continuous time. The 
dependency between repeated measures could be induced implicitly by including 




with random intercepts and slopes. However we required a modelling framework that 
would be suitable also for the POD Study data and its research aims. One solution 
was to think of the unevenly spaced observations as an incomplete picture of a 
hypothetical, complete dataset consisting of regular and frequent values.  The set of 
complete data from each patient then consisted of both observed and unobserved 
values that in principle should have been observed. Replacing the idea of irregularly 
spaced data with a mental picture of a partially observed, complete dataset allowed 
us to approach the problem with methodology developed for analysis with missing 
data. 
  
2.3 The missing data framework 
Analysis in the presence of missing data broadly presents three types of challenges 
(Fitzmaurice, Laird & Ware, 2002). Firstly, with missing data there is a loss of 
information which will result in less precise estimates (i.e. larger standard errors, 
wider confidence intervals and larger p-values) and analyses are therefore more 
likely to be inconclusive. Secondly as the number (and timing) of observations will 
vary between patients, missing data impose restrictions on the methods of analysis 
that may be applied as not all methods will handle unbalanced data. Finally, and 
perhaps most importantly, missing data may compromise the validity of the data and 
careful thought should be given to the mechanisms that cause the data to be missing. 
 
2.3.1 The missing data mechanism 
The type of assumptions that can be made about the missing data has important 
implications for the appropriate analysis strategy necessary for valid inference. Rubin 
(1976) developed the taxonomy for the missing data mechanism. This general 
framework can be extended to the case of repeated data (e.g. Laird, 1988). Most 
work on methods for analysis with missing data since the introduction of Rubin’s 
taxonomy has used the general idea behind this taxonomy to classify the mechanisms 
for missing data. The following description of three types of missingness 
mechanisms relevant to incomplete longitudinal data is loosely based on Fitzmaurice, 




Completely At Random (MCAR), Missingness At Random (MAR) and Missingness 
that is Not At Random (MNAR) as described below.  
 
Missing completely at random 
Assuming all patients have at least one observed value, a missing value can be 
thought of as missing completely at random (MCAR) when the probability of 
missingness is unrelated to both observed responses from the same patient as well as 
the values of unobserved responses that in principle should have been observed.  
 
If Yi denotes the complete vector of all responses for the ith subject we can partition 






 is the vector of the observed responses 
and Yi
M
 is the vector of unobserved responses that in theory should have been 
collected. Associated with Yi is a vector Ri of missing data indicators (Ri1, Ri2, …) 
where Rij is equal to 1 when the jth response for subject i is observed and zero 
otherwise. 
 
The MCAR assumption is then satisfied when the distribution of Ri (conditional on 






, Xi) = f(Ri | Xi) 
 
When data are MCAR the governing distributions of the observed, Yi
O
, and the 
complete data, Yi, are the same. The means, variances and covariances of the 
observed data are equal to those of the complete data on average. 
 
The important implication of this is that inferences can be drawn about the 
distribution of the complete data from moments of the observed data alone. As a 








Missing at random 
If the probability of a value being missing is unrelated to values of the unobserved 
responses, but not necessarily independent of other observed responses from the 
same patient, the data are said to be missing at random (MAR). Thus, missingness 
completely at random is a special case of missingness at random. 
 
Data are MAR when the conditional distribution of Ri (conditional on covariate data) 











When data are MAR the distributions of the missing and observed responses are 
identical within strata of the data defined by covariates and the vector of observed 
responses. By analysing the observed data appropriately it is therefore possible to 
draw inferences about the complete distribution of Yi from the observed data alone.   
 
When data are no longer MCAR more care will have to be exercised in the analysis 
of the data. In particular, the moments of the observed data are no longer equal to 
those of the complete data. Consequently, biased estimates will result from a naïve 
analysis of only the complete cases or in any analysis of the available data (see 
below) that does not adequately account for the missing data.  
 
Missing not at random 
When data are Missing Not At Random (MNAR) the probability of missingness is 
dependent on the values of the unobserved responses. Under MAR it is possible to 
model the complete data without having to specify the distribution for the missing 
data indicators Ri. This is not the case when the probability of an observation being 
missing is related to the value of the unobserved responses. That is, even after 
stratifying by all the observed values (and covariate data), missingness within a 
particular stratum of observed values is no longer random but is dependent on the 




dependency between the missing data indicators Ri and the unobserved responses 
Yi
M
. Careful attention to the cause of missing data is required especially in the 
presence of a large amount of missing data that are MNAR. The probability of an 
observation being missing can be modelled, for example, in a logistic regression 
model as a function of both the observed and unobserved responses (Diggle & 
Kenward, 1994). The joint likelihood is then a function of both the outcome and 
missingness processes. The nature of the relationship between the missing data 
indicators and the unobserved responses cannot be verified from the data and it is not 
generally possible to know with certainty the parameters governing the missing data 
mechanism. Analysis under a MNAR mechanism therefore often focuses on 
sensitivity of conclusions reached in a main analysis to alternative scenarios for the 
missingness process. Little (1995) discusses two commonly used methods for 
modelling the data and the drop-out mechanism together, selection models and 






The previous chapter introduced a formal framework for characterising missingness 
in longitudinal studies. We will now provide details of some of the prevailing 
methods for analysis with incomplete multivariate data. The chapter is introduced 
with a brief overview of some common approaches to handling missing data. The 
main focus of the chapter will be on more recent, principled approaches to modelling 
incomplete data under named assumptions for the missingness mechanism.  
 
3.1 Common approaches to analysis with missing data 
Traditionally many analysis methods required a rectangular dataset to proceed. This 
meant that incompletely observed cases were a nuisance to analysts. Many 
conventional methods for handling missing data, sometimes referred to as ad hoc 
methods, were therefore primarily concerned with generating analysable datasets and 
less concerned with the underlying missingness mechanism and potential bias 
present in the incomplete sample. 
 
Complete-case 
Perhaps the simplest way of dealing with the nuisance of incomplete cases in 
longitudinal studies is to omit all patients with any missing data from the analysis. 
The resultant dataset can then be analysed using conventional complete-data 
methods. Although appealing due to its simplicity the use of this method, also known 
as list-wise deletion, is generally not regarded as good practice and is commonly 
criticised (e.g. Fitzmaurice, 2003; Schafer & Graham, 2002; Little & Rubin, 2002, 
Chapter 3). Except from situations where missingness is MCAR, the distribution of 
data from patients with complete data will not in general be identical to that of the 
study population and the method can yield potentially seriously biased results. 
Analyses based on this method are also typically very inefficient, especially in 
studies where there are many follow-up occasions or several outcome variables that 






A more efficient use of the data is through methods that will use all available data. 
Such methods, referred to as available-case methods, are capable of handling 
unbalanced datasets, so that patients with partially observed responses still contribute 
with data where it is available. The method of Generalised Estimating Equations 
(Liang & Zeger, 1986) can be thought of as an available-case method. The 
assumption about the missingness mechanism underlying this class of methods is still 
that of MCAR. That is, analysis with missing data through available-case methods 
will generally only provide unbiased results when missing data are not related to 




A commonly used alternative to complete-case and available-case methods is to use 
one of the many methods of imputation to generate a complete dataset thereby 
avoiding wasting information belonging to patients where some measurements are 
unobserved. The basic idea behind these techniques is to replace missing 
observations with plausible values, and then use standard methods of analysis on the 
complete (imputed) dataset. 
 
The simplest imputation methods replace a missing value from a patient with a single 
imputation, for example using the mean of a patient’s observed values. In clinical 
studies when some values are unobserved due to drop-out another common 
imputation method is the Last Observation Carried Forward method (LOCF) 
whereby unobserved measurements are simply filled in using a patient’s last 
observed value. The implicit premise is that a patient’s last observed value provides a 
good estimate of the subsequent unobserved outcomes over the remaining follow-up 
time. Although widely criticised (e.g. Ware, 2003; Carpenter et al., 2004; 
Mallinckrodt et al., 2004) this method is still used in clinical trials of pharmaceutical 
products. (It should be noted that methods such as LOCF are not inherently wrong. 
For example, there might be situations where the researcher genuinely believes that 




general to be the case, it is sometimes argued that LOCF is conservative. It is argued 
that the method assumes that the effect of the trial intervention is less in patients who 
drop-out. In fact it is not hard to think of situations where the use of LOCF will bias 
estimates in favour of a trial intervention. Molenberghs & Kenward (2007, pp. 47-
49) compare the complete case and LOCF methods in the context of missingness 
mechanisms. They show that, in general, effect estimates from either analysis are 
biased under a MAR mechanism and that LOCF generally produces biased estimates 
even under a MCAR mechanism with the bias working in either direction depending 
on the parameters involved. The authors conclude that it is not immediately clear 
what conditions need satisfied for the LOCF method to be unbiased or conservative.  
 
Of course there are other strategies for imputation that can be employed. It might be 
assumed that the (unmeasured) value of the outcome variable is zero when a patient’s 
measurement is unobserved or that the outcome variable returns to baseline levels 
when a patient drops out. Unconditional mean imputation uses the overall average of 
observed scores from other patients at the follow-up time being imputed. Several 
other variants of mean imputation exist where the aim is to use the existing data in an 
optimal way to best predict the missing values. Fitzmaurice (2003) provides a brief 
overview of more advanced techniques that use regression methods to fill-in a 
patient’s missing values using the conditional means (conditional on observed 
responses). The incomplete variable is regressed on all other observed variables and 
the resultant regression coefficients, together with the patient’s observed responses 
are then used to predict the missing values. Usually a random term is added on from 
a simulated normal distribution with variance equal to the residual error variance in 
the regression model. This is to avoid the problem of small variances in the imputed 
values mentioned above. Other methods include predictive mean matching where the 
missing value is imputed using an empirical value from the observed data that is 
close to the predicted value (e.g. Little & Rubin, 2002) and propensity scores 
methods (Rosenbaum & Rubin, 1983) that associate a probability (or propensity) of 
drop-out with each patient and impute missing observations using values from 





However even if the analyst succeeds in producing imputations that on average are 
unbiased under a MAR mechanism, a conventional analysis based on singly imputed 
data will still produce estimates with overstated precision (Schafer & Graham, 2002). 
That is, the standard errors will be too small and confidence intervals too narrow. 
The random element inherent in producing the imputed values is unaccounted for 
since the imputed observations are analysed as if they had actually been observed.  
 
This problem which is common to all single imputation prompted Rubin’s work on 
Multiple Imputation (MI) in sample surveys (Rubin, 1977, 1978, 1987) marking the 
beginning of extensive work on multiple imputation methods.  Multiple imputation 
has been researched and developed extensively since Rubin’s initial work, and still 
occupies a very important role in the current literature on principled approaches to 
analysis with missing data. The theory of MI is also integral to much of the analysis 
in the present project and will be covered in detail below. 
 
Likelihood based methods 
When data are MAR valid inference can also be gained from maximum likelihood 
(ML) estimation based on the full joint distribution of the multivariate responses. In 
the presence of missing data, this method also produces estimates that account for the 
loss of information (or uncertainty arising from the missing observations) and will 
produce correct standard errors. Likelihood-based methods require correct 
assumptions about the joint distribution of the repeated data. These methods will not 
in general provide valid estimates in the presence of missing data if the likelihood 
function is incorrectly specified, for example if the covariance structure is not 
modelled correctly. When there is missing data, and the missing data pattern is non-
monotone (section 3.4.6), maximising the likelihood function algebraically is not 
usually possible. Generally in this situation, no closed-form expression exists for the 
maximum likelihood estimate and maximisation will have to be done through an 
iterative and computationally intensive procedure. Expectation-Maximisation (EM) 
algorithms (Dempster, Laird & Rubin, 1977) can provide maximum likelihood 
parameter estimates from incomplete data by alternately estimating the unknown 





Little & Rubin (2002) provide a comprehensive reference text on missing data 
methods and divide these methods into four broad classes: Complete data methods 
such as the list-wise deletion methods; weighting methods that use algorithms to 
compensate for observations that are essentially underrepresented in the observed 
sample; imputation-based methods; and finally model-based methods. We will be 
concerned with principled approaches such as imputation-based (particularly 
multiple imputation) and model-based methods (also known as direct likelihood or 
joint modelling methods). For now however we shall return briefly to the building 
blocks of the missing data paradigm.  
 
3.2 Ignorability 
We saw in Chapter 2 that incomplete longitudinal data may be classified according to 
Rubin’s taxonomy as MCAR, MAR or MNAR. An important related concept is that 
of ignorability (Rubin, 1976; Little & Rubin, 2002, Chapter 6). Informally, when the 
data are MCAR or MAR and we wish to make inference about the parameters 
governing the response process, then the missingness function may be ignored under 
likelihood-based inference. (Strictly, a further requirement for the ignorability 
condition to be satisfied is that the parameters governing the response and the 
missingness processes are distinct.)  
 
In general we can define the complete set of data arising from a study that is subject 
to missingness as consisting of Y
O
, the observed responses, Y
M
, the unobserved 
responses and R, the missing data indicators. The missing data indicators are simply 
binary variables that record whether a given response, yij say, was observed (rij=1) or 
missed (rij=0).  
 
Having defined the complete set of data in this way we can now define the complete-
















Here θ are the parameters governing the response process and ψ are the parameters 
governing the missingness process. 
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The first part of this likelihood is the function governing the missingness process 
(conditional on the responses and ψ). The second part is the function defining the 
response process. 
 
In most cases we are concerned with estimating θ whereas ψ and the functional form 
of the missingness mechanism typically are not of direct interest. The ignorability 
condition implies that the full-data likelihood (with respect to θ) is proportional to 
the partial likelihood consisting of the response process on its own (i.e. ignoring the 
missing data process). In other words, when the missing data process is ignorable 




, ψ), the part 
of the likelihood arising from the missingness process. 
 










by definition. When the missingness process does not depend on the Y
M
 then there is 
no information about θ to be extracted from the missing data indicators. The 
likelihood arising from the missingness process is effectively constant over the 
parameter space for θ. Direct likelihood estimates for θ under the ignorability 
assumption can then be obtained in the usual way by maximising the marginal 
likelihood for the Y
O

















3.3 The direct likelihood method 
Sometimes referred to as the model-based or joint modelling approach, the method of 
direct likelihood is one of the central principled methods for handling incomplete 
longitudinal data. When the data are MAR, and the likelihood function for the non-
response mechanism is ignorable, one can obtain unbiased inferences about the 
parameters governing the response mechanism, θ, “simply” by maximising  the 
observed-data likelihood, f(Y
O
 | θ). Generally when the data are not MAR, one is 




, R | θ, ψ) to obtain valid 
inference about θ. We return to this latter scenario in section 3.6. For now we will 
focus on the situation when data are MAR. 
 
Generalised Least Squares (GLS) regression which is the multivariate generalisation 
of Ordinary Least Squares Regression will produce estimates for the means and 
precisions that are biased when data are not MCAR. This is not generally the case 
when using distribution based regression methods. Molenberghs & Kenward (2007, 
pp. 50-52) illustrate how likelihood-based estimation of mean parameters under a 
bivariate normal distribution are based on the conditional expectation of unobserved 
responses given the observed responses. GLS estimates however do not draw on 
distributional assumptions to utilise information from the whole sample, but rely 
simply on the isolated information available for each parameter. 
 
In practice of course, maximising f(Y
O
 | θ), the observed-data likelihood, is not 
generally straightforward. When the missing data pattern is monotone it is possible to 
construct closed-form expressions for the maximum likelihood estimate (Little & 
Rubin, 2002), however with non-monotone patterns we are generally required to use 
numerical maximisation techniques. The Expectation-Maximisation (EM) algorithm 
(Dempster, Laird & Rubin, 1977) is widely used for maximising likelihoods arising 
from incomplete data and is commonly implemented in software procedures capable 





Consequently, the use of the direct likelihood method for handling missing data 
typically requires very little effort on the part of the analyst since most modern 
statistical packages use procedures such as the MIXED procedure in SAS that easily 
accommodate incomplete data records and use numerical methods for maximising 
the likelihood.  
 
When using the direct likelihood method to obtain parameter estimates from 
incomplete data, it is important to assess the modelling assumptions. In principle it is 
the case that parameter estimates are only valid when the multivariate distributional 
assumptions are correct. To what extent parameter estimates are impacted when the 
assumptions do not hold depends on the amount of missingness and the degree of 
deviation from the distributional assumptions. When data are MAR the maximum 
likelihood estimates of the mean parameters can be expressed as a function of the 
variance-covariance parameters; it follows that misspecification of the covariance 
matrix structure will impact on the mean parameter estimates. Finally, 
misspecification of the linear predictor, whether through the functional form, 
omission of endogenous variables or variables related to both missingness and the 
response, can equally result in biased estimates. 
 
We have seen that it is possible to make valid inferences about the response 
mechanism from incomplete MAR data while ignoring the missingness mechanism. 
It should be noted that it may still be desirable to model the missingness mechanism 
in these circumstances if understanding this process adds to the overall value of the 
study findings. 
 
3.4 Multiple Imputation 
Some common strategies for simple imputation were discussed above. Many of these 
posited assumptions about the missing data that may not be realistic in many 
situations. But even where single imputation methods succeed in predicting missing 
values correctly the problem still remains that conventional analysis of singly 
imputed data tends to overstate precision in the estimates by not taking account of 




problem in singly imputed data (Little & Rubin 2002, Chapter 5) although Multiple 
Imputation (MI) has become the method of choice. Below we give an account of MI 
methods under an ignorable missing data mechanism. 
 
Under MI missing values are imputed multiple times through an imputation model. 
The imputation model is implemented within a Bayesian imputation scheme which 
generates predictions of the unobserved data that are valid under some named 
assumption for the missingness mechanism. Unlike single imputation where analysis 
is based on a single imputed dataset, MI produces a number of completed datasets to 
be analysed in combination. The datasets each consist of an observed part and an 
imputed part where the observed parts are identical across datasets but the imputed 
parts vary. Once the imputation step is complete each imputed dataset is analysed 
separately using the appropriate methods that would have been applied had the data 
been fully observed. Finally the results of the separate analyses are combined using 
the rules formulated by Rubin (1987) to produce overall (pooled) estimates with 
correct standard errors that take account of the variation between the imputed 
datasets. 
 
3.4.1 The analysis step 
3.4.1.1 Rubin’s rules: combining the imputations 
For the single-parameter case Rubin (1987) developed the following general rules for 
pooling the point estimates (and associated errors) across m imputed datasets to form 
a single estimate with correct standard error that accounts for both within and 
between imputation error. 
 
Suppose some parameter A is estimated separately with each of the m imputed 























the mean of the m individual estimates. Now, let Vi denote the variance of the 
parameter estimate from the ith imputed dataset. Rubin’s variance formula then gives 














The between-imputation variance is simply estimated as  
 

















And the total variance of Â  is then 
 






) factor corrects for the uncertainty arising from having a finite number of 
imputations. Therefore as m approaches infinity the total variance simply reduces to 
the sum of V and B, the within- and between-imputation error, in which case the use 
of the data is fully efficient in the sense that all the information available in the 
incomplete data about the parameter is utilised. Hypothesis tests are conducted by 






to the appropriate t distribution. The degrees of freedom here depend on the number 
m of imputed datasets as well as the sample size. However with large m this is less of 






These results readily generalise to the multi-parameter case (Little & Rubin, 2002, p. 
211). A is then a vector of parameters and Â  are the associated parameter estimates. 



















is the between-imputation covariance matrix. For the multi-parameter case with large 
m the test statistic may be compared to the usual Chi square distribution with degrees 
of freedom equal to the length of the parameter vector A. 
 
3.4.1.2 Fraction of missing information 
Considering again the variance formula T = V + (1+m
-1
)B we note that V, the 
average variance within each (imputed) dataset, is an estimate of the full-data 
variance. In other words, V estimates the variance of the parameter estimate in the 
(hypothetical) fully observed data. It is also clear that the additional variance caused 
by the missing data is (1+m
-1
)B which reduces to B as m approaches infinity. 
 
The relative increase in variance caused by the missing data is therefore B/V. In a 
sense this represents the penalty arising from having unobserved data: the variance of 
the parameter estimate will always be inflated by at least this amount regardless of 
the number of imputations generated. 
 
Another important quantity is the fraction of missing information, λ, about the 
parameter to be estimated. Defining the variance components above in terms of 
Fisher information this can be shown to be λ=B/(V+B). Some authors suggest using 
this fraction as a guide for deciding on the number of imputations needed to obtain 
good efficiency (relative to estimates based on infinite m) and stability in the results. 
 
The relative efficiency of an estimate based on m imputations relative to an estimate 





































Using this formulation it is immediately obvious that the number of imputations 
needed to achieve a given relative efficiency increases with the fraction of missing 
information about the parameter. The additional error incurred from basing estimates 
on a finite number of imputations is referred to as the Monte Carlo error. The 
variance formula can be written as 
 
 T = V + B + (B/m)  
 
(B/m) is the variance arising from the fact that MI is a stochastic procedure that, with 
finite m, yields different results when repeated. The square root of this variance term 
(B/m)
1/2
 is the Monte Carlo error. 
 
3.4.1.3 How many imputations are needed 
We saw above that the number m of imputed datasets affects the precision with 
which we can estimate an unknown parameter. m should be chosen such that the 
relative efficiency is acceptably close to unity or it may be the case that independent 
repeats of the analysis leads to different conclusions because of the sampling 
variability in separate MI runs. Historically many authors (e.g. Shafer, 1997; Rubin, 
1987) have suggested using only a small number of imputations arguing that the 
efficiency gain diminishes rapidly as m increases beyond 5 to 10 imputations. 
However more recently it has been recognised that the reproducibility requirement 
necessitates a much larger number of imputations. White, Royston & Wood (2011) 
suggest as a rule of thumb that the number of imputations should be no less than the 




m=30. With recent gains in computational speed the number of imputations is 
(usually) no longer restricted by computational resources. There is however an 
argument for parsimony since results based on 3 to 5 datasets are arguable more 
transparent and easier to verify than results based on hundreds of imputed datasets. 
 
3.4.2 The imputation model 
The imputation model is the crucial link that binds together the predicted values and 
the observed data. As an example, suppose we had planned to observe a quantitative 
variable at baseline, Y1, and again at follow-up, Y2, some time afterwards. As is not 
unusual in longitudinal studies we are concerned here with the value of Y2, the 
outcome at the last planned appointment. Suppose further that the baseline 
measurements were fully observed but that some patients failed to provide outcome 
data on the follow-up occasion. When the distribution of Y2 is approximately normal 
the missing outcomes may be modelled through a linear model of the form 
 
 E[Y2] = α + β Y1 + γ1 X1 + γ2 X2 + … + γp Xp (3.1) 
 
Here X1, X2, …, Xp  are covariate data related to the outcome through the regression 
coefficients γ1, γ2, …, γp, α is the intercept and β relates the baseline outcome to the 
outcome at follow-up. Broadly, the imputation procedure then consists of the 
following two steps: In the first step Y2 is regressed on Y1 and covariates; in the 
second step the coefficients estimated in this regression are used to predict the 
missing Y2 after adding random components. Parts of the random components 
contribute to variability in the predictions within each imputed dataset, and parts 
contribute to variability between the m sets of imputed data. 
 
3.4.2.1 Building the right imputation model 
If the imputation model is misspecified in some way, for example by omitting 
important predictors of the missing responses, then the predictions of the missing 
values may be biased which in turn can lead to serious bias in the overall analysis 





Sterne et al. (2009), Spratt et al. (2010) and White, Royston & Wood (2011) set out 
strategies for the implementation and reporting of MI models and consider a number 
of scenarios including clinical trials, missing covariate data and what to do when the 
substantive model includes interaction and higher order terms. Generally the 
following variables should be considered for inclusion in the imputation model: all 
previously (and subsequent) observed outcomes, all variables related to the outcome 
being imputed and all variables predictive of missingness. The imputation model 
should retain all structures that are modelled in the substantive analysis such as 
interactions and higher order terms. In the case of imputation of missing covariate 
data it is important to include the outcome variable as a predictor of the covariate. 
This is especially true when the substantive analysis investigates associations 
between the outcome and incomplete covariate data since omitting the outcome from 
the imputation model would force the regression coefficient to be zero in the imputed 
data. 
  
When the imputation and the substantive models are perfectly consistent in the sense 
that they include the same explanatory variables in their linear predictors and posit 
the same functional forms to describe the relationships between the explanatory 
variables and the outcomes then the two models are said to be congenial. Conversely 
when the imputation and the substantive models are not consistent in the manner just 
described the models are said to be uncongenial which is a situation of special 
interest (Meng, 1994). The possibility of having uncongenial models is often put 
forward as one of the major strengths of MI. The direct likelihood method for 
handling missing data requires the full specification of the analysis model, but is only 
useful with that one analysis. With MI the imputer can impute the data using a model 
that is consistent with the underlying missingness mechanism while the subsequent 
analyst may subject the data to a number of different analyses and summaries that 
were not necessarily anticipated by the imputer. Molenberghs & Kenward (2007) 
point to a number of situations where uncongenial models are very useful including 
when using multiply imputed data with Generalised Estimating Equations that are 
generally only valid under MCAR to obtain valid inference under MAR missingness. 




This can be done for example through altering the imputation model to accommodate 
a non-random missingness process thereby assessing the robustness of the results 
from the (uncongenial) substantive model to MNAR missingness. Kenward & 
Carpenter (2007) refer to examples of a variety of such sensitivity analyses.  
 
3.4.3 Making proper imputations 
The term proper imputations refers to the idea that the imputations should not only 
reflect the variance present in the observed part of the data but also the uncertainty 
about the true underlying parameters governing the responses. Proper imputations are 
therefore generated by first formulating (and drawing from) a distribution for the 
parameters and then using each realisation of the parameters to generate one set of 
predictions for the missing values according to the relations defined in the imputation 
model. At its heart MI is a Bayesian procedure with imputations generated from the 














where f(θ | Y
O
) is the Bayesian posterior distribution for the parameters given the 
observed-data likelihood. The imputations are generated by simulating draws from 








, θ) (3.2) 
 
at m different realisations of  
 




Essentially the imputation task proceeds as follows. A random draw is made first 
from the posterior distribution of the parameters (3.3). Second, this realisation of the 
parameters is used in (3.2) to create one imputed dataset by drawing from the 
predictive distribution of Y
M






As was mentioned earlier this two-step procedure for making imputations is often 
referred to as proper because it properly accounts for uncertainty in the underlying 
parameters. Conversely, imputations based on (3.2) with θ replaced by a fixed 
observed-data estimate are sometimes referred to as improper. When making proper 
imputations a Bayesian prior distribution has to be chosen for the parameters. 
Typically this is chosen to be non-informative (e.g. the SAS software uses the non-
informative Jeffreys prior as a default (SAS OnlineDoc®, MI procedure)). This 
seems to be a sensible strategy when MI is used within an otherwise frequentist 
analysis. 
 
Sometimes it is straightforward to define the Bayesian posterior distribution for the 
parameters in (3.3). But depending on the missingness pattern the observed-data 
likelihood may be a complicated function and a numerical iterative procedure is 
required to obtain the distribution. This situation is considered in more detail below. 
 
3.4.4 When the response is not normally distributed 
Imputations based on the imputation model in (3.1) are typically imputed under a 
normal distribution. However, it is common in clinical research to have outcomes 
that are skewed or that are measured on discrete scales, ordered categorical or binary 
scales. One approach to imputation in non-normal variables is simply to proceed 
regardless and apply a linear regression model such as that in (3.1). Many authors 
have reported good results using normal linear regression for imputation with highly 
non-normal data (e.g. Schafer 1997, Chapter 5).  Misspecification of the distribution 
governing the imputation model affects only the imputed data and the effect of such 
misspecification is therefore negligible when the fraction of missing data is small. 
Nonetheless, there are clear limitations to this approach. Many quantitative variables 
take values only within a certain range. Consequently, imputations above or below 
the permissible range may have to be handled in some way, for example by assigning 
the lowest permissible value within the range to all imputations below the lower limit 
and the highest permissible value to all imputations above the upper limit. 




quantitative data before using the normal linear model for imputation. Another way 
to ensure that the imputed data mirror the observed data is through the use of 
predictive mean matching methods. These ensure that the missing observations are 
imputed using only values that already exist within the observed part of the data. 
This is done by matching each individual with missing data to a number of observed 
individuals with similar linear predictors. The imputation is then drawn at random 
from one of the matches (Little, 1988). 
 
However MI is not confined to imputations from the normal distribution. In the case 
of imputation with a single incomplete variable it is straightforward to use a non-
normal imputation model that is compatible with the type of variable being imputed. 
For example, a logistic regression model may be used to impute univariate binary 
data and an ordinal logistic regression to impute univariate ordered categorical data. 
 
3.4.5 Sequential imputations 
The problem of modelling different types of variables as described above is more 
challenging in the multivariate setting. When more than one variable is subject to 
missingness then the missingness pattern plays an important role in how we may 
proceed with the imputation task. With monotone missingness the incomplete 
variables may be imputed sequentially with the most observed variable being 
imputed first. This is done in the usual way by relating the incomplete outcome to 
other fully observed variables through an imputation model. Next, the second most 
observed variable is imputed by extending the imputation model to include the 
previously imputed variable as well. The process continues until the least observed 
variable has been imputed. The whole procedure is repeated m times to produce m 
imputed datasets.  
 
The strength of this method is that different models may be employed with each 
imputed variable as appropriate. E.g. a logistic regression model may be used to 
impute one variable, a normal model to impute a second variable and predictive 
mean matching to impute a third variable. The monotone pattern implies that 




modelling dependencies with more observed variables. Consider the monotone 
missingness pattern of the three variables shown in Figure 3.1. Var3 is less observed 
than Var2, which is less observed than Var1. Unobserved values in Var1 depend on 
neither of the other two variables. Var2 may depend on Var1, but not on Var3. And 
Var3 may depend on both Var1 and Var2. 
 
 
Figure 3.1. Monotone and non-monotone 
missingness patterns. 
 
3.4.6 Non-monotone patterns 
It is not uncommon in longitudinal studies from clinical research to have missingness 
that is caused by individual missed observations rather than drop-out. When 
missingness is intermittent in this way the resultant missingness pattern is non-
monotone. Contrary to the situation just described there is no hierarchical 
dependency structure to guide the imputation process with non-monotone missing 
data. Using the example of the non-monotone pattern illustrated in Figure 3.1 it is 
clear that missing values in Var2 may depend on Var3 (as well as Var1), and equally 
that missing values in Var3 can depend on Var2. Because of this interdependency 
between the incomplete variables we now have to model the variables jointly in some 
way rather than in succession.  
 
Some authors (e.g. Robins & Gill, 1997) have pointed out that the MAR mechanism 




one variable may be predicted using data from other variables only when these other 
variables have been observed, i.e. the missingness mechanism that dictates the way 
in which the missing outcomes depend upon the observed outcomes changes with 
each observed missingness pattern in the dataset. Under a MAR assumption we do 
not have to model this mechanism. This is just as well because the number of non-
monotone patterns grows exponentially with higher dimensional data. However even 
if we can avoid specifying these mechanisms we should still like to think that they 
exist in theory and that they are in some way plausible since the MAR assumption 
may otherwise not be justified.  
  
3.4.6.1 Imputation based on a multivariate normal model using MCMC 
When the missingness pattern is non-monotone an approach to the joint modelling of 
the multivariate data is needed. Clearly one multivariate distribution whose 
properties are well known is the multivariate normal distribution.  
 
While the observed-data posterior distribution, f(θ| Y
O
), is generally not a standard 
distribution from which realisations of θ are easily simulated, the full-data posterior 




 ), is typically more readily simulated but requires 
predictions for the missing values (Schafer, 1999). This circular problem can be 
solved iteratively by alternating between predicting the missing values and predicting 
the parameters. In each step, the predictions of either the parameters or the missing 
data are based on the latest prediction of the other. The iterations are set in motion by 
choosing some initial values of either the parameters or the missing data. The starting 
values may be simply a qualified guess or some estimate based on the available data. 
Eventually the sequence converges to the stationary distributions f(θ| Y
O
), the 




), the predictive distribution 
of the missing data (Schafer, 1997, Chapter 3). The rate of convergence depends on 
the fraction of missing data and on the choice of starting values. Iterative algorithms 





3.4.6.2 Making imputations with MCMC 
The iterative chain is started off by choosing a set of initial values for either the 
missing data or the parameters. Let θ
(0)
 denote some initial values for the parameters. 
These initial parameter estimates could for example be based on the complete cases. 
Next, the initial parameters are used to generate the first iteration Y
M(1)
 of the missing 
values. These in turn are fed back into the posterior for the parameters to create θ
(1)
. 




















are then repeated many times until convergence is reached. The Y
M 
from the last 


















) generated by 
cycling through (3.4) and (3.5) defines a Markov chain where, at each step in the 









) from the previous step (Schafer, 1999). MI requires independent draws 
from the stationary distributions to produce m separate datasets. These may all be 
obtained from the same chain by allowing for a large number of iterations between 
each draw to ensure that the correlation between consecutive draws is negligible. 
Alternatively separate chains may be used for each of the m imputed datasets. 
 
3.4.6.3 When is convergence obtained? 
Although convergence to the stationary distributions can be demonstrated to have 
been obtained in some simple examples it is notoriously difficult to ascertain exactly 
when this happens in general. Various techniques exist for assessing when 
convergence has occurred. These include inspecting time-series plots of the 
simulated draws from consecutive iterations of the MCMC chain, running parallel 
chains initiated with different starting values and calculating measures of 





3.4.6.4 Why the multivariate normal distribution? 
In principle the above modelling method could be applied with other 
multidimensional probability distributions other than the multivariate normal 
distribution. In practice such alternative multivariate distributions are a challenge 
because we would need to specify the full joint distribution to generate the random 
draws. This is in contrast to MI methods using Chained Equations (see below) that 
do not require the specification of a genuine joint distribution. 
 
Interestingly, some good results have been obtained with MI based on the 
multivariate normal model even for variables that are clearly not normally 
distributed. Success has been reported not only with ordered categorical, but even 
binary data (Schafer, 1997, Section 5.1). MI based on the multivariate normal model 
can perform well when the fraction of missing data is small and when the imputed 
variables are not too skewed. 
 
Molenberghs & Kenward (2007) point out that the sequential regression method and 
the MCMC method should yield almost identical results when the data to be 
modelled are from a genuine multivariate normal distribution and the missingness 
pattern is monotone. However there may still be small discrepancies depending on 
the choice of prior for the parameters and when the sample size is too small to rely 
on asymptotic normality.  
 
3.4.7 MI using chained equations (MICE) 
More recently an alternative MI method for the imputation of multivariate non-
normal data has been put forward. The method known as MI using Chained 
Equations (MICE) or MI using Fully Conditional Specification (van Buuren, 2007) 
differs from the multivariate normal imputation previously described in that it does 






The use of MICE is particularly useful with non-monotone missing data in datasets 
involving different types of variables. For example, using MICE it is straightforward 
to impute inter-dependent binary, ordinal, categorical and quantitative variables 
within the same dataset. A separate univariate model is specified for each variable to 
be imputed such that an appropriate model can be chosen for the particular type of 
data being imputed. E.g. a logistic model can be used for binary variables, an ordinal 
regression for ordered categorical variables etc. MICE then uses an iterative 
algorithm to model the conditional distribution of each incomplete variable 
conditional on all the other variables in the model. Starting with a set of initial 
imputations for the missing data, the conditional models are processed in sequence 
and the imputations updated at each iteration. By continually conditioning on the 
most recently updated version of the predictor variables the imputed variables 
eventually converge to a stationary distribution which, it is hoped, correspond to a 
true underlying joint distribution of the incomplete variables. 
 
In fact it is not guaranteed that the limiting distribution of the imputations obtained in 
this manner will converge to some theoretical joint distribution (Kenward & 
Carpenter, 2007). However, despite the lack of a theoretical basis this method has 
produced good results in practical applications and simulation studies (e.g. Lee & 
Carlin, 2010). van Buuren (2007) concludes that MICE provides: “a useful and easily 
applied flexible alternative to JM [joint modelling] when no convenient and realistic 
joint distribution can be specified.” 
 
3.4.8 Is MI just making up data? 
MI is a powerful method for gaining inference with incomplete data through efficient 
use of the available data. Unlike the direct likelihood method, MI does rely on 
stochastic imputations of the missing data. Some find this idea unsettling and may 
dismiss MI as a procedure for making up data where none was observed. Certainly 
the gain in efficiency from using MI over a simple analysis of the available data may 
seem to suggest that we are getting something for nothing. However this efficiency 
gain is just as real as that achieved through a likelihood-based analysis and is simply 




provides a flexible alternative when direct likelihood methods are impractical or 
demand the specification of unfeasibly complicated models. In fact, MI and the 
method of direct likelihood are asymptotically equivalent in the sense that one would 
obtain virtually identical results using either approach when the number of 
imputations m is large. 
 
There are assumptions behind any analysis with missing data. A complete-case or 
available-case analysis may be less controversial with some researchers than an 
analysis based on MI as these types of analysis do not force us to make explicit 
assumptions about the missing values. In fact a complete-case analysis relies on 
much stronger (but implicit) assumptions about the unobserved values than does a 
MI analysis.  
 
3.5 The fully Bayesian approach 
In a fully Bayesian analysis missing data are treated as unknown quantities on a par 
with unknown parameters (Lunn et al., 2013). Just as an unknown parameter is 
estimated in terms of a posterior distribution, a posterior-predictive distribution, 
f( y~ |y) for the missing data can be derived from the data likelihood and prior 
specifications for the parameters. The predictive distribution can then be used to 
simulate realisations of the missing values as is the case with MI. However deriving 
the posterior-predictive distribution for the missing data is not a requirement for 
obtaining valid posterior estimates of the parameters. Posterior distributions for the 
model parameters can be readily obtained as long as the data likelihood has been 
fully specified along with the relevant prior distributions. This method deviates from 
the direct likelihood method only to the extent that the prior distributions contribute 
to the Bayesian analysis.  The two methods are essentially equivalent when the prior 
distributions are flat relative to the data likelihood. There are obviously also very 
close ties between the fully Bayesian approach and multiple imputation methods 
since the latter rely on the Bayesian predictive distribution to simulate realisations of 
the missing data, the m imputed datasets. Thus MI and the fully Bayesian approach 
are essentially equivalent when m approaches infinity. The use of Bayesian methods 





3.6 Informative missingness 
In the present chapter we have primarily discussed methods for handling data under 
the assumption that the data were MAR. However in practice it is rarely possible to 
rule out the possibility that the data are MNAR. 
 
When that is the case, missingness is said to be informative because the very fact that 
an observation is missing has a direct bearing on the unobserved value itself.  The 
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This is known as the pattern-mixture model (PMM) factorisation. (Molenberghs & 
Kenward (2007, Chapters 17 and 24) also give details of a third family of models, 
shared-parameter models, that allow the joint distribution for Y and R to be specified 
in terms of shared random effects or latent variables. These model are less common 
and, although interesting and with the offer of added flexibility, we are unable to 
consider these further within the scope of the current project). 
 
Whether fitting a selection model or a PMM, when the missingness process is non-
ignorable it is necessary to specify the relationship between R and Y
M












 | R, θ) in the 
pattern-mixture model.  
 
The nature of this relationship cannot be estimated from the incomplete data itself. 
The model specification is therefore often the result of untestable assumptions based 
on the context that gave rise to the data, and perhaps some external evidence.  
 
Because of the inherent uncertainty associated with analysis of MNAR data it is not 
unusual to base a main analysis around the MAR assumption, but then refit the 
model under several different MNAR scenarios as a means of testing the sensitivity 
of the main findings to deviations from the MAR assumption. For example, using a 
selection model it may be reasonable to specify the non-response mechanism, 
conditional on the unobserved data, such that the deviation from the MAR 
assumption is quantified in a single parameter. Letting πi denote the probability that 




such that β=0 is consistent with the MAR assumption while any non-zero value for β 
represents a deviation from the MAR assumption. β cannot itself be estimated from 
the data. α represents the level of missingness in Yi when Yi=0 and is estimated from 
the data once β is fixed. The model is evaluated under a range of plausible values for 
β and the impact on the main findings assessed.  
 
In the present chapter we have presented the principled approaches of direct 
likelihood, MI and the fully Bayesian approach primarily in the context of ignorable 
missingness. Each of these methods can be applied when the missingness process is 
non-ignorable. As we have seen this requires that the full joint likelihood for the 
response and non-response mechanism be fitted. Such likelihood functions tend to be 
intractable and require numerical optimisation techniques. MNAR models are not 
easily accommodated in most standard statistical software packages, although it is 




models using MCMC methods, for example as implemented in WinBUGS. Analysis 





4 REGRESSION TO THE MEAN 
The Symptom Monitoring Service (SMS) was introduced briefly in section 1.2 and 
serves as an example of a clinical service that routinely collects patient outcomes 
over time at intervals determined by the timing of patients’ appointments. Patients 
were asked to complete the distress symptom screening questionnaire in the waiting 
areas of screened oncology outpatient clinics, either on paper or on touch screen 
computers, whilst waiting for their consultation.  
 
The SMS questionnaire enquired about symptoms of psychological distress and it 
was therefore important to assess whether a medical clinic is a suitable setting in 
which to screen patients for distress. It is possible that patients’ distress scores were 
affected by the clinic surroundings, and in anticipation of the imminent appointment. 
If it were the case that distress scores were transiently inflated due to the clinic 
setting, it would question the clinical usefulness of the ratings and the validity of the 
screening approach in general.  
 
The POD Study, which is the subject of Chapter 5, examines the persistence and 
development over time of symptoms in cancer outpatients who were identified with 
significant distress symptoms in clinic. It is relevant therefore whether a high score 
in clinic is a good indicator of patients’ true underlying distress status, and whether 
the clinic scores are comparable to scores obtained over the telephone from patients 
when in their own homes.  
 
In addressing these questions this chapter will focus on the nature of repeated distress 
scores. We will consider how scores are correlated and how the correlation may be 
used to model changes over time including regression to the mean, and how this 
relates to the idea of persistence. 
 
4.1 Background 
The Symptom Monitoring Service (SMS) operated in selected National Health 
Service oncology outpatient clinics in Scotland, UK, between May 2008 and August 




clinic waiting area and asked to complete a questionnaire which enquired about 
physical and psychological symptoms. The questionnaire answers were used to help 
the oncologists address issues that were of concern to the patients, and also to help 
identify patients with major depression for subsequent eligibility assessment for 
enrolment into the SMaRT Oncology-2 and -3 trials. 
 
Prior to each clinic the SMS received a complete list of names of patients scheduled 
for appointments. The service aimed to screen all patients who attended, although a 
small proportion of patients did not complete screening because they were missed 
(typically because they were taken straight for their appointments before the SMS 
could approach them), were excluded from the screening service on medical grounds 
or refused to complete the symptom screening questionnaire.  
 
There were three parts to the SMS questionnaire. The first part consisted of the 
Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983), which 
asks patients about symptoms of emotional distress. It consists of two subscales: an 
anxiety and a depression subscale each containing 7 items scored on a 0 to 3 scale, 
resulting in a total HADS score ranging from 0 (no distress) to 42 (maximal distress). 
The second part consisted of the five questions from the EQ-5D (The EuroQol 
Group, 1990). Finally in the third part, patients were asked to rate on a 0-to-10 scale 
how bothered they had been over the last week by each of the following symptoms: 
pain, fatigue, disturbed sleep and nausea or vomiting.  
 
To identify patients likely to suffer from depression, the SMS sought to follow up on 
everyone who was identified with symptoms of significant distress. Scoring 15 or 
more on the HADS has been shown to provide a good indication of depressive or 
anxiety disorder (Walker et al., 2007). Patients who scored 15 or more on the HADS 
in clinic were therefore telephoned one or two weeks later and asked to complete the 
part of the SCID (Structured Clinical Interview for Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV); First et al., 1999) that relates to depression. Because 
the HADS scores that were collected in clinic were used to identify patients likely to 




picture of patients’ psychological well-being. Might the service be labelling high 
scoring patients as distressed when actually their scores were artificially inflated due 
to the potentially stressful circumstances? The implications would be that too many 
patients were interviewed for depression during the subsequent follow-up telephone 
call causing unnecessary inconvenience to patients and wasting the resources of the 
service.  
 
To address the issue, the service conducted an audit during the period from March to 
April 2009. Patients who scored high on the HADS in clinic (score ≥ 15) during this 
period were extraordinarily asked to complete the HADS a second time at the 
beginning of the telephone interview for depression routinely carried out in the high 
scorers approximately seven days after the clinic appointment. Patients’ scores on the 
second HADS were then compared to the scores obtained in clinic.  
 
Specifically, the purpose of the audit was to (a) determine the number of patients 
who scored 15 or above on the HADS in clinic who no longer scored above 15 when 
assessed at home, and (b) determine the mean change in scores over the two 
assessments. 
 
4.2 A challenging design 
Ideally the questions posed above would be addressed using a suitable test-retest 
design in which all patients were followed up regardless of their clinic HADS score. 
This would allow for a direct interpretation of the mean scores and observed 
proportions at the two time points. 
 
The SMS screened a large number of patients each day. Around a fifth of those who 
were screened scored high on the HADS and needed further assessed over the 
telephone. To follow up on everyone, the service would have had to interview five 
times as many patients. As this was not a feasible option, only patients who scored 





However, unless there is perfect correlation between repeated HADS scores we 
would expect to see some regression to the mean. This means that at least some of 




Figure 4.1. Simulation of 1000 test-retest patient scores from a stationary distribution. The 
cut point separates low scores from high scorers on the two occasions. Patients who scored 
on different sides of the threshold on the two tests are indicated in red. The diagonal line is 
the line of perfect agreement. 
  
Senn (2009) used an illustration similar to that in Figure 4.1 to illustrate the artificial 
effect induced by regression to the mean. Patients who score high will on average 
score lower on reassessment. Of the patients who score above the threshold on the 
first assessment (right side of the vertical dashed line) a considerable proportion 
proceed to score below the threshold on the second assessment (bottom right corner) 
despite there being no overall change in scores between the two assessments.  
 
4.3 Why might patients score differently on reassessment? 
Conceptually we may think of an observed HADS score as resulting from three 




representing their actual distress level. Secondly the observed score is affected by 
factors influenced by the patient’s immediate environment (e.g. was the 
questionnaire read out to the patient over the telephone, or handed to them on paper). 
Finally, the score is also affected by random measurement error. 
 
All three contributing factors can change over time. Indeed, patients who took part in 
the HADS audit were reassessed approximately one week after the clinic assessment; 
it would be naïve to assume that the underlying distress levels of individual patients 
were constant over this interval. In the immediate environment things were different 
too. The HADS was completed over the telephone from the patient’s own home, and 
not on paper or touch-screen computer in the clinic. Finally, random error also has 
the potential to cause two very different scores. The possible causes behind patients 
in the HADS audit scoring differently at home compared to when in clinic are listed 
in Table 4.1.  
 




Patients’ true underlying scores could have changed since 
the first assessment. 
 
2. The questionnaires were administered over the telephone 
on the second occasion. This might have caused patients 
to score the instrument differently. 
 
3. Patients might have been anxious about the outcome of 
the upcoming appointment when assessed in clinic. This 
could have caused them to score higher in clinic. 
 
4. Random error in the measurements (not including 
regression to the mean) may have resulted in spurious 
change. 
 
5. The findings may have been confounded by regression to 
the mean due to the design. 
 
 
Considering each of these causes we note firstly that while individual patients may 
experience changes in their underlying, true distress levels over a period of seven 
days there is no reason to believe that the sample as a whole should have changed. 
Secondly, it does not seem very likely that patient scores were considerably different 




Indeed Pinto-Meza et al. (2005) examined the method of administration of the PHQ-
9, a similar instrument to the HADS, and found that there was good agreement 
between self-administered and telephone-administered questionnaires. Lastly, the 
fluctuations caused by random error will average out with increasing n, the number 
of patients sampled, since the mean of the error term is zero. Practically therefore, 
the only plausible reasons for an overall change in the scores are the different setting 
(clinic versus home) and regression to the mean. 
 
4.4 Regression to the mean 
Having established that any observed change in scores on reassessment is likely to be 
due, at least in part, to regression to the mean (RTM), can we say anything more 
about the likely size of this effect? 
 
The RTM effect depends on the strength of the correlation in the data. If there is no 
correlation between repeated scores, a sort of memory-less sequence, then the RTM 
effect will be at its greatest. The distribution of individual patients’ scores will be the 
same as that of scores in the overall population. If there is perfect correlation then 
there is no measurement error, and repeated scores from the same patient will be 
exactly equal, i.e. there is no RTM effect. 
 
Crucial to the question is therefore what we might expect the correlation to be 
between repeated scores on the HADS. Distress is a dynamic variable, so the answer 
presumably depends on the time between the assessments. Perhaps we should expect 
a near-perfect correlation in assessments obtained just after one another, while, as 
time goes on, symptoms change and correlations become weaker. Although we might 
expect a weakening correlation over time it seems unlikely that this would ever 
approach zero: Even after many, many months there might still be some subject 
effect due to invariable personality or mood traits. Further on in section 4.7 we shall 
focus on modelling this correlation over time in order to estimate the correlation of 





The effect of regression to the mean has been well known for a long time. Galton 
(1886) described the phenomenon in his article “Regression towards mediocrity in 
hereditary stature” examining the relationship between the heights of adult children 
and their parents. Nonetheless, researchers unaware of the pitfalls of RTM continue 
to misinterpret their findings from time to time. Numerous papers have been 
published on the topic warning researchers of the untoward effect, recommending 
study designs to alleviate the effect, and advising on how to analyse data 
appropriately in the presence of RTM (e.g. Davis, 1976; Das & Mulder, 1983; Beath 
& Dobson, 1991; Senn, 2007; Barnett, van der Pols & Dobson, 2005).  
 
We know that changes observed within the HADS audit test-retest design would 
have been affected by regression to the mean, and we wish to estimate the size of this 
effect. The effect can be described as the expected difference between a pair of 
repeated HADS scores, conditional on the first score being equal to, or more than, 
15: 
E[H1 – H2 | H1 ≥ 15] 
 
Above, H1 and H2 are random variables denoting the HADS scores at time one and 
two respectively. In sections 4.6 – 4.9 we will apply the approach developed by Das 
& Mulder (1983) to estimate this quantity. For now however we will focus on the 
scores actually observed in the HADS audit.  
 
4.5 Results 
During the audit period 395 patients were identified as high scorers in clinic. Eighty 
three percent of these (329 patients) were eligible for a follow-up assessment and 218 
patients (66% of those eligible) were successfully assessed a second time and their 
data included in the analysis. Reasons for exclusion are shown in Figure 4.2. The 
main reason for exclusion was that the patient could not be telephoned by the service 





   
Figure 4.2. Derivation of sample of patient data used in the analysis. 
 
The patients whose data were included in the analysis had attended clinics that 
specialised in breast (83), colorectal (18), gastrointestinal (15), gynae (33), lung (47), 
sarcoma (4), urology (14) and miscellaneous cancers (4). Seventy three percent 
(159/218) of the patients were female and the median age was 61 years (interquartile 
range: 53 to 70 years). The HADS scores, age and sex distributions of the sample 
included were similar to those of eligible patients who were not included in the 
analysis (Table 4.2). 
 
The median interval between the clinic and follow up assessments was six days 
(interquartile range: 5 to 8 days). The distributions of HADS scores when: (a) 
patients were assessed in clinic and (b) when followed up approximately one week 
later at home are shown in Figure 4.3. 
Cognitive impairment  n = 4 
Exclusion by clinician  n = 8 
Hearing or language difficulties n = 13 
Recent interview for depression n = 41 
 
Patients with follow up HADS 
included in analysis  
n = 218 
 
Patients identified with distress 
(HADS ≥ 15) 
n = 395 
Not included in analysis  n=111 
 
   Admitted to hospital  n = 1 
   Deceased   n = 1 
   Refused   n = 21 
   Not contacted in time window n = 88 
Distressed patients
 
(HADS ≥ 15) 
eligible for follow up HADS 




Table 4.2. Characteristics of the analysed sample compared with those of eligible patients 
not included. 
 Eligible patients 
included for analysis 
 Eligible patients not 




 n = 218  N=111   
      
Age in years     0.954 
  Mean (SD) 61.4 (11.5)  61.3 (12.2)   
  Median (range) 61.4 (25.3 to 87.7)  62.5 (28.7 to 89.8)   
      
Age categories:     0.736 
  ≤50 38 (17%)  23 (21%)   
  51-60 67 (31%)  28 (25%)   
  61-70 66 (30%)  35 (32%)   
  ≥ 71 47 (22%)  25 (23%)   
      
Gender     0.396 
  Male 59 (27%)  35 (32%)   
  Female 159 (73%)  76 (68%)   
      
HADS scores     0.356 
  Mean (SD) 20.1 ( 4.7)  20.6 ( 4.8)   
  Median (range) 19 (15 to 37)  19 (15 to 34)   
      
HADS score categories     0.604 
  15-19 115 (53%)  59 (53%)   
  20-24 66 (30%)  29 (26%)   
  ≥ 25 37 (17%)  23 (21%)   
      
a
 Age in years and HADS scores were compared using Wilcoxon rank sum test.  The three 
other p-values were from chi-square tests. 
 
Figure 4.4 shows the change in HADS score from clinic to follow-up plotted against 
initial HADS score in clinic. There was considerable variability in the change scores 
with some patients scoring much higher and some much lower on reassessment. 
Most patients whose scores fell below 15 at follow up scored only slightly above 15 
in clinic. 
 
Almost three quarters (72.5%; 158/218) of patients remained high scorers on the 
follow up assessment (95% CI: 66.6 to 78.4%). Most patients who were no longer 
high scorers continued to have elevated scores (between 10 and 14). The mean score 
at follow-up was 18.4, a reduction of 1.74 units (95% CI from 1.09 to 2.39) from the 
clinic visit. The reduction in the anxiety subscale score was 1.26 units (95% CI: 0.84 
to 1.67) while the depression subscale dropped by just 0.48 units (95% CI: 0.12 to 








Figure 4.3. HADS scores of patients (n=218) in the study sample (a) when assessed in clinic 






Figure 4.4. Change in HADS total score from clinic to follow up plotted against initial HADS 
score in clinic. Circles indicate patients whose reassessment score fell below 15. Patients 
plotted above the dashed line had a higher HADS score on reassessment while those below 





4.6 Estimating the RTM effect 
When completing the HADS at home patients scored on average 1.74 points lower 
on the total scale than they had done a week earlier in the clinic, with a larger 
reduction on the anxiety subscale. Between a quarter and a third of patients scored 
below the distress threshold of 15 on the follow up HADS. Some of this change may 
reflect a real difference in scores on the two occasions, presumably because of the 
change in setting. On the other hand, we would expect part of this change to be an 
artefact caused by regression to the mean. In the following sections we will attempt 
to quantify this effect. 
 
 
Figure 4.5. Distribution of outpatient HADS scores. 
 
The distribution of HADS scores as collected by the Symptom Monitoring Service 
from the outpatient cancer population is presented in Figure 4.5. The scores are 
treated as random variables that are subject to variance terms. Some of the variance 
comes from inter-subject variability: patients are different and will score according to 
their individual mood characteristics. The remainder of the variance will be 
attributed to intra-subject variability, akin to random variation or measurement error 





The total variance, 2t , can therefore be written: 
222
est   . Here, 
2
s  denotes 
the variance arising from heterogeneity between subjects, while 2e  is the random 
error. 2s  is also the covariance between repeated measurements within the same 
subject, and ρ = 2s / 
2
t  is the correlation. 
 
The HADS score, H, can then be thought of as the sum of the random variable S, 
denoting the patients’ true score, and e, the random error. S is distributed according 
to some density function f with variance 2s . We will assume that the random errors 
are distributed according to N(0, 2e ). 
 
We wish to estimate the expected difference between a pair of repeated HADS 
scores, H1 and H2, conditional on the first score being equal to, or more than, 15,  
E[H1 – H2 | H1 ≥ 15] . 
 
For a continuous H it can be shown that 
 












Above g(hc) is the probability density function for H evaluated at hc and G(hc) is the 
corresponding cumulative distribution function. This approach by Das & Mulder 
(1983) allows for an arbitrary g, although the errors are assumed normally 
distributed.  
 
From the large sample of scores collected by the Symptom Monitoring Service we 
may obtain estimates of g(hc) and G(hc). Estimating these quantities is the topic of 
section 4.8. 
 
Given appropriate values for g(hc) and G(hc) the effect size depends on (1-ρ)
2
t . The 
RTM effect is proportional to (1-ρ). A central task is therefore estimating ρ, or 





4.7 Estimating correlation parameters 
Only a very small proportion of patients screened by the Symptom Monitoring 
Service were followed up more frequently than once a month. Hence there is very 
little data available on scores collected just one week apart. Even if the service had 
followed-up sufficiently many patients at this short an interval, such patients would 
likely differ from patients in the audit on disease and demographic characteristics. 
Estimates of the correlation, and indeed of the RTM effect, would not necessarily 
generalise to outpatients in general. 
 
Instead the SMS data will be used to model the variance-covariance parameters as a 
function of time between repeat assessments. Once the model has been fitted it can 
be used to evaluate the parameter values at just seven days.  
 
In the first instance we will assume that the covariance of repeated scores is 
independent of the time between the assessments, i.e. that the covariance is constant 
over time. 
 
The following linear model (Model 1) was fitted to the data 
 
Yi = Xiβ + ei 
 

































is the design matrix with tij denoting the time (in weeks) of the jth visit for patient i 

































is the vector of random errors. The eij‘s are distributed according to the multivariate 
normal distribution with 0 mean vector and covariance matrix Σ with all diagonal 




The model parameters were fitted by (restricted) maximum likelihood estimation 
(REML) using the Mixed Procedure in the SAS software.  
 
Fitting this model the variance was estimated to be 2t = 52, the covariance 
2
s =37, 
and therefore the correlation between repeated measurements within the same subject 
ρ=0.71. 
 
It seems unlikely that the covariance, or equivalently the correlation, should be 
constant over time. A time-dependent covariance pattern was therefore fitted instead 
(Model 2) to allow correlations to deteriorate over time using the following 
functional form: 
 
)(2 ikij tt   
 
Here (tij – tik) is the time (in weeks) between the jth and the kth measurement. This 
so-called exponential covariance pattern will ensure perfect correlation when tij = tik, 
but also imposes an increasingly weak correlation when assessments are further 
separated in time. Using this pattern for the covariance yielded the following 
estimates: 2 =53 and Ρ=0.95. According to this model the correlation between two 
measurements one week apart was therefore 0.95. The correlations quickly weakened 
to 0.85 after four weeks, 0.60 after three months and 0.30 after half a year. The 
correlation coefficient between two measurements one year apart was just 0.08 




some dependency to remain between measurements taken from the same subject 
regardless of the time between the assessments. This feature will be accommodated 
in Model 3. 
 
Before introducing the final model, we note that the compound symmetry from the 
covariance matrix in Model 1 can equally be achieved by fitting a linear model with 
a random intercept.  
 
Yi = Xiβ + bi + ei 
 
Here bi ~ N(0,
2
s ) is a subject-specific random offset imposing dependency between 
repeated measurements within the same subject. ei = [ei1, ei2, …, eini]′ is the vector of 
independent, identically distributed measurement errors with eij ~ N(0, 
2
e ). With 
this model the covariance matrix for the responses is Cov(Yi) = V with all diagonal 
elements of V equal to 22 es    and all off-diagonal elements equal to 
2
s  exactly as 
in the first model. 
 
We wish to induce a time-dependency in the correlations without forcing a near-zero 
correlation when measurements are far apart or a perfect correlation when 
measurements are close in time. This may be achieved by relaxing the assumption of 
independence among the eij’s in the random intercept model. Instead eij will be 
modelled according to the multivariate normal distribution with mean 0 and 




  and all off-
diagonal entries equal to 
)(2 ikij tt  . The four covariance parameters fitted using this 
model (Model 3) were 2s =34, 
2
e =7, 
2 =10  and Ρ =0.86. The variance  
 
Var(Yij) = 
222   se = 51.8 
 












is time-dependent but bounded by 22  s = 44 when tij – tik  = 0 and 
2
s = 34 when  
tij – tik = ∞. This means that ρ, the correlation between repeated measurements, is 
between 0.66 and 0.86 depending on the separation in time between the assessments. 
Evaluated at tij – tik = 1 week the correlation is ρ=0.83.  
 
We opted not to base the analysis on the observed correlation between pairs of 
measurements obtained seven days apart for fear that patients with such abnormal 
clinic visit patterns would not be representative of the sample in general (and due to 
the limited number of such observed pairs). Nonetheless, having modelled the 
correlation it is still of interest to compare the resultant estimate with the observed 
correlation between measurements obtained seven days apart because good 
agreement between the two should increase our confidence that the modelled 
estimate is a reasonable one,  more so than if the two differed markedly. (Of course 
there is still the possibility that both estimates could be wrong albeit for different 
reasons.) The observed correlation coefficient between 64 pairs of measurements 
obtained seven days apart in the SMS data was 0.86 (95% CI: 0.78 to 0.91). The 
modelled estimate therefore appears to be in good agreement with the observed 
correlation in the data.  
 
The -2 x log-likelihood statistics for Models 1, 2 and 3 above were 90727, 92023 and 
90548 respectively. Model 2 is a special case of Model 3 with 2e  = 
2
s  = 0. 
Model 1 is also a special case of Model 3 with 
)(2 ikij tt  = 0. Likelihood ratio tests 
comparing Model 3 to Model 1 (G
2
=180; df=2; p<0.001) and to Model 2 
(G
2
=1475; df=2; p<0.001) provide evidence that Model 3 provided in a better fit. 
The Akaike Information Criterion (AIC) values were 90731.4, 92027.0 and 90555.7 






Extensive exploratory analysis of the correlation structures in the data suggested a 
slow decay of the strength of correlation between pairs of observations with 
increasing time separation. The covariance structure fitted under Model 3 allows for 
a correlation between pairs of observations that decreases exponentially with the 
separation in time between the points. The exponential correlation model is 
immediately obvious when using the parameterisation P = e
-θ
. This, when coupled 
with 2e  and 
2
s , provides a flexible model that allows for a wide range of 
covariance patterns. We could have justified this model by testing it against an even 
more flexible model with further covariance parameters, however as is apparent from 
the variograms (Diggle et al., 2002) presented in Figure 4.6, the covariance structure 









Figure 4.6. Diggle’s variogram (a) under Model 3, and (b) derived from the sample 
residuals for time lags ≤ 20 weeks. The lower and upper horizontal lines indicate the 
model estimates of 2e  and 
2
e +





4.8 The continuity problem 
In the best fitting model for the covariance above, the covariance of two 
measurements, Y1 and Y2, obtained one week apart was estimated to be 
Cov(Y1,Y2) = 43, accounting for ρ = 43.0/51.8 = 0.83 of the total variance. We now 
need to determine the values of g(hc) and G(hc), the density and the cumulative 
distribution functions evaluated at hc, the cut-off for significant distress. 
 
Determining these quantities requires knowledge of the overall distribution of HADS 
scores in the outpatient population. While we may not know the algebraic form of the 
probability density function, we can obtain the empirical distribution from the 
thousands of HADS scores collected by the Symptom Monitoring Service.  
 
In some cases these data consist of several repeated scores from the same patients. 
We are interested in the distribution of a HADS score obtained at random from the 
population of outpatients where each patient is weighted equally. To obtain the 
distribution of HADS scores we will therefore sample one score randomly from each 
patient in the SMS database, then record the observed frequencies. The empirical 




Table 4.3. Empirical distribution of HADS scores among 17,599 cancer outpatients seen by 









H0 P(H=H0) P(H≤H0)  H0 P(H=H0) P(H≤H0) 
       
0 0.037 0.037  22 0.016 0.929 
1 0.049 0.085  23 0.013 0.943 
2 0.054 0.139  24 0.010 0.953 
3 0.056 0.196  25 0.009 0.962 
4 0.060 0.255  26 0.007 0.970 
5 0.065 0.320  27 0.006 0.976 
6 0.059 0.379  28 0.005 0.981 
7 0.059 0.438  29 0.004 0.985 
8 0.054 0.492  30 0.003 0.988 
9 0.051 0.544  31 0.003 0.991 
10 0.049 0.592  32 0.002 0.993 
11 0.043 0.636  33 0.002 0.995 
12 0.041 0.676  34 0.002 0.996 
13 0.037 0.714  35 0.001 0.997 
14 0.035 0.749  36 0.001 0.998 
15 0.034 0.783  37 0.001 0.999 
16 0.029 0.812  38 0.000 1.000 
17 0.024 0.836  39 0.000 1.000 
18 0.021 0.857  40 0.000 1.000 
19 0.021 0.878  41 0.000 1.000 
20 0.019 0.897  42 0.000 1.000 
21 0.017 0.913     
       
 
 
Having obtained the empirical distribution of HADS scores we can proceed to 
evaluate g(hc) and G(hc). These are the theoretical density and cumulative 
distribution functions of a truly continuous score. Of course with a truly continuous 
random variable, H, the probability of H taking the exact value hc is zero. For a 
continuous H therefore    
 
E[H1 – H2 | H1 > hc] = E[H1 – H2 | H1 ≥ hc] 
 
This is clearly not the case when H is discrete, and the challenge is therefore how to 
choose hc. We wish to determine E[H1 – H2 | H1 ≥ 15], which for a discrete H is 
equivalent to E[H1 – H2 | H1 > 14]. But letting hc = 14 means evaluating g(hc) and 





For the discrete case, G(14) = p(H ≤ 14). Therefore 1-G(14) is the proportion of 
patients who score 15 or more, which is the quantity we are seeking. On the other 
hand g(14) is the probability of a patient scoring 14 on the HADS, whereas we wish 
to evaluate g exactly where the cut-point is. 
 
Suppose that underlying each observed HADS score, H, is a true continuous score, Z, 
and that H=H0 when H0 – 0.5 < Z < H0 + 0.5. Patients would then score above the 
cut-off when Z > 14.5, and below otherwise. The values of g evaluated at hc=14 and 
hc=15 are 0.03540 and 0.03415 respectively. In approximating the continuous curve 
at hc=14.5 we shall let g(14.5) assume the middle value of 0.03478. From table 4 we 
also find that G(14) = 0.749 (or equivalently that G(14.5) = 0.749 under the above 
scenario for an underlying continuous mechanism). 
 
The expected change caused by regression to the mean can then be estimated as 
 











               E[H1 – H2 | H1 > 14.5] = (8.754) 
25104.0
03478.0
 = 1.213 
 
That is, we would expect patients to score lower on the follow up assessment by an 
average of 1.21 units on the HADS scale. Any reduction of this magnitude may 
therefore be attributed to regression to the mean rather than an actual difference in 
HADS scores on the two occasions.  
 
4.9 Quantifying uncertainty 
The estimate of the RTM effect obtained above is subject to random variation. The 
estimated effect size is a function of four covariance parameter estimates as well as 
the two estimated functions g and G evaluated at hc. It was therefore important to 





To do so, Model 3 from section 4.7 was applied with 500 bootstrap samples to obtain 
500 sets of covariance parameter estimates. Similarly, the distribution of HADS 
scores was derived repeatedly from 500 bootstrap samples to obtain 500 estimates of 
g and G evaluated at hc. Together these bootstrap estimates were used to obtain 500 
estimates of the RTM effect which, when arranged in ascending order, could be used 
to obtain a 95% quantile-based confidence interval for the true RTM effect. 
 
Using this method we found that the central 95% quantile-based confidence interval 
ranged from 1.02 to 1.43.  
 
4.10 The subscale dimensions 
We had hypothesised that any additional distress experienced by patients in clinic, 
either as a result of the clinical environment or due to concerns about the possible 
outcomes of their upcoming appointment, would cause an increase in the anxiety 
scores but have less of an influence on the depression scores.  
 
We found that the anxiety subscale scores fell by 1.26 points on average compared 
with just 0.48 points on the depression subscale. But does the larger drop on the 
anxiety subscale reflect fundamental differences between these two dimensions? 
Alternatively, could it simply be that the regression-to-mean effect is larger on the 
anxiety subscale? 
 
In addressing this question one would need to estimate the expected change in the 
subscale scores conditional on the HADS total score from the first assessment being 
equal to or higher than 15. If we let A1, D1, A2 and D2 denote the anxiety and 
depression subscale scores on two occasions respectively and further let  
H1 = A1 + D1 be the HADS total score as before, we would then need to determine 
 
E[A1 – A2 | H1 ≥ 15] 
 





E[D1 – D2 | H1 ≥ 15] 
 
to estimate the effect on the depression subscale. Clearly, the estimation task is 
complicated by the higher dimensionality of the problem. Not only does the size of 
the effect depend on the joint distribution of longitudinal scores over time; it also 
depends on the joint distribution of the subscale scores. The problem of estimating 
the RTM effect individually for each subscale will not be pursued any further here. 
 
4.11 Discussion 
The audit described in this chapter was conducted to evaluate the strategy of asking 
patients to fill out a distress questionnaire while waiting for their appointment in 
clinic. The screening service routinely contacted patients who scored high in clinic 
for further assessment; it was therefore important to find out if patients’ HADS 
scores were artificially inflated due to transient anxiety in anticipation of the 
upcoming appointment since identifying a large number of false positives would be 
inefficient. 
 
When patients who scored 15 or more on the HADS in clinic were asked to complete 
the scale at home, a week later the mean change in scores was a reduction of 1.74 
units (95% CI from 1.09 to 2.39) from the clinic visit. 72.5% (158/218) of the 
patients remained high scorers. However it was estimated that patients would score 
1.21 units lower (95% CI from 1.02 to 1.43) on reassessment because of regression 
to the mean. This means that most of the observed drop could be accounted for by 
regression to the mean rather than an actual difference in scores on the two 
occasions.  
 
In conclusion, there was evidence of a good agreement between scores obtained in 
clinic and scores obtained from patients at home one week later. The method of 
asking patients to complete a distress questionnaire while they wait for their 






There were limitations to this study. We analysed data collected by a depression 
screening service operating in cancer clinics; the findings may not therefore 
generalise to other settings. The service only administered a second HADS to 
patients who had scored high in clinic. However, by analysing the data appropriately, 
taking into account the regression to the mean, the aims of the study were addressed 
adequately using the available data. The service only administered the second HADS 
as part of their follow-up call for a one month period; some patients could not be 
contacted during this limited period. However, the characteristics of patients on 
whom we had analysable data and those on whom we did not were similar; 
systematic bias is therefore unlikely. There may be limits to the intrinsic test-retest 
reliability of the HADS (as opposed to real changes in symptoms) but this is unlikely 
to be large over this time period or to represent a systematic bias. Finally, we were 
not able to assess the content of patients’ clinical consultations, the nature of which 
might have accounted for some of the changes in scores; for example, if patients had 
been given good news this may have contributed to a fall in the HADS score and if 
they were given bad news, to a rise. Although the average change in scores was small 
the intra-patient variability was high with some patients scoring very differently on 
reassessment. It is possible therefore that a minority of patients are affected 
considerably by the clinic surroundings while the majority of patients remain 
unaffected. At the individual patient level we cannot rule out the possibility of an 
important ‘clinic effect’ in some cases. 
 
The robustness of the RTM effect estimate was assessed in terms of sensitivity to 
random error. However sensitivity to a different model for the covariance was not 
assessed. Alternative models would yield different estimates for the covariance 
parameters. Nonetheless, the model selected fitted the data significantly better than 
the more parsimonious models, and the estimates from the model used were in good 
agreement with observed correlations in the SMS data. Even if the true correlation 
between repeated measurements obtained one week apart was as high as 0.90, the 
RTM effect would still be around 1.12. Similarly, a true correlation coefficient as 





We applied the Das & Mulder approach for continuous random variables to the 
quantitative, but discrete HADS scores. This was a particular problem when deciding 
how to choose hc, the cut-off used to indicate a high score. We considered the nature 
of a theoretical underlying continuous HADS score and argued that a 
dichotomisation of the continuous process, that separates subjects into those who 
score below and those who score equal to or above 15 on the discrete scale, should 
be somewhere between a score of 14 and 15. We used the Das and Mulder approach 
with some simulated data from a continuous random variable that had been 
discretised in the way postulated in section 4.8 for the theoretical continuous HADS 
score. The method produced very similar results whether applied with the discrete or 
the continuous data.  
 
We also assumed that the measurement errors or intra-patient variations were 
normally distributed. While this assumption is unlikely to hold entirely, it is at least 
likely that the intra-patient variations are symmetrically distributed about their means 
when S, the patient’s true score, is close to 15.  
 
The fitted model assumed homoscedastic error terms. We did not investigate this 
assumption although it is quite possible that individuals with elevated levels of 
distress were subject to greater intra-patient residual error. Since the variance 
parameters were modelled on the entire sample, the error variance and consequently 
the RTM effect are possibly somewhat underestimated as a result. However the 
presence of such a bias would not contradict our finding that the RTM effect 
accounted for most of the observed change in scores. 
 
Finally, it is possible that the method of administration of the HADS instrument 
produces an effect. Perhaps patients scored differently on follow up because the 
HADS was read out to them over the telephone? As mentioned in section 4.3 this 
effect is likely to be small. Moreover, from the point of view of aiming to provide an 
efficient symptom screening service it is almost immaterial what factors caused the 




out a questionnaire in clinic is a reasonably reliable one for identifying patients with 
symptoms of distress. 
 
4.11.2 In context 
The findings from the SMS audit are of relevance to the present project because they 
provide evidence that HADS scores obtained from patients in clinic are comparable 
with scores obtained from patients at home over the telephone, and may be used to 
identify patients likely to suffer from long-term distress. The problem of identifying 
patients likely to suffer from persistent distress is at the centre of the POD Study 






5 ANALYSIS OF THE POD STUDY 
The POD Study addresses some very concrete examples of research questions that 
could potentially be addressed using the SMS data. Because PODS was specifically 
designed to address these questions the study may be regarded as providing the 
correct answers in the sense that any analysis addressing these questions using SMS 
data should lead to similar findings.  
 
5.1 Background 
Symptoms of psychological distress are common in cancer patients. Some patients 
with such symptoms develop major depression and are likely to require treatment. 
Less is known about the development of symptoms in patients who are identified 
with psychological distress, but who are not clinically depressed. Are their symptoms 
likely to persist and therefore to require treatment? And do most of these patients 
eventually develop major depression? 
 
The POD Study was designed to investigate the course of symptoms over time in 
cancer outpatients who had been identified with distress by the SMS in a screened 
oncology outpatient clinic during a medical appointment, but who did not meet the 
criteria for major depression. A main aim of the study was to examine the persistence 
of patients’ distress symptoms over an extended period. The study also sought to 
determine the demographic, disease and early distress characteristics that might 
predict cases of persistent distress. In particular it was thought that a second ‘high 
reading’ would be instructive, a confirmation of the patient’s elevated distress level 
some time after the initial assessment. Another question of particular interest was 
therefore when to re-screen. What is the optimal time lag between the initial 
assessment and the confirmatory reading? 
 
5.2 Design overview 
Patients were followed up for a period of around seven months after the initial 
oncology outpatient clinic appointment. Patients who had scored 15 or more on the 
self-reported Hospital Anxiety and Depression Scale (HADS) in clinic (and who 




approximately four weeks later and asked to participate in the study. Patients who 
gave their consent proceeded to complete the first follow-up questionnaire and were 
subsequently asked to complete the questionnaire again over the telephone at 





Patients were recruited into the study between June 2009 and April 2010. Patients 
were identified through the Symptom Monitoring Service (SMS) which operated in a 
large number of cancer outpatient clinics in NHS Lothian and NHS Greater Glasgow 
and Clyde in Scotland. The procedures of the SMS were described in detail in section 
4.1.  
 
Patients who scored 15 or more on the HADS in clinic were telephoned one or two 
weeks later and asked to complete a clinical interview for depression using the SCID 
(Structured Clinical Interview for Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV); First et al., 1999). The SCID interviews were tape recorded for 
quality purposes and were conducted by trained nurses or psychology graduates 
under the supervision of a psychiatrist. A small number of patients who had been 
short listed for this interview either refused, were excluded on medical grounds, or 
because they had recently had an interview for depression, or could not be contacted 
within a reasonable time period. 
 
Of the patients who were interviewed, approximately one third were found to meet 
the criteria for Major Depressive Disorder (MDD). When a patient was identified 
with MDD a letter was issued to the patient’s General Practitioner informing them of 
this. In addition, if found eligible, the patient was also offered trial participation in 
one of the SMaRT-Oncology trials of specially designed interventions for patients 
with depression and cancer (SMaRT-Oncology 2, ISRCTN: 40568538; SMaRT-
Oncology 3, ISRCTN: 75905964). Descriptions of the two trials can be found in the 





The contact details of those who did not meet the criteria for MDD were passed on to 
the POD Study team with the permission of the patients. To be eligible for 
participation patients had to be aged 18 years or more and have a predicted survival, 
estimated by their cancer specialist, of 12 months or more. Eligible patients were sent 
a patient information leaflet informing them of the POD Study and were contacted 
within a couple of weeks by the PODS research team and asked to participate in the 
study. 
 
5.3.2 Data collected at follow-up 
The questionnaire completed in clinic was used as the baseline measure. The follow-
up questionnaires at four, eight, 16 and 28 weeks contained the same scales as the 
SMS questionnaire. In addition to the questions about pain, fatigue and disturbed 
sleep the follow-up questionnaires also asked about dry mouth, lack of appetite, 
numbness or tingling, shortness of breath and drowsiness. The follow-up 
questionnaires also asked about nausea and vomiting separately. In addition to the 
questionnaire data the PODS team obtained information from patients’ medical 
records after consent had been obtained at four weeks. Data on significant clinical 
events that occurred during the follow-up period were also obtained at the end of the 
study. 
 
5.3.3 Sample size 
A total of 325 patients were enrolled in the study during the recruitment period. The 
recruitment target of 350 patients was based on the number needed to obtain 
adequate stability in a logistic regression analysis at 28 weeks involving 10 
predictors. It was assumed that around one third of patients would still be distressed 
on the final assessment. With 350 patients enrolled, and an expected attrition rate of 
15% over the follow-up period, we anticipated around 100 events (distress cases) at 





5.4 Development of the study aims 
An important question was whether most patients identified with distress in clinic 
developed persistent distress. To address this question it was necessary to define the 
meaning of persistence. Patients’ HADS scores were measured at the oncology 
outpatients clinic visit and again at four, eight, 16 and 28 weeks afterwards. One very 
stringent criterion for meeting persistence would require that a patient score high (15 
or more on the HADS) on all four follow-up assessments. However this would 
exclude anybody who fell just below the threshold on any of the assessments. A less 
exclusive rule could define a patient with persistent distress as someone who had 
scored high on the HADS on at least two occasions, although this rule could 
potentially assert someone as persistently distressed who had not scored high since 
week eight.  Other alternative definitions included having a high score on both of 
week 16 and week 28 and having an average score of 15 or more across week 16 and 
28. We defined a patient with persistent distress as someone with a single high score 
at 28 weeks. This decision was based on a number of considerations. It was seen as a 
suitably uncomplicated endpoint that would allow for a clear clinical message in a 
published article. The definition had face validity since persistently distressed 
patients were required to have significant symptoms of distress at the end of the 
follow-up period. Having significant distress symptoms at clinic appointment and 
again seven months later was judged to be a likely indicator of serious clinical 
distress. Finally the number of missing data points were minimised using this 
definition since only a single observation at 28 weeks was required for a patient to be 
included in the analysis of persistence.  
 
Originally the study also sought to determine the number of patients who had 
developed major depression at 28 weeks. A depression screening interview was 
therefore conducted with all patients who had scored high on the HADS at the final 
assessment. Unfortunately, due to limited resources we were unable to carry out 






Another important aim of the study was to identify baseline demographic, clinical 
and early distress characteristics that might be associated with an increased 
probability of persistent distress. We hypothesised that repeating the screening one 
month after the oncology outpatient clinic would be useful in predicting long-term 
distress. Identifying such early predictors could potentially inform the recruitment 
strategy of a trial of an intervention for significant psychological distress.  
 
Finally, and somewhat unrelated to the present research project, the POD Study also 
sought to describe the quality of life and symptom burden of the study sample over 
the follow-up period. The questionnaires rated patients’ quality of life using the 
EQ5D and the symptom burden using the CSQ (see below). The analysis of the 
EQ5D and CSQ outcomes is not of direct relevance to this project and will not be 
presented here. 
 
5.5 Some design considerations 
5.5.1 Two alternative ways of anchoring the follow-up times 
Initially the intention was to only enrol patients who had scored high on the HADS 
on two separate occasions, first in the screened oncology outpatient clinic and second 
at a subsequent, confirmatory assessment carried out over the telephone 
approximately four weeks later. This was to avoid following up a large number of 
patients with transient distress whose symptoms were likely to stabilise within a 
short period of time once away from the hospital surroundings.  
 
However, before the recruitment phase commenced we decided to follow-up all 
eligible patients who had scored high on the clinic assessment without the need for a 
second high score. Having to score high on the second assessment placed a 
restriction on the pool of eligible patients. It also became clear that we needed to 
know how symptoms evolve in patients with early signs of transient distress as it was 
unclear when would be the optimal time to re-screen. An illustration of the designs is 














Figure 5.1. The PODS design with nominal time points anchored at (A) the first follow-up 
telephone call and (B) the oncology outpatient clinic visit. 
 
The initial plan was to carry out all analyses with reference to the first telephone 
assessment as the baseline assessment (approximately four weeks after the clinic 
assessment). Patients’ follow-up times were therefore calculated relative to the time 
of the four-week assessment rather than the time of the clinic visit. Figures 5.2 and 
5.3 illustrate the spread of the actual follow-up times around the nominal time points 
when times are anchored at the clinic visit, and when anchored at the first follow-up 






Figure 5.2. Actual follow-up times plotted for the entire sample when calculated from the time 






Figure 5.3. Actual follow-up times plotted for the entire sample when calculated from the time 
of the first follow-up telephone call. 
 
It is clear that there is a considerably larger spread in the follow-up times when these 
are calculated from the time of the clinic visit. This is not surprising however. When 
follow-up times are anchored at the week-four visit, the variance of the actual 
follow-up times is simply Var(X), where X is the time between the week-four 
assessment and the time of the follow-up assessment in question. In contrast when 
times are anchored at the time of the clinic visit the variance of the actual follow-up 
times is given by Var(X+Y), where Y is the time between the week-four assessment 
and the clinic visit, and X is defined as before. Therefore, unless Var(Y)=0 a post-hoc 
re-anchoring of the nominal time points will inevitably cause an increase in the 
variance of the actual follow-up times. In the present analysis all follow-up times are 





5.5.2 The six week appointment 
Initially a further follow-up assessment was planned six weeks after the clinic 
appointment. This assessment was quickly dropped from the design after recruitment 
had commenced because the spread of the actual follow-up times around the nominal 
time points was larger than anticipated thereby making it unfeasible to assess patients 
at all of four, six and eight weeks. Missing assessments from week eight have been 
replaced with assessments from week six where available. The small number of 
remaining outcomes from week six will not be used in the analysis.  
 
5.6 External validity 
The analysis of the POD Study presented in this chapter is focussed on the handling 
of missing data, i.e. the treatment of unobserved outcomes from patients who are 
already enrolled in the study. How we handle missing data can have important 
implications for the internal validity of a study. But internal validity is not the only 
thing needed for a study to lead to meaningful findings. Equally important is the 
question of where the study participants came from and what selection procedures 
took place before the arrival of the final sample ultimately enrolled and followed up.  
 
The design was such that patients were only asked to participate if they were 
available to be contacted for the first follow-up telephone call four weeks after the 
clinic visit. As a result we have complete data on each of the first two occasions. 
However this particular presentation of the design is somewhat misleading as it 
masks the group of patients who, on the basis of their clinic visit, were eligible to 
participate, but who could not be contacted, or declined participation at four weeks. 
The studied sample therefore consisted of adult cancer patients, with a good 
prognosis, who scored high on the HADS in clinic without meeting the criteria for 
MDD, and who were available (and willing) to give consent four weeks later. 
 
While this is no different from all other studies where only consenting patients are 
followed up, the one exception is the added limitation that eligible patients had to be 
available to be contacted via telephone within a narrow time window approximately 




criteria rather ambitious and narrowed down the pool of eligible patients 
considerably. Figure 5.4 describes the flow of patients starting from the overall 
number screened by the Symptom Monitoring Service to the number of patients 
ultimately enrolled in the study. 
 
5.7 Main analysis 
5.7.1 Participants 
A total of 567 patients were found eligible for study inclusion after completing the 
symptom screening questionnaire and the interview for depression. Of these, 138 
(24%) declined the offer of participation, and 104 (18%) could not be contacted 
within the limited time window. Three hundred and twenty five patients were 
subsequently enrolled into the study. Basic demographic, cancer and distress 
characteristics collected during the oncology outpatient clinic visit by the SMS on all 
eligible participants and non-participants suggested that the study participants were 
younger by two years on average than patients who did not enrol. The two groups 
were remarkably similar on the other variables including HADS scores (Table 5.1).   
 
Sixty one percent of the 325 enrolled patients were recruited from NHS Greater 
Glasgow and Clyde; the remaining patients were from NHS Lothian. The mean age 
was 61 (range 26 to 90) years. Eighty six percent of patients were female with the 
majority recruited from breast (57%) and gynae oncology clinics (23%). At baseline 
the majority of patients were disease-free (70%) with a median time since diagnosis 
of one and a half years. In the two months prior to screening 37% of patients had 
received no treatment, 34% had received chemo- or radiotherapy and 21% had 
received hormone treatment only. The remaining 9% had had surgery only (Tables 








Figure 5.4. Recruitment flowchart.
‡
 Exclusion reasons were poor prognosis (<12 months) or 
prognosis unknown, patient too unwell to take part, patients referred outside study window 




during study period 
n = 6658 
High scorers 
(HADS≥15) 
n = 1633 
Patients without 
MDD 
n = 833 
Patients with MDD 
 
n = 507 
Patients not 
assessed for MDD 
n = 293 
Excluded 
‡
  n = 266 
 
Eligible patients  
 
n = 567 
Patients included in 
the study 
n = 325 
Declined participation n = 138 
Could not be contacted  




5.7.2 Mean follow-up times 
Patients were scheduled to be followed up approximately four, eight, 16 and 28 
weeks after the clinic visit. The distributions of the actual follow-up times were 
shifted somewhat away from the nominal assessment times (Figure 5.2). The four 
week assessments were completed on average 4.9 (IQR 3.6 to 6.1) weeks after the 
clinic visit. The eight, 16 and 28 week assessments were completed on average 10.0 
(8.6 to 11.4) weeks, 18.2 (16.4 to 19.7) weeks and 33.1 (31.1 to 34.4) weeks after the 
clinic visit.  
 
5.7.3 Marginal distribution of HADS scores at each time point 
Figure 5.5 presents the marginal distribution of HADS scores at each of the five time 
points. At the clinic visit the distribution is highly skewed as it has been truncated to 
include only the high scores. At subsequent assessments the distributions quickly 
appear more symmetrical. For comparison the overall distribution of HADS scores 
among patients screened by the SMS is presented in Chapter 4 (Figure 4.5). 
 
5.7.4 Distress scores over time 
Individual HADS profiles from each of the participants are plotted in Figure 5.6 
revealing a high degree of variability in the scores both between and within patients. 
The (smoothed) mean HADS profile over the follow-up period is presented in Figure 
5.7. The mean distress level in the sample appears to be declining slightly over the 
duration of the follow-up period. 
 
The observed mean scores at each of the nominal time points are reported in Table 
5.3. Also presented are the proportions of patients that scored at or above the 
threshold of 15 at each time point. At the end of the study 37.0% (108/292; 95% 






Table 5.1. Characteristics recorded in clinic on the study participants compared with eligible 












 n = 325  n=242   
      
Age (years)     0.046 
  Mean (SD) 61.0 (12.4)  63.1 (12.2)   
  Median (range) 62.4 (26.3 to 89.7)  63.6 (33.7 to 88.4)   
      
Age group      
  < 50 years   68 (21)    39 (16)  0.086 
  50 to 64 years 129 (40)    86 (36)   
  > 65 years 128 (39)  117 (48)   
      
Gender     0.452 
  Female 280 (86)  203 (84)   
  Male   45 (14)    39 (16)   
      
Cancer clinic 
b
     0.752 
  Breast oncology 184 (57)  125 (52)   
  Colorectal   18 (  6)    15 (  6)   
  GI-clinic     9 (  3)      7 (  3)   
  Gynae oncology   76 (23)    58 (24)   
  Miscellaneous
 c
     11 (  3)      8 (  3)   
  Urology   27 (  8)    29 (12)   
      
HADS score in clinic     0.830 
  Mean (SD) 18.7 (3.7)  18.6 (3.6)   
  Median (range) 18 (15 to 34)  18 (15 to 35)   
      
Study centre     0.798 
   Edinburgh 127 (39)    92 (38)   
   Glasgow 198 (61)  150 (62)   
      
Data are number (%) unless otherwise specified. 
a
 Age in years and HADS score in clinic 
were compared using t tests. All other p-values are from chi-square tests. 
b
 Out-patient clinic 
where the patient was screened at baseline. 
c
 Miscellaneous clinics included sarcoma (n=6), 







Table 5.2. Disease characteristics at baseline. 
 n (%) 




  Bowel   26 (  8) 
  Breast 184 (57) 
  GU (urology)   28 (  9) 
  Gynae   72 (22) 
  Other   15 (  5) 
Disease activity  
  Disease-free 228 (70) 
  Local disease   36 (11) 
  Metastatic disease   60 (18) 
Persistence of cancer  
  Yes   54 (17) 
  No 271 (83) 
Recurrence of cancer  
  Yes   29 (  9) 
  No 296 (91) 
Cancer treatment in the two months prior to screening   
  No treatment 119 (37) 
  Chemo/radiotherapy 110 (34) 
  Surgery only   29 (  9) 
  Hormone treatment only   67 (21) 
Time since diagnosis (years)  
  Mean (SD) 3.0 (4.4) 
  Median (range) 1.5 (0.0 to 39.6) 
Marital status  
  Married/in a relationship 219 (67) 
  Divorced   28 (  9) 
  Separated     8 (  2) 
  Widowed   34 (10) 
  Single   36 (11) 
Patient-reported duration of distress  
  < 3 months 160 (49) 
  3 to 6 months   52 (16) 
  6 to 12 months   43 (13) 
  1 to 2 years   25 (  8) 
  > 2 years   44 (14) 
Employment status  
  In full-time employment   51 (16) 
  In part-time employment   32 (10) 
  Retired 153 (47) 
  Unemployed (due to ill health)   61 (19) 
  Unemployed (other reasons)   28 (  9) 
  
Patient-reported duration of distress and disease activity were missing for one patient.Date 
of diagnosis was missing for four patients. 
a
 GU (urology) included bladder (n=1), kidney 
(n=1), prostate (n=22), testis (n=3) and ureters (n=1); Gynae included cervix (n=14), 
fallopian tube (n=1), ovary (n=38), uterus (n=13), vagina (n=3), vulva (n=3); Other included 
haematological cancer (n=4), malignant melanoma (n=3), sarcoma (n=3), cancer of the liver 






Table 5.3. Mean HADS scores and number of cases with significant distress (HADS≥15) 
during the follow-up period. 
 Clinic 
appointment 1 month 2 months 4 months 7 months 
      
All available data     
n 325 325 307 296 292 
mean (SD) 18.7 (3.7) 13.4 (5.7) 13.7 (6.4) 13.4 (6.5) 12.5 (6.7) 
cases (%) 325 (100%) 130 (40.0%) 133 (43.3%) 120 (40.5%) 108 (37.0%) 
      
Complete cases 
a
     
n 269 269 269 269 269 
mean (SD) 18.6 (3.6) 13.4 (5.6) 13.4 (6.2) 13.3 (6.5) 12.2 (6.6) 
cases (%) 269 (100%) 107 (39.8%) 112 (41.6%) 109 (40.5%) 96 (35.7%) 
      
a
 The analysis of complete cases is of the 269 patients for whom data were collected at 
every follow-up occasion. 
 
5.7.5 Distress trajectories 
One of the aims of the study was to characterise patients’ distress trajectories over 
time. With 325 individual patient profiles this posed a challenge. To simplify the 
problem the scores were dichotomised at each time point again using the threshold of 
15. Consequently, with four time points and two distress states at each time point 
there were a total of 16 ways in which a patient could progress over the period. (In 
fact there were three possible outcomes at each time point since scores might also be 
missing. However the analysis was restricted to complete cases only so as not to 
complicate the findings unnecessarily.) 
 
The number and proportions of patients falling into each of the possible categories 
are shown in Table 5.4. Of the 16 possible trajectories two in particular were clearly 
very common: Not being distressed at any of the time points, and being distressed at 

















Figure 5.6. HADS profiles over the study period plotted in a single plot.  
 
 
Figure 5.7. Smoothed (lowess) mean HADS profile over the follow-up period (continuous 


















8 & 16 
weeks 
Distress at 
8 & 28 
weeks 
Distress at 
16 & 28 
weeks 
Distress at 
8, 16 & 28 
weeks 
Distress at 4 weeks        
   Yes   12 (  4) 15 (  6)   2 (  1)   4 (  1) 14 (  5)   2 (  1)   6 (  2) 52 (19) 
   No 104 (39)   5 (  2) 13 (  5) 11 (  4)   8 (  3)   7 (  3)   5 (  2)   9 (  3) 
         
Data are number (percentage) 
 
 
Table 5.5. Distress persistence over time. 
 
 




Distress on all four follow-up occasions    52   (19%) 
Distress on three follow-up occasions   31   (12%) 
Distress on two follow-up occasions   41   (15%) 
Distress on one follow-up occasion   41   (15%) 






5.7.6 Persistence of distress 
The 269 patients with complete data were then grouped into just five categories 
according to the number of times they scored high on the HADS (Table 5.5). 
 
The prevalence of distress cases in a similar general outpatient cancer population has 
been estimated to be around 22% (Sharma et al., 2011). But is it the same group of 
patients who remain distressed over time? We found that approximately 40% of 
patients score high on the HADS up to seven months after being identified with 
distress in clinic. It appears therefore that symptom levels do not simply revert to 
background levels on follow-up, but tend to persist in a particular group of patients. 
The data in Table 5.5 provide further evidence that the distress is recurrent in a 
consistent group of patients and that there is a large group of patients (19% of the 
sample) who are constantly subjected to elevated levels of distress.  
 
Fifty eight percent of patients (156/269) fell into either of the two extreme categories 
of not being distressed at all or of being distressed at every time point. Under the 
hypothesis of statistical independence between distress status at four, eight, 16 and 
28 weeks, conditional on the observed prevalences, we would expect far fewer 
patients in either of these two extreme categories (Table 5.6). The probability of 
observing frequencies as extreme as or more extreme than those actually observed is 
practically zero. This is hardly a surprising finding since the null hypothesis of 
independence between the repeated measurements is clearly an unreasonable one 















    
Distress on all four follow-up occasions   52 7.0 <0.0001 
Distress on three follow-up occasions   31 41.8  
Distress on two follow-up occasions   41 93.4  
Distress on one follow-up occasion   41 92.5  
Not distressed at any follow-up occasions 104 34.3  
    
†
 patients with complete data only (n=269). 
 
5.7.7 The utility of a confirmatory reading 
It was originally hypothesised that a reassessment approximately four weeks after the 
initial high reading in clinic would be helpful in identifying patients with persistent 
distress. Of patients who scored high on the confirmatory reading at four weeks, 60% 
(71/118) remained distressed at 28 weeks, up from 37% in the overall sample of 
patients who scored high in clinic (Table 5.7). The sensitivity estimate of around 
66% implies that a third of patients with distress at 28 weeks would be missed (i.e. 
would score below the threshold) in the confirmatory reading at four weeks. While 
the sensitivity can be somewhat improved upon by delaying the confirmatory reading 
until eight weeks, little is gained in terms of the positive predictive value. For 
comparison the diagnostic qualities of the outcomes at four and eight weeks together, 
and at 16 weeks are also presented, although waiting 16 weeks for a confirmatory 
reading is not a practical option.   
 
Table 5.7. Distress status at four, eight, and 16 weeks as a diagnostic tool to predict 





   
In clinic - 37.0 
4 weeks 65.7 60.2 
8 weeks 73.1 62.8 
16 weeks 75.8 67.0 
4 & 8 weeks 55.8 65.2 






5.7.8 Associations with distress at seven months 
Univariate analyses of associations with patient characteristics at baseline showed 
that patients who scored 20 or more on the HADS in clinic were more likely to be 
distressed at 28 weeks (Table 5.8). This was confirmed in the multivariable analysis 
with odds of persistent distress estimated to be 1.85 times higher in the group of 
patients who scored 20 or more in clinic (95% CI: 1.08 to 3.15). The type of cancer 
treatment in the two months prior to the clinic appointment was also found to be 
independently associated with persistent distress. Patients who had received chemo- 
or radiotherapy (OR: 0.47, 95% CI: 0.25 to 0.89) or who had undergone surgery 
(OR: 0.31, 95% CI: 0.11 to 0.87) were less likely to have persistent distress than 
patients who were not in receipt of treatment (p=0.034).  
 
Overall the model did not reveal any particularly strong predictors at baseline and did 
not discriminate well between patients with and without persistent distress (c-index: 
0.65). The overall likelihood ratio test of the full model compared to the null model 
did not reach statistical significance (χ
2
=19.4, df=13, p=0.111) and individual 
significant associations should therefore be interpreted with caution.  
 
Distress status at four weeks after clinic screening was subsequently added to the 
multivariable model in a separate analysis (Table 5.8; analysis (2)) and was shown to 
be a strong independent predictor of persistent distress (OR: 5.48, 95% CI: 3.13 to 
9.60). Scoring 20 or more on the HADS in clinic carried little additional information 
having adjusted for distress at four weeks and was no longer a significant predictor. 
 
We also sought to investigate how the occurrence of a significant worsening in 
clinical status over the study period might affect patients’ distress levels. We defined 
such occurrences as either a worsening in disease status from disease-free to local 
disease, or from local disease to metastatic disease, or as a recurrence of cancer 
during the follow-up period. We found that there were too few such events to 
conduct a meaningful analysis, perhaps unsurprisingly, since the study sample 





Table 5.8. Prevalence of significant distress (HADS≥15) at seven months and associations 
with patient characteristics (continued on next page). 
















      
Total 292 108 (37) 184 (63)   
Gender     0.138 
   Female 252   89 (35) 163 (65) 1  
   Male   40   19 (48)   21 (53) 1.66 (0.85, 3.25)  
Age     0.623 
   < 50   60   25 (42)   35 (58) 1  
   50 to 64 118   44 (37)   74 (63) 0.83 (0.44, 1.57)  
   ≥ 65 114   39 (34)   75 (66) 0.73 (0.38, 1.38)  
Primary cancer     0.379 
   Bowel   20     8 (40)   12 (60) 1  
   Breast 173   65 (38) 108 (62) 0.90 (0.35, 2.33)  
   GU (urology)   25   13 (52)   12 (48) 1.63 (0.49, 5.34)  
   Gynae   60   18 (30)   42 (70) 0.64 (0.23, 1.84)  
   Other    14     4 (29)   10 (71) 0.60 (0.14, 2.60)  
Disease activity 
† ₣ 
    0.800 
   Disease-free 218   80 (37) 138 (63) 1  
   Active disease   73   28 (38)   45 (62) 1.07 (0.62, 1.85)  
Cancer treatment 
¥
     0.059 
   No treatment 105   46 (44)   59 (56) 1  
   Chemo/radiotherapy   95   29 (31)   66 (69) 0.56 (0.32, 1.01)  
   Surgery only   28     6 (21)   22 (79) 0.35 (0.13, 0.93)  
   Hormone treatment 
only 
  64   27 (42)   37 (58) 0.94 (0.50, 1.75)  
Marital status      0.929 
   Not married   91   34 (37)   57 (63) 1  
   Married 201   74 (37) 127 (63) 0.98 (0.59, 1.63)  
HADS score at 
screening 
 
   0.028 
   Score < 20 196   64 (33) 132 (67) 1  
   Score ≥ 20   96   44 (46)   52 (54) 1.75 (1.06, 2.88)  
Distress status 1 month 
after screening 
    
<0.001 
   No significant distress 174   37 (21) 137 (79) 1  
   Significant distress 118   71 (60)   47 (40) 5.59 (3.33, 9.38)  





Table 5.8. (Continued). 
₣
 Disease activity at screening. 
†
 Disease activity was unknown for one subject in the group 
without significant distress at 7 months. Total n = 291. 
‡
 (1) including baseline information 
only, (2) Including distress status at 1 month as well as baseline information. 
¥
 Cancer 
treatment in the 2 months prior to screening. Surgery could have included hormone therapy; 
Chemo/radiotherapy could have included surgery and/or hormone therapy.
  Multivariate analysis
 † 













      
Total      
Gender   0.432  0.488 
   Female  1  1  
   Male  1.83 (0.40, 8.34)  1.78 (0.35, 9.09)  
Age   0.383  0.635 
   < 50  1  1  
   50 to 64  0.85 (0.44, 1.65)  0.98 (0.48, 2.00)  
   ≥ 65  0.63 (0.32, 1.26)  0.75 (0.35, 1.58  
Primary cancer   0.619  0.834 
   Bowel  1  1  
   Breast  1.25 (0.34, 4.61)  0.87 (0.21, 3.63)  
   GU (urology)  1.16 (0.28, 4.77)  0.68 (0.15, 3.18)  
   Gynae  0.87 (0.22, 3.48)  0.79 (0.18, 3.56)  
   Other   0.51 (0.11, 2.41)  0.39 (0.07, 2.13)  
Disease activity 
† ₣ 
  0.779  0.410 
   Disease-free  1  1  
   Active disease  1.09 (0.60, 1.97)  1.31 (0.69, 2.49)  
Cancer treatment 
¥
   0.034  0.044 
   No treatment  1  1  
   Chemo/radiotherapy  0.47 (0.25, 0.89)  0.42 (0.22, 0.84)  
   Surgery only  0.31 (0.11, 0.87)  0.38 (0.12, 1.14)  
   Hormone treatment only  0.83 (0.42, 1.64)  0.86 (0.41, 1.81)  
Marital status    0.878  0.718 
   Not married  1  1  
   Married  1.04 (0.60, 1.81)  1.12 (0.62, 2.02)  
HADS score at screening   0.025  0.347 
   Score < 20  1  1  
   Score ≥ 20  1.85 (1.08, 3.15)  1.32 (0.74, 2.37)  






   No significant distress    1  
   Significant distress    5.48 (3.13, 9.60)  




5.8 Missing data 
An unusual feature of the design was that study participants were asked for their 
consent at the start of the four week follow-up telephone call instead of at the time of 
the first assessment (in clinic). As was noted above, the study sample was therefore 
not defined until the first follow-up time point; there were consequently no missing 
data from either the clinic visit or at four weeks. As for the remaining time points, 
94% (307/325) of patients completed the questionnaire at eight weeks, and 91% 
(296/325) and 90% (292/325) of patients completed the questionnaires at 16 and 28 
weeks respectively.  
 
The analysis presented in section 5.7 is based on only partially observed data. To see 
why this is important we will consider initially the estimated proportion of patients 
still distressed after 28 weeks. This was estimated to be 37.0% and was based on the 
292 patients with observed distress status at 28 weeks. Implicit in this estimate 
therefore is the assumption that the 33 patients with missing data had similar distress 
levels at 28 weeks to those patients whose distress was measured. This means that 
one would expect around 12 of the 33 patients with missing data to be distressed at 
28 weeks. 
 
To see if this is a reasonable assumption it is helpful to investigate how the 33 
patients scored at earlier time points compared to the 292 patients with observed 
data. The mean HADS scores (and percentage with a high score) in the group of 33 
were 18.8 (100%), 13.7 (36%), 15.8 (48%) and 15.2 (44%) in clinic, at four, eight 
and 16 weeks respectively. In comparison, the mean scores (percentage with a high 
score) in the 292 patients with complete data at 28 weeks were 18.6 (100%), 13.4 
(40%), 13.5 (43%) and 13.3 (40%) at the same time points. While it is difficult to 
conclude anything on the basis of these numbers it would appear that patients with 
missing data at 28 weeks might experience somewhat higher distress levels at earlier 
time points. Table 5.3 supports this idea. The estimates from the complete cases are 
consistently lower than those based on the available cases suggesting that patients 
who comply more with data collection procedures are somewhat less distressed on 




more than 12 of the 33 missing scores at 28 weeks would have been high had they 
been observed. In the following we shall assess the sensitivity of the findings in 5.7 
to different treatments of the missing data. 
 
5.8.1 Missing data patterns 
The missing data patterns are tabulated in Table 5.9. Two hundred and sixty nine 
(83%) patients provided complete data at all time points. Of the 56 patients with at 
least one missing data point, 39 patients had just a single missed assessment, while 
the remaining 17 patients missed two (n=10) or three (n=7) assessments. The most 
frequently observed missingness pattern was having a single missed assessment at 





Table 5.9. Patterns of missingness over the four follow-up time points. 
 
Pattern 
no. Week 4 Week 8 Week 16 Week 28 
Number (%) of patients with 
the indicated pattern 
      
1 O O O O 269 (83) 
2 O O O M   17 (  5) 
3 O O M O   13 (  4) 
4 O M O O     9 (  3) 
5 O O M M     8 (  2) 
6 O M M M     7 (  2) 
7 O M O M     1 (  0) 
8 O M M O     1 (  0) 
      
 
Note: O (M) indicates that the data point was observed (missed). E.g. a patient with 
missingness pattern 2 provided data at each of four weeks, eight weeks and 16 weeks, but 
not at 28 weeks. 
 
The mean HADS trajectories are plotted separately for each of the missingness 
patterns 2 to 6 (Figure 5.8). Also shown in each plot is the mean trajectory from the 
complete cases for comparison. Figure 5.9 presents the mean HADS trajectories 
plotted separately for the complete and the incomplete cases (mean scores pooled 
across missingness patterns 2 to 8). The observed mean scores are higher on average 
in the incomplete cases. It seems we cannot assume similar levels of distress in 










Figure 5.8. Mean HADS trajectories over the study period plotted separately for missingness 
patterns 2 to 6 (line segments connected by circles) alongside the trajectory from the 
complete cases (line segments connected by crosses). The four letter combinations denote 
the missingness patterns. E.g. OOMO indicates patients were observed at four, eight and 28 






Figure 5.9. Mean HADS trajectories plotted separately for complete and incomplete cases. 
Sample sizes for the incomplete cases vary: week 0: n=56; week 4: n=56; week 8: n=38; 
week 16: n=27; week 28: n=23. 
 
5.9 Reanalysis using Multiple Imputation 
Patients with some missing data were likely to score higher on the HADS on those 
occasions when their scores were observed than patients with complete data on all 
occasions. As a result the MCAR assumption underlying the analysis presented 
above does not appear to be justified. A logical next step was therefore to conduct an 
analysis assuming the more general MAR mechanism for the missing data and assess 
the influence on the findings to see if the results presented were robust to a relaxation 
of the MCAR assumption. 
 
The distributions of covariates were compared between patients with and without 
outcome data. All collected variables that were potentially relevant were analysed for 
associations with missingness. The following variables were included in the 
imputation model and used to predict the missing data: Gender; age in years (<50, 50 
to 64, ≥65); primary cancer site (bowel, breast, GU (urology) gynae, other); disease 
activity (disease-free, active disease) and cancer treatment (no treatment, 
chemo/radiotherapy, surgery only, hormone treatment only) at study entry; marital 
status (married, not married); health board (NHS Lothian, NHS Greater Glasgow and 
Clyde); all available HADS scores collected previously or subsequently. 
 
The missing HADS scores (range 0 to 42) were imputed 100 times each using the MI 




Markov Chain Monte Carlo (MCMC) methods appropriate for non-monotone 
missingness patterns and were sampled from a single Markov chain with an initial 
burn-in sequence of 200 iterations, leaving 100 iterations between each imputation to 
avoid serial dependence. 
 
The results from the multiple imputation analysis were broadly similar to those of the 
main analysis. The estimated mean HADS scores from the imputed datasets were 
13.7, 13.6 and 12.7 at two, four, and seven months respectively. The levels of 
caseness were 43% at two months, 42% at four months and 38% at seven months. 
These estimates were somewhat higher than those based on the incomplete data 
suggesting that patients with higher levels of distress were more likely to have some 
observations missing. The analysis of the utility of a confirmatory assessment some 
time after the original screening episode in clinic also resulted in findings very 
similar to those from the main analysis. The results from the analysis of patient 
distress trajectories over time were also largely similar, although the estimated 
proportion of patients without significant distress at any of the follow-up occasions 
was reduced from 39% to 37% when taking account of the missing data using 
multiple imputation. Finally, results from the regression analysis were almost 
identical to those of the main analysis again confirming the finding that distress 
status at four weeks was the only strong predictor of persistent distress at 28 weeks. 
 
In summary, the results from the multiple imputation analysis (under a MAR 
mechanism) were very similar to the results of the main analysis. The findings from 
the POD Study therefore appear reasonably robust despite the limited amount of 
missing data. In practice the MCAR assumption is probably rarely correct. Arguably 
therefore the MAR mechanism should be the working assumption with a robust 
sensitivity analysis subjecting the data to a range of alternative scenarios.  
 
5.10 Discussion 
We found that 37.0% of patients (95% CI: 31.4% to 42.5%) were still distressed at 
28 weeks with little improvement in average HADS scores over the follow up period. 




patients scoring high on the HADS on every occasion. We found that there were no 
strong predictors at baseline that would allow clinicians to discriminate well between 
patients at risk, and those not at risk, of becoming persistently distressed. However, a 
second high score approximately four weeks after the original screening episode 
increased the odds more than five fold of persistent distress half a year later. The 
introduction of a confirmatory reading should therefore be considered when 
screening for long-term distress.  
 
There were some missing data, especially towards the latter part of the follow-up 
period when data completeness rates fell to around 90%. Exploratory analysis 
suggested that patients with missing data scored higher on the HADS on average 
than patients with complete data. A sensitivity analysis using multiple imputation to 
impute the missing values under a MAR mechanism was conducted. Analyses of the 
imputed datasets resulted in very similar findings to those of the main analysis. The 
findings therefore appear to be reasonably robust, certainly to a relaxation of the 
MCAR assumption.  
 
5.10.1 Limitations 
The response rate of eligible patients ultimately enrolled into the study was relatively 
low. As discussed in section 5.6 this was mainly due to the unusual design where 
only patients available to be contacted within a narrow time window could be 
enrolled. Comparisons of basic characteristics between eligible participants and non-
participants showed that those enrolled were two years younger on average, but that 
there were no other differences on the variables compared. Indeed the HADS scores 
were remarkably similar between the two groups leaving little evidence on the basis 
of the comparisons that eligible non-participants would have progressed substantially 
differently from those who participated. 
 
The study was carried out in cancer outpatients attending clinics in Edinburgh and 
Glasgow in Scotland, UK. The findings may not therefore generalise to other settings 
or medical conditions. As this was a longitudinal study of distress in cancer patients 




in the patients’ medical conditions during the follow up period affect distress levels. 
Unfortunately it was not possible to investigate this point since too few patients 
experienced such events to conduct a meaningful analysis. Finally, due to limited 
resources we were unable to ascertain the number of patients whose distress 
developed into major depression during the study. 
 
5.10.2 Implications 
A significant proportion of cancer outpatients who present at clinic with symptoms 
of psychological distress are still distressed half a year later. A second ‘high reading’ 
four weeks after the initial screening episode was found to be a strong predictor of 
long-term distress; the introduction of a confirmatory reading might help screening 
services identify patients likely to require treatment, and might also inform the 
recruitment of clinical trials in patients with psychological distress. 
 
5.10.3 In context 
The POD Study was a longitudinal study investigating the development of patients’ 
distress scores over time. Patients were followed up at regular intervals, and retention 
rates were good with only 10% of patients failing to provide data after seven months. 
In contrast, the distress data routinely collected by the Symptom Monitoring Service 
are incomplete and unevenly spaced between patients, depending on the timing of 
their clinic appointments. Analysis with the screening data collected by the Symptom 
Monitoring Service is the topic of Chapter 7. But before that: some exploratory work 







6 BAYESIAN ANALYSIS WITH MISSING DATA USING WINBUGS 
The present chapter does not set out to answer a research question, and the work 
reported is not intended to add value to the literature on analysis with missing data or 
Bayesian modelling using WinBUGS. Rather, the chapter is a narrative describing 
experimental work that was carried out by the author to gain experience necessary 
for the analyses presented in Chapters 7 and 8, and it represents an important step in 
the early development of the author’s understanding of practical analysis with 
incomplete data. Some of the ideas presented in Chapter 3 are illustrated in the 
present chapter, and as such it may also be seen as an extension to Chapter 3. 
 
The chapter is introduced with some exploratory work with alternative approaches to 
multivariate incomplete data modelling in WinBUGS. We study the POD Study data 
under a MAR assumption and lastly consider alternative non-response processes 
through analysis with simulated data. 
 
6.1 Inducing dependency through a linear predictor 
Assume that variable Y is a quantitative variable measured on two occasions, t1 and 
t2, resulting in two potential observations, Yi1 and Yi2, from the ith subject. Further 
assume that Y1 is fully observed and that Y2 is missing in some cases. Y1 and Y2 are 
typically correlated since they are repeated measurements within the same subject. 
One way to express the dependency is through a linear regression of Y2 on Y1. 
Specifically we can model Y2 using the following model: 
 
Yi2 = α + βYi1 + ei 
 
Here α is the intercept, β is the regression coefficient, and the ei are independent error 




6.1.1 Bayesian predictions  
Under the Bayesian framework the parameters α and β are random variables. These 
are assigned prior distributions that represent our beliefs about them before 
considering any empirical data (usually this is also true for σ
2




in practice). When the data are complete, and the prior distributions are non-
informative relative to the data likelihood, the posterior means of these two 
parameters are asymptotically normal and coincide, in large samples, with the 
ordinary least squares estimates obtained in a frequentist setting (also equivalent to 
their maximum likelihood estimates).   
 
When there is missingness in Y2 the posterior distributions of α and β can be used to 
obtain predictions of the missing Y2 values. Under a MAR mechanism this can be 
done for subject k, with observed Y1 and missing Y2, by obtaining the predictive 












( 122  
 
Here θ = (α, β)’ are the parameters, Y
O
 are the observed parts of Y1 and Y2, and 2
~
kY  is 
the missing value to be predicted. p(θ| Y
O
) is the posterior distribution for the 
parameters and ),|
~
( 12 kk YYp   is the predictive distribution of the missing Y2 value 
given a particular set of parameters θ and the baseline Y1 value. 
 
6.1.2 Links to Multiple Imputation and classical predictions 
The posterior means of the predictive distributions for the missing values coincide 
with the predicted values 12
ˆˆˆ
kk YY    that can be obtained after fitting a linear 
regression in the classical setting. Since multiple imputation is essentially a Bayesian 
procedure for predicting values through the predictive distribution given above, the 
posterior means also coincide asymptotically with the means of multiply imputed 
values as the number of imputed datasets, m, increases. 
 
6.2 Joint modelling assuming a multivariate distribution for the 
outcomes 
Instead of creating a dependency through the linear predictor (essentially making one 
the dependent and the other the independent variable) the outcomes Y1 and Y2 can be 





 Yij ~ MVN(μ, Σ) j=1,2; i=1,…,n.  
 
Here MVN is the multivariate normal density, μ = (μ1, μ2)’ are the marginal means of 
Y1 and Y2 and Σ is the covariance matrix for Y. 
 
In a Bayesian analysis we need to specify prior distributions for μ and Σ. In 
WinBUGS this can be done by using a multivariate normal for μ and a Wishart 
distribution for the precision matrix defined as Σ
-1
. The Wishart distribution can be 
treated as a multivariate extension of the chi-squared distribution and is often 
specified as the prior distribution for precision parameter matrices in WinBUGS 
(Spiegelhalter et al., 2003).  
 
Having specified appropriate priors for the parameters we may obtain predictive 
distributions for Y2 conditional on the data as before. The posterior means of these 
predictive distributions can be used to estimate μ2=E[Y2] under MAR. Similarly, the 
posterior means for μ = (μ1, μ2)’ can be used to obtain valid estimates of E[Y1] and 
E[Y2] under MAR, and will coincide with the estimates derived through the 
regression formulation above. 
 
Under the regression formulation Y2 was dependent on Y1 and could therefore be 
predicted using Y1, but there was no feedback mechanism enabling prediction of Y1 
from observed values of Y2. With the joint model formulation we can model 
missingness in both Y1 and Y2 simultaneously. That is, we are no longer restricted to 
the situation where only Y2 is subject to missingness. Under the joint model 
formulation it is possible to generate predictions of non-monotone missing values. 
The incomplete outcomes are modelled jointly and explanatory variables can enter 





6.3 Inducing dependency through hierarchical models with 
exchangeable parameters 
Another similarly flexible way of modelling repeated outcomes is through a model of 
the form 
 Yij ~ N(si, 
2
e )  j=1,2; i=1,…,n. 
  
where si is a subject-specific parameter akin to a random intercept.
2
e  is the variance 
of Y (assuming equal variances at t1 and t2) and, conditional on si, Y1 and Y2 are 
assumed independent, i.e. Cov(Yi1,Yi2 | si) = 0. 
 
Prior distributions are required for the si parameters (as well as 
2
e ). We could 
assume that the si are independently distributed by assigning a separate, independent 
prior to each si. 
 
si ~ N(μ, 
2
s ), for i=1,…,n, 
 
and choosing values for μ and 2s to ensure flat priors relative to the data likelihood. 
Alternatively, instead of assuming independent vague priors for the si we may let μ 
and 2s  carry information by modelling these as parameters (known as hyper-
parameters), and specifying prior distributions for these also. 
 
This latter alternative recognises that data collected on other subjects in the sample 
are useful in predicting missing observations from incomplete cases. The individual 
si are estimated using data from the whole sample, not just those belonging to subject 
i. This is equivalent to the way that a random effects model combines information 
from all subjects with data from the individual subject to predict subject-specific 
random effects (known as shrinkage; e.g. Fitzmaurice, Laird & Ware, 2004; Chapter 
8). Indeed with this model we obtain results that are exactly equal to those obtained 
using a random intercepts model in a classical setting. When using vague priors the 
two approaches are equivalent and yield identical estimates, valid under MAR, of 
μ2=E[Y2], 
2







6.4 Bayesian analysis of the POD Study data under a MAR assumption 
using WinBUGS 
Using a hierarchical model (exchangeable parameters) 
The following model was fitted to the PODS data.  
 
E[Yij] = μij = bi + Timej 
 
Here Yij is the jth response from the ith patient, bi are the subject-specific means 
(imposing random intercepts), and Timej are the freely modelled additional effects of 
time at month 4, 8, 16 and 28 (i.e. Time1=0).  
 
Using WinBUGS, the data likelihood was then modelled according to 
Yij ~ N(μij, 
2
e ). Vague normal prior distributions were specified for the parameters 
Time2,…, Time5. A hierarchical prior was used for the subject-specific 
 




with vague priors for the hyper-parameters μb and 
2
b . WinBUGS requires a 
different parameterisation of the normal distribution using the precision τ = 1/σ
2
 in 
place of the variance parameter σ
2
. Vague gamma prior distributions were specified 
for all precision parameters where applicable. The means and standard deviations of 
the posterior distributions for the parameters are shown in Table 6.1. 
 








μb 18.66 0.33 
Time2 -5.25 0.31 
Time3 -4.93 0.32 
Time4 -5.16 0.32 











These results were compared with the results of an equivalent random intercept 
model fitted in SAS (Table 6.2). 
 







μb 18.66 0.32 
Time2 -5.25 0.31 
Time3 -4.93 0.32 
Time4 -5.16 0.32 








As would be expected the results are virtually identical. Using the above parameter 
estimates, the estimated mean scores under a MAR assumption were 13.73, 13.50, 
12.57 at 8, 16 and 28 weeks. At 0 and 4 weeks the estimated means coincided with 
the observed data means since there were no missing data on these two occasions. 
These estimates are also in good agreement with the results obtained in Chapter 5 
using multiple imputation. 
 
Explicit multivariate normal likelihood 
Next as an alternative approach to the analysis of the mean responses in WinBUGS, 
the outcomes at 4, 8, 16 and 28 weeks were modelled jointly by specifying a 
multivariate normal distribution. 
 
Yij ~ MVN(μ, Σ) 
 


































is the associated covariance matrix. Vague prior distributions were specified for μ 
and Σ
-1




outcomes were from a truncated distribution and had the potential to affect the 
multivariate modelling procedure in an untoward manner. 
 
As described in detail in Chapter 5 there were missing data at 8, 16 and 28 weeks. 
Having fitted the above model to the relevant outcomes, posterior mean estimates 
were obtained for all of the above parameters (Table 6.3).  
 

















μ1 13.37 0.28  2
44  
45 3.8 
μ2 13.66 0.31  
12  25 2.5 
μ3 13.52 0.33  
13  
23 2.5 















43 3.5  
34  
29 3.1 
       
 
Finally, when pooling the means of the predictive distributions for the missing data 
with the means of the observed outcomes at 8, 16 and 28 weeks, the following 
estimates for the average scores were obtained: 13.73 at 8 weeks, 13.56 at 16 weeks 
and 12.61 at 28 weeks. These results were confirmed in a multiple imputation 
analysis in SAS including in the imputation model all outcomes from 4, 8, 16 and 28 
weeks and using m=100 imputed datasets. The means of the imputed data at the three 
time points subject to missingness were 13.73, 13.55 and 12.61. 
 
6.5 Modelling the non-response mechanism: a simulation exercise 
The previous sections focussed on the response processes from incomplete data but 
ignored the missingness process. In this section we will consider in detail some 
alternative missingness processes and the practical implications arising when 
attempting to model these. We will do this through analysis of simulated incomplete 





6.5.1 Missingness At Random (MAR) 
Consider again the scenario from section 6.1: Variable Y is measured on two 
occasions, t1 and t2, resulting in two potentially observed responses, Yi1 and Yi2, from 
the ith subject. In simulation work we let Y have a multivariate normal distribution 
with mean parameters μ = (5 6)’ and covariance matrix Σ of dimensions (2 x 2) with 
the two diagonal elements equal to 1 and off-diagonal elements equal to 0.5. That is, 
the marginal means at t1 and t2 are 5 and 6 respectively, Var(Yij) = 1, and 
Cov(Yi1,Yi2) = 0.5. 
 
MAR under monotone missingness patterns 
In the first instance we let Y2 be missing in some cases while Y1 was fully observed. 
Letting Mij=1 when Yij is missing (and Mij=0 otherwise) we denote P(Mi2=1) = πi2, 


















Because the covariate is mean centred α has the straightforward interpretation of the 
overall log odds of missingness in Y2. β is the increase in the log odds of missingness 
for each unit increase in Y1. 
 
We simulated data from 3500 subjects according to the above mechanism with α = 0 
and β = 0.7. These translate into modelled probabilities of missingness as shown in 
Table 6.4. The complete (observed and unobserved) data means were 1Y  = 5.03 and 
2Y  = 6.04. The observed data mean at t2 was 
OY2  = 5.85; there was 51% missing data 
on Y2. 
 
Table 6.4. Probability of missingness in Y2 as a function of Y1. 
Y1 1 2 3 4 5 6 7 8 9 
P(M2|Y1) 0.06 0.11 0.20 0.33 0.50 0.67 0.80 0.89 0.94 
 
The data were analysed in WinBUGS using the following random intercepts model 





Yij ~ N(μij, 
2
e ) 
μij = bi + Timej 
 
bi are the subject-specific intercepts and Timej is the additional effect of the 
measurement occasion with Time1=0. Vague prior distributions were specified for 
Time2 and
2
e . We specified a hierarchical prior for bi: 
bi ~ N(µb, 
2
b ) 
with vague prior distributions on the hyperparameters µb and 
2
b . A separate model 
was specified for the missing data indicators: 
 
Mi2 ~ Bernoulli(πi2) 
logit(πi2)=α+ β(Yi1- 1Y ) 
 
Here 1Y  is the sample mean at t1. Vague normal priors were specified for α and β. 
The means and standard deviations of the posterior distributions for the parameters 
are shown in Table 6.5 (a) ignoring the missing data mechanism and (b) when 
including the missing data mechanisms in the model. 
 
Table 6.5. Results from analysis with MAR data with a monotone missingness pattern. 
(a) Ignoring the non-response 
mechanism 
 (b) Joint modelling of the response 

















µb 5.03 0.02  µb 5.03 0.02 
Time2 1.01 0.02  Time2 1.01 0.02 
2
e  





0.53 0.02  2
b  
0.53 0.02 
    α 0.03 0.04 
    β 0.77 0.04 
       
 
Under a MAR mechanism the missingness function is ignorable; the two modelling 




means for the parameters governing the non-response mechanism were close to the 
true parameter values behind the simulated data of α =0 and β =0.7. 
 
Multiple incomplete variables with monotone missingness patterns 
The scenario above can be extended to include monotone missingness in two or more 
variables. Much of the literature on missing data is concerned with modelling drop-
out mechanisms rather than intermittent missing data of a non-monotone nature 
(wave non-response). There is often a preference to avoid modelling non-monotone 
missingness patterns under a MAR assumption. One way to avoid this is to assume a 
MCAR mechanism for wave non-response, but to treat drop-out under a MAR 
assumption (e.g. Carrigan et al., 2007). At first this may seem an unrealistic 
simplification, however it is often difficult to think of a plausible missing data 
process that causes a non-monotone missingness pattern under a MAR mechanism.  
 
MAR under a non-monotone mechanism 
Recall that under a MAR mechanism the probability distribution for the missingness 
indicators may depend on the observed elements of the response vector, but cannot 
depend on the unobserved elements. 
 
With monotone missing data as caused by drop-out this leads to a relatively 
straightforward process whereby the probability of drop-out is determined by (all or 
some of) the previously observed responses. We can imagine a simple process where 
the probability of drop-out at time j is random conditional on the response at time j-1. 
 
With non-monotone data it is not as straightforward. To see why, consider a situation 
where the probability of missingness at time j is determined by all or some of the 
observed elements of Y. Since with non-monotone data none of the time points are 
uniformly more observed than others, and because MAR missingness cannot depend 
on unobserved values, the missingness process at any particular time point is 
necessarily dependent on which elements of Y are observed. In other words, the 
probability of missingness in Y2 can depend on Y1 only if Y1 is observed, but will 





When forced to think about the functional forms of the missing data process under a 
MAR mechanism in non-monotone data it is often apparent that such processes are 
possible only in rather contrived constructions. Conveniently the non-response 
process is often not of direct interest, and one can proceed to estimate the response 
model under a MAR assumption without having to consider the form of the missing 
data process. However some authors have pointed out that statistical convenience 
alone does not justify the reliance on implausible assumptions and that more 
plausible processes under a MNAR mechanism should be considered instead (e.g. 
Robins & Gill, 1997). 
 
Simulation exercise 
Using the same bivariate normal data example from before we simulated non-
monotone missing data that were MAR. We generated missing data under a process 
where 
 
P(M1=1) = π1 =0.3 
 






























log   ,  for M1=1 
 
Again we simulated data from 3,500 subjects. The complete data means were: 
1Y =5.00; 2Y =6.02. The observed data means were: 
OY1 =4.99; 
OY2 =5.94. There was 
51% missingness on Y2 and 32% on Y1. The results from modelling these incomplete 






Table 6.6. Results from analysis with non-monotone missing data from a MAR mechanism 
(n=3,500). 









µb 5.00 0.02 







   
 
6.6 Missingness Not At Random (MNAR) 
Again using the bivariate normal data example from above we simulated 3500 sets of 
data. Missingness was then induced in Y1 and Y2 with probabilities π1 and π2 


































with α1 = –0.85 (i.e. a constant missingness probability of π1 = 0.3), α2 =0 and 
β=0.7. (Notice how missingness in Y2 now depends on the potentially unobserved 
value of Y1.) The complete (observed and unobserved) data means were 1Y  = 5.03 
and 2Y  = 6.04. The observed data means were 
OY1  = 5.03 and 
OY2  = 5.86. There was 
30% missingness on Y1 and 49% on Y2. 
 
These data were again analysed in WinBUGS using the same hierarchical model 
from before for the response mechanism. The results from fitting this model ignoring 




Table 6.7. Results from analysis with MNAR data, ignoring the non-response mechanism 
(N=3,500).  
 
(a) Random effects model 


















µb 5.02 0.02  μ1 5.02 0.02 
Time2 0.95 0.03  μ2 5.97 0.02 
2
e  





0.53 -  2
22  
1.03 0.04 
    2
12  
0.51 0.03 
       
 
The results obtained from fitting this model did not agree entirely with the complete 
data means. In particular it seems that Time2, or equivalently E[Y2] was 
underestimated, albeit to a very small degree. Since we have previously encountered 
disagreements between the multilevel modelling approach and the model specifying 
an explicit multivariate likelihood, it was important to rule out the modelling 
approach as a reason for the discrepancy. For this reason the data were modelled a 
second time specifying a bivariate normal distribution for the Y values with mean 
vector µ=(µ1, µ2)’ and Cov(Yj,Yk)=
2
jk  (Table 6.7(b)). The two approaches agree as 
we would expect with normally distributed data, but do not agree with the complete 
data means. We therefore repeated the analysis but on a larger dataset using 10,500 
sets of observations (Table 6.8). The complete (observed and unobserved) data 
means were 1Y  = 5.00 and 2Y  = 6.01. The observed data means were 
OY1  = 5.00 and 
OY2  = 5.86. As before there was 30% missingness on Y1 and 49% on Y2. 
 










μ1 4.99 0.01 















Again E[Y2] was underestimated compared with the complete data mean. In 
conclusion, although missingness in Y2 did not depend on the value of the 
unobserved Y2 value itself, modelling the response mechanism alone is not sufficient 
for unbiased estimation of E[Y2] even under this type of MNAR mechanism. 
 
6.7 Summary 
This chapter provided an account of early exploratory analysis with simple practical 
examples conducted by the author to gain experience necessary for subsequent 
analyses presented in the thesis. The chapter was introduced with an exploration into 
some alternative ways in which correlated data might be modelled using WinBUGS. 
Some well-known ideas were illustrated using practical examples. We then applied a 
few simple analyses with the incomplete PODS data comparing results from analyses 
with SAS and WinBUGS to ensure it was possible to obtain results as expected, and 
to gain familiarity with Bayesian analysis with incomplete data in WinBUGS. We 
then simulated bivariate data in SAS and induced missingness in the data through 
simple non-response mechanisms. The incomplete data were simulated under 
monotone MAR, non-monotone MAR and MNAR mechanisms. We experimented 
with alternative model fits to the simulated data in WinBUGS (including joint model 
specifications for the data and missingness mechanisms) and obtained results that 
were consistent with theory. These reassuring results illustrated that WinBUGS is a 
powerful, practicable tool that can be used for fitting models to the incomplete data 







7 ANALYSIS WITH THE SCREENING DATA USING SAS AND 
WINBUGS 
The previous chapter was concerned with the practicalities of modelling incomplete 
longitudinal data in WinBUGS with the aim of building up a practical understanding 
of ways to approach the modelling exercise. In this chapter we shall return to the 
core problem of how routinely collected repeated patient outcomes might be used to 
address research questions. 
 
The routine collection of patient outcomes may be of direct benefit to the patient in 
terms of the care they receive by facilitating communication and enabling clinicians 
to react to significant worsening of symptoms etc. On the other hand it is less clear 
how, at the aggregate level, such data may be used for research. Often the amount of 
routinely collected data exceeds by far what researchers can hope to collect in a 
purpose-designed clinical study since recruitment of patients into research projects is 
notoriously difficult and expensive. An interesting question is therefore whether 
small, but purpose-designed studies are better equipped to address research aims than 
large-scale routinely collected data. The POD Study, which was the subject of 
Chapter 5, was a purpose-designed, clinical study executed to address a set of pre-
defined research questions. In this chapter we ask if the aims of the POD Study could 
have been addressed using data that were routinely collected by the Symptom 
Monitoring Service. Specifically, we aim to replicate the POD Study analysis of 
mean distress levels and prevalence of distress after one, two, four and seven months 
among patients identified with distress (HADS score≥15) at an initial (qualifying) 
clinic appointment, and secondly, in the same cohort, the associations with persistent 
distress at seven months. 
 
7.1 The screening service 
The Symptom Monitoring Service which was described in detail in section 4.1 
routinely administered a questionnaire containing the HADS to patients when they 
attended clinics. Patients with frequent clinic appointments were consequently 





The service also recorded a reason when patients with appointments failed to 
complete the screening: some patients declined the offer of screening, others were 
unable to complete screening due to very poor health or communication difficulties. 
Sometimes patients were simply missed by the screening service, usually because 
they were taken straight to their consultation before being screened. The service also 
did not ask patients to repeat the screening if their appointments were less than four 
weeks apart. The limitations to the data were therefore considerable, partly because 
of missing data from patients who attended the clinics, and partly because of the 
opportunistic data collection method whereby patients were sampled only when they 
attended medical appointments. 
 
7.2 Derivation of the analysis sample  
During its three year period of operation the depression screening service logged 
over 100,000 appointments from more than 30,000 patients (Figure 7.1).  Of these 
24,260 patients completed the screening questionnaire at least once and gave 
permission for their questionnaire data and data about their cancer to be used for 
research in anonymised form. It was important that the sample selected for the 
current analysis corresponded to the POD Study sample as this would allow for a 
direct comparison. To be eligible for inclusion in the analysis set patients therefore 
had to:  
 
(1) have scored 15 or more on the HADS when screened during a clinic appointment 
(2) not meet criteria for major depression in the subsequent telephone interview  
(3) have a prognosis of at least 12 months as estimated by their cancer specialist  
(4) meet the first three criteria before October 2010 to allow for a reasonable period 
for follow-up data to accumulate.  
 
Patients who met the above eligibility criteria on more than one occasion were 
included in the analysis on the basis of the first occasion the criteria were satisfied. 





We also obtained NHS Caldicott approval and approval from the NHS Scotland 
Privacy Advisory Committee to link patients’ questionnaire data with data about 
their cancer held centrally by the Scottish Cancer Registry. The Registry is managed 
by NHS Scotland Information Services Division (ISD) who linked our data to the 
oncology records and prepared a merged database in anonymised form. We 
identified 2,180 cases that satisfied the eligibility criteria. Of these ISD had linked 
oncology records to 2,149 (99%) cases that were subsequently included in the 
analysis. 
 
7.3 Characteristics of the analysis sample 
The basic demographic and clinical characteristics of the analysis sample are 
presented in Table 7.1. The mean age was 62.3 years (SD: 11.9 years). The majority 
of patients included were female (81%), had breast (47%), gynaecological (18%) or 
bowel cancer (17%), and were treated with curative intent (81%). The median time 
since diagnosis was 1.4 years (IQR: 0.4 to 3.9 years). Most patients scored 15 or just 










Figure 7.1. Derivation of the analysis sample. N indicates number of appointments. n in 
parentheses indicates number of patients. 
† 
When patients met eligibility criteria more than 
once we used the first occasion as baseline in the analysis. * Patient screened very recently, 
under 18 years of age, too unwell or distressed, had cognitive or visual impairment, hearing 
or language problems, clinician advised against screening, patient’s diagnosis unclear, 
including other reasons. ** Typically patients were missed in the waiting area because they 
were called in for their appointment before the screening service could approach them.
 
§
Reasons include cancellations of scheduled clinics, patient appointment changed to a 
different clinic. 
‡ 
To ensure a reasonable follow-up period we excluded patients whose 
baseline appointment occurred after 1
st
 October 2010. 
Clinic appointments  
12 May 2008 to 24 Aug 2011 
N = 109,291 (n = 31,329) 
Patient appointment ineligible* N = 21,476 
Patient missed the appointment N = 12,438 
Service missed the patient** N = 12,032 
Patient preferred not to be  
   screened       N =   6,634 
Not screened for administrative  
   reasons
§
 N =   4,711 
Screening started but interrupted N =      738   
Patient declined permission for   
   data to be used for research N =      865 





with research consent 
N = 50,397 (n = 24,260) 
High distress score 
(HADS ≥ 15) 
N = 12,033 (n = 8,015) 
Low distress score  
(HADS < 15) 
N = 38,364 (n = 19,361) 
Refused interview    N = 911 
Could not be contacted     N = 566 
MDE diagnosis in last year   N = 683 
Recent SCID interview    N = 704 
Communication/cognitive 
   Impairment     N = 372 
Clinician advised not to interview  N = 165 
Deceased     N =   86 
Other      N = 326 
Completed interview for 
depression 
N = 8,220 (n = 6,489) 
Major depression diagnosed 
 
N = 2,868 (n = 2,568) 
Absence of major 
depression 
N = 5,352 (n = 4,360) 
Patients not matched with 
ISD clinical records 
(n = 31) 




(n = 2,180) 
Poor / unknown prognosis N = 2,183 
Baseline visit after Oct 2010
‡
  N =    616  
 
Patients included in the 
analysis sample 




Table 7.1. Demographic and clinical characteristics of the analysis sample at baseline. 
Total  2149 (100%) 
Gender   
   Female  1745 (81%) 
   Male    404 (19%) 
Age (years)   
   mean (SD) min – max  62.3 (11.9) 20 – 92 
   median (IQR)  63 (54 – 71) 
Age group   
   < 50 years  328 (15%) 
   50 to 64 years  858 (40%) 
   ≥ 65 years  963 (45%) 
Health board*   
   Lothian  627 (29%) 
   Glasgow  506 (24%) 
   Argyll & Clyde  314 (15%) 
   Lanarkshire  247 (11%) 
   Forth Valley  147 (  7%) 
   Fife   106 (  5%) 
   Tayside    97 (  5%) 
   Other
†
   105 (  5%) 
Cancer type   
   Bowel    370 (17%) 
   Breast  1003 (47%) 
   Genitourinary    185 (  9%) 
   Gynaecological    386 (18%) 
   Other    205 (10%) 
Time since diagnosis (years)   
   mean (SD) min; max  2.9 (3.8) 0.0 to 30.1 
   median (IQR)  1.4 (0.4 – 3.9) 
Treatments started in the past 2 months 
‡
   
   Surgery  251 (12%) 
   Radiotherapy    34 (  2%) 
   Chemotherapy  100 (  5%) 
Care objective 
§
   
   Curative  1473 (81%) 
   Palliative    351 (19%) 
Deprivation SIMD quintile score**   
   1  480 (22%) 
   2  450 (21%) 
   3  370 (17%) 
   4  373 (17%) 
   5  476 (22%) 
HADS score at baseline   
   mean (SD) min; max  18.8 (3.7) 15 – 38 
   median (IQR)  18 (16 – 21) 
   
Data are number (%) unless otherwise indicated. 
*
 Health board where patient was resident 
when cancer was registered. 
**
 Scottish Index of Multiple Deprivation quintile score: 1=most 
deprived, 5=least deprived. 
†
 Ayrshire and Arran, Borders, Dumfries & Galloway, Grampian 
and Western Isles. 
‡
 Variables incompletely observed: surgery N=2056, radiotherapy 
N=2000, chemotherapy N=2048. 
§





7.4 Four time points 
The sample of 2,149 patients had more than 8,000 scheduled appointments logged in 
the screening database following the initial (baseline) clinic visit. Most patients had 
just a few appointments while a small number of patients had numerous.    
 
In the POD Study, participants were followed up for a period of seven months after 
scoring high on the HADS at the baseline clinic visit; HADS measurements were 
obtained again at 1, 2, 4 and 7 months. The clinic appointments in the screening data 
did not naturally follow this temporal structure of the PODS data. We therefore 
divided the screening data into four bins where observations obtained between Day 1 
and Day 52 were classed as Month 1 data, observations between Day 53 and Day 98 
were classed as Month 2 data, observations between Day 99 and Day 177 were 
classed as Month 4 data and observations between Day 178 and Day 277 were 
classed as Month 7 data.  
 
We required just one observation per patient per time point. Where multiple 
observations were available within a single time bin, we selected the observation 
closest in time to the median time point observed in the PODS data for the relevant 
time point. Thus, for each patient we selected observations nearest in time to 34, 70, 
127 and 227 days for each of the nominal times at 1, 2, 4 and 7 months. The 
boundaries separating each of the four bins at 52, 98 and 177 days were the 
midpoints between the median time points and were chosen on the basis of providing 
good separation between the time points in the PODS data (Figure 7.2). Although 
somewhat arbitrary, the upper limit of 277 days for the Month 7 window ensured a 
symmetrical window about the median time for that time bin. The derived time 
windows fitted around the observations included for analysis from the screening data 






Figure 7.2. Timing of questionnaires collected in PODS. 
 
It is possible that a bias was introduced in prioritising patient appointments where the 
HADS was completed instead of appointments closest in time to the median time 
point, whether or not the HADS was observed. However the effect arising from such 
a bias is likely to have also been present in the POD Study where patients had the 
opportunity to complete questionnaires later if they felt unwell when first 
approached. 
 
7.5 Exploratory analysis 
All 2,149 patients necessarily provided data at the baseline visit. Table 7.2 lists the 
number of patients with appointments during follow-up and the HADS 
measurements obtained at those appointments. (The lower proportion of patients with 
observed data at 1 month relative to the number of patients with appointments was 
due to a change in procedures whereby patients screened after October 2009 were not 
asked to complete a screening questionnaire in the clinic if they had been screened 






Figure 7.3. Timing of observations included for analysis from the screening data. 
 
Table 7.2. Appointments and data completeness. 




   
Baseline 2149 (100%) 2149 (100%) 
1 month   632 (  29%)   226 (  11%) 
2 months   738 (  34%)   437 (  20%) 
4 months   814 (  38%)   499 (  23%) 
7 months   825 (  38%)   490 (  23%) 
   





Baseline Month 1 
  
Month 2 Month 4 
  
Month 7  
 
 
Figure 7.4. Marginal distributions of the observed HADS scores obtained at baseline and 
during follow-up 
  
The marginal distributions of the observed HADS scores are presented in Figure 7.4. 
The distribution was truncated at baseline, but quickly became more symmetrical at 
subsequent time points. The variance appears to remain fairly constant during 
follow-up. 
 
7.5.1 Maximum likelihood estimation of the covariance matrix 
We fitted a multivariate normal linear model to the HADS scores allowing for 




matrix using maximum likelihood estimation (Table 7.3). The associated correlation 
matrix is shown in table 7.4. 
 
Table 7.3. Maximum likelihood estimates of the variance-covariance matrix. 
 Month 1 Month 2 Month 4 Month 7 
     
Month 1 35.9    
Month 2 22.0 38.4   
Month 4 23.9 27.4 45.7  
Month 7 20.9 25.1 31.4 42.3 
     
 
Table 7.4. ML estimates of the correlation matrix. 
 Month 1 Month 2 Month 4 Month 7 
     
Month 1 1    
Month 2 0.59 1   
Month 4 0.59 0.65 1  
Month 7 0.54 0.62 0.71 1 
     
 
We also fitted a reduced model with a compound symmetry covariance instead of the 
unstructured pattern thereby reducing the number of covariance parameters from 10 
to just 2. The resultant (constant) variance estimate was 41.4, the covariance was 
26.4, and the correlation was therefore 0.64. There was no statistically significant 
evidence that the full model provided a better fit (likelihood ratio test statistic = 14.6, 
d.f. = 8, p=0.067). 
 
7.5.2 Why the missing data? 
There was a considerable amount of missing data, although this was mostly due to 
lack of patient appointments within the four time windows. The main reasons for 
missing data from patients with clinic appointments are listed in Table 7.5.  
 
The majority (51%) of the sample did not provide data at any of the follow-up time 
points. Twenty-eight percent provided data at one time point only, 13% were 
observed on only two occasions, 6% on three occasions only, and just 1% were 




Table 7.5. Reasons for missing data in patients with clinic appointments. 
 Week 4 Week 8 Week 16 Week 28 
     
Total missing 406 (100%) 301 (100%) 315 (100%) 335 (100%) 
     
Recently screened 271 (  67%)   58 (  14%)   56 (  14%)   24 (    6%) 
Patient cancelled/did 
   not attend appointment 
  37 (    9%)   44 (  11%)   49 (  12%)   67 (  17%) 
Patient was missed by  
   the screening service 
  37 (  9%)   92 (  23%)   86 (  21%)   84 (  21%) 
Patient refused screening   34 (  8%)   58 (  14%)   65 (  16%)   86 (  21%) 
Other reasons   27 (  7%)   49 (  12%)   59 (  15%)   74 (  18%) 
     
Other reasons included patient visually impaired, too ill or too upset, patient’s clinician 
advised against screening and administrative problems. 
 
Table 7.6. Patterns of missingness over the four follow-up time points. 
Pattern 
no. Week 4 Week 8 Week 16 Week 28 
Number (%) of patients with 
the indicated pattern 
      
      
1 M M M M 1106 (  51%) 
2 M M O M   197 (    9%) 
3 M M M O   195 (    9%) 
4 M O M M   148 (    7%) 
5 M M O O     82 (    4%) 
6 M O M O     72 (    3%) 
7 O M M M     67 (    3%) 
8 M O O O     65 (    3%) 
9 M O O M     58 (    3%) 
10 O O M M     34 (    2%) 
11 O M O M     28 (    1%) 
12 O O O O     24 (    1%) 
13 O M O O     24 (    1%) 
14 O O O M     23 (    1%) 
15 O O M O     13 (    1%) 
16 O M M O     13 (    1%) 
      
Total     2149 (100%) 
      
Note: O (M) indicates that the data point was observed (missed). E.g. a patient with 
missingness pattern 2 provided data at each of four weeks, eight weeks and 16 weeks, but 
not at 28 weeks. 
 
7.5.3 Means by missingness patterns 
To determine if an obvious relationship existed between the observed distress scores 
and patients’ missingness patterns we plotted the mean distress scores over time 
separately for each missingness pattern. There were no obvious indicators that 
patients with less observed data had scored differently on those occasions when their 
HADS scores were observed than patients with more observed data. To see if a better 




distress scores over time, separately for each appointment pattern in the sample. 
However there did not seem to be any obvious relationship between the level of 
distress among the available scores and patients’ appointment patterns. It seemed 
there might be other factors, not captured in patients’ appointment and missing data 
patterns, contributing to variations in patients’ distress scores. 
 
7.6 The response model 
Our goal was to fit models that could predict the missing observations. Taking a 
principled approach, we hoped to use bits of observed information about the patients 
to account for variation in the distress scores thereby making the missing data MAR. 
In that sense a MAR mechanism is a property, not of the data itself, but of the model 
used to fit the data. 
 
We collected data on the following two stochastic variables: Y, the vector of HADS 
responses and R, the vector of indicator variables. R takes the value 1 when the 
associated Y is observed, and 0 otherwise. The covariate data X are treated as 
completely observed constants for now. The joint distribution for the data from 
patient i is then 
 
f(Yi, Ri | θ, ψ, Xi)  
 
where θ and ψ are the parameters governing the response and the missingness 
processes respectively. The joint distribution can be partitioned into 
 
f(Yi | θ, Xi) f(Ri | Yi, ψ,  Xi) 
  
which is the selection model decomposition. We are interested in the complete-data 
distribution for the responses, f(Yi | θ, Xi); the missing data process is mostly a 
nuisance. We assume initially that the missingness was governed by a MAR process 
and, by definition, that the missingness process was independent of the unobserved 









, ψ, Xi) = f(Ri | Yi
O






 are the observed and unobserved segments of Yi respectively). 
With the right choice of X we would therefore be able to estimate θ by modelling 
only the data likelihood for Y while treating the contribution from the missingness 
process as a constant.  
 
We fitted the below hierarchical model to the HADS responses at 1, 2, 4 and 7 
months which were denoted by Yi1,...,Yi4.  
 




μij = αj + Xi
T
β + bi 
 




Yij is the normally distributed HADS score from patient i (i=1,…,2149) at time j 
(j=1,…,4) with mean μij and variance σe
2
. The αj are the four freely varying intercepts 
over time, Xi is the vector of time-invariant covariates from patient i with β the 
associated regression coefficients. bi are the independent, normally distributed 
subject-specific random intercepts. 
 
This model assumes a multivariate normal distribution for the repeated HADS scores 
at follow-up. The compound symmetry imposed by the multi-level model restricts 
the variances to be equal at all four time points, and likewise for the covariances 
Cov(Yij,Yik) = ρ0 for all j ≠ k, so that the correlation between any pair of scores from 
the same individual is assumed constant regardless of the separation in time between 
the measurements. These restrictions are arguably unlikely to hold entirely. We 
chose to impose these in the name of parsimony, to maintain as simple a model as is 






We fitted the model using Bayesian methods. This required that we specify prior 
distributions for the stochastic parameters. We specified a multivariate normal 
distribution for the vector of regression coefficients with zero mean vector and 
diagonal precision matrix with all entries equal to 1/1000 (WinBUGS parameterises 
the normal distribution in terms of the mean and precision which is defined as the 
reciprocal of the variance). We also specified prior gamma distributions for 1/σe
2
, 
and for the hyper-parameter 1/σs
2
. To ensure that inferences about the parameters 
were based predominantly upon the observed data, the prior distributions were all 
parameterised so as to be flat relative to the data likelihood.  
 
7.7 The covariate model 
The covariates included in the linear predictor were those of the available variables 
that were either found in exploratory analyses to be associated with the responses or 
considered important on clinical grounds. The covariates included were: gender, age 
group (<50 years; 50-64 years; ≥65 years), years since diagnosis (<1 year; 1-5 years; 
>5 years), cancer type (breast; genitourinary; gynae; lower gastrointestinal; benign; 
other), therapeutic objective (curative; palliative), surgery, chemotherapy or 
radiotherapy started in the two months prior to baseline screening (yes; no), patient’s 
residing health board (one of nine, smaller health boards were pooled together), 
Scottish Index of Multiple Deprivation (SIMD) quintile score, and whether the 
patient was still alive one year after the follow-up period. Finally, the baseline HADS 
score (range 15-42) was included as a continuous covariate. The covariates were 
mostly observed except for the treatment variables (surgery, 4% missing; 
radiotherapy, 7% missing; chemotherapy, 5% missing), and therapeutic objective 
(15% missing).  
 
In section 7.6 we noted that the joint distribution of the data could be decomposed in 
the following way 
 





Under a MAR mechanism the last factor on the right, the missingness process, can be 
treated as a constant in the likelihood expression and can effectively be ignored (that 
is unless the missingness process is itself of interest). This leaves us with the task of 
modelling f(Yi | θ, Xi), the distribution of the HADS scores conditional on the 
covariate data and the model parameters.  
 
Because the covariate data also are subject to missingness it is helpful at this point to 
divide the vector of covariates X into two parts. The first part, W, consists of the 
completely observed elements of X and are thought of as non-stochastic constants. 
The second part, Q, consists of the incompletely observed elements of X; the 
covariates subject to missingness. In contrast to the completely observed covariates 
the elements of Q will be treated in the analysis as random variables.  The joint 
distribution of the random variables (omitting the missingness indicators) can then be 
factorised in the following way 
 
f(Yi, Qi | Wi, θ, γ) = f(Yi | Qi, Wi, θ) f(Qi | Wi’, γ) 
 
where θ are the parameters governing the response process as before, γ are the 
parameters governing the distribution for Qi, the incompletely observed covariates, 
and Wi’ is a subset of Wi predictive of the missing Qi. (The elements of Wi’ were: 
years since diagnosis, cancer type and patient’s residing health board). We have 
assumed that the incomplete covariates are MAR conditional on Wi’. 
 
We specified the distribution for the responses as in section 7.6. Letting Qik denote 
the kth covariate in the Q vector from patient i we specify the joint distribution for 
the four incomplete binary covariates Q1, Q2, Q3 and Q4 (with data on surgery, 
chemotherapy, radiotherapy and curative intent respectively) through a series of 
chained logistic regressions: 
 
Qik ~ Bernoulli(πik) ,  k=1,…,4 
 









Here δk are the intercepts and Wi’
T
γk are the effects of the predictor variables on the 
dependent variable, the incomplete covariate being modelled. The last term of the 




 ={Qi1, …, Qi4}\{ Qik} 
 
with associated regression coefficients 
 
λk={λk1, …,  λk4}\{ λkk}. 
 
and amounts to the effects of the three elements of Q not being modelled as the 
dependent variable. That is ikQ
~ T
λk =  )( kl ilklQ . 
 
The four binary incomplete covariates were modelled in a series of four linked 
logistic regressions, each modelling the conditional probability of the covariate being 
present conditional on all other variables in the model, including the other three 
jointly modelled covariates. This somewhat convoluted setup of chained models is 
used to account for dependency between the elements of Q and requires iterative 
numerical estimation methods. We were able to use WinBUGS to fit the model for 
the incomplete covariate data jointly with the response model of section 7.6. The 
underlying assumption is that the simulated draws from the chained conditional 
distributions amount to the true joint distribution for the four binary covariates. 
Although the theoretical justification for this approach is lacking, in practice results 
with Multiple Imputation using Chained Equations (MICE, van Buuren & 
Oudshoorn, 2000) have been broadly promising, and the method is increasingly 
regarded as an acceptable approach for imputing non-monotone missing data from 






7.8 Auxiliary data 
Many of the patients included in the analysis had either no or only very few observed 
HADS scores during the seven months of follow-up. However a considerable 
proportion of these patients had observed HADS data from screening episodes 
completed either before the baseline visit or after the follow-up period had ended.  
 
Patients with very little observed data during follow-up contributed for obvious 
reasons with less data to the analysis than patients with more observed data. If these 
patients were systematically different from the rest of the sample in some way that 
affected their (unobserved) HADS scores, the omission of data from these patients 
would be causing bias.  
 
To increase the amount of information available in the analysis from such patients 
we extended the response model to include data from an auxiliary time point 
collected outside the study period. It was expected that the inclusion of these 
auxiliary scores would improve estimation of bi, the random subject effects, 
particularly in patients with no observed response data during follow-up whose 
predicted scores otherwise depended purely on covariate data and shrinkage effects.  
 
We experimented with the number of auxiliary data points to include from each 
patient and with the timing of them. The inclusion of an early auxiliary data point 
obtained before the baseline screening episode was problematic for two reasons: 
Firstly the effects of the covariates on the distress scores were assumed to be 
constant over time, but with increasing gaps in the time between the first and the last 
measurements this assumption became increasingly unlikely (and for some of the 
covariates, such as treatments started in the two months prior to baseline screening, 
this was clearly not the case). Secondly the estimated common correlation of 
repeated scores imposed by the hierarchical model was considerably lower when also 
including responses from before the baseline screening. Eventually we included one 
auxiliary time point from each patient where available within the first year of the 




patients in the sample), 226 of whom contributed with no data during follow-up. The 
median time since the baseline visit was 11.9 months (IQR: 10.5 to 13.5 months). 
 
The model specified in section 7.6 was thus extended to accommodate the additional 
time point simply by letting j range from one to five instead of four. 
 
7.9 Conditioning on missingness reason 
We learned in section 7.5 that there was no discernible association between patients’ 
average distress scores and patterns of missingness, at least not on those occasions 
when their scores had been observed. However, further analysis suggested that 
certain types of missingness were associated with variations in patients’ observed 
distress scores. Patients who had refused the option of screening on one or more 
occasions (the Refusers) had higher distress scores on average when their scores 
were observed, compared with those who had never refused screening. On the other 
hand, patients who were excused from screening because they had already been 
screened at a clinic appointment in the preceding four weeks (the Excused) scored 
lower on average on those occasions when their scores were observed. 
 
It is reasonable to assume that the value of the unobserved scores had they been 
observed would likewise have been higher in patients who were Refusers and lower 
in patients who were Excused. This does not violate the MAR assumption since the 
missingness process can still be independent of the unobserved responses conditional 
on the observed responses (and covariate data). But what exactly is the nature of the 
relationship between the missing data indicator and the unobserved score, between 
being a Refuser, say, and the unobserved HADS score? In its current form the model 
specified in section 7.6 (and extended in 7.7 and 7.8) imposes a dependency between 
being a Refuser and the unobserved response only via the correlation between 
repeated responses (and possibly through associations with covariates). But suppose 
Refusers have some inherent characteristic that affects their HADS score by an 





Observed scores from the Refusers would then naturally be an average of δ higher 
than scores from patients who never refused screening. But the joint modelling 
approach would only mediate part of the δ effect onto the unobserved scores unless 
the correlation between repeated scores is perfect, i.e. ρ=1. Therefore, if we believe 
the hypothesis that patients who occasionally refuse screening share a trait that 
makes them likely to be more distressed on average than patients who never refuse 
screening, then we ought to condition the responses on the presence of this trait by 
including it as a covariate in the model. Doing so will ensure that both observed and 
unobserved scores from patients who are Refusers are higher by an amount δ on 
average. 
 
A similar argument can be made for patients who were excused from screening 
because they had already been screened at a clinic appointment in the preceding four 
weeks. We therefore included two additional covariates, Refi and Exci, in the model 
specified in section 7.6 as follows: For patients who had refused the offer of 
screening at any (or all) of 1, 2, 4 or 7 months, or at the auxiliary time point, we let 
the time-invariant indicator Refi = 1 (and Refi = 0 for patients who had never 
refused). Similarly, for patients who on at least one of those measurement occasions 
were excused from screening because they had been screened at a clinic appointment 
in the preceding four weeks, we let Exci = 1 (and Exci = 0 otherwise). Importantly, 
the addition of the two indicator variables had a large effect on predictions of 
missing scores from patients with no observed follow-up data because these effects 
when otherwise exercised through the joint modelling alone disappear when there are 
no observed scores to correlate with. 
 
7.10 The refusal mechanism 
Following on from the previous section, it seems possible that patients’ unobserved 
distress scores were higher on those occasions when patients refused screening than 
on those occasions when screening was completed. The probability of a response 
being missing at time j due to patient refusal might therefore be dependent on the 
unobserved response at time j. The missing data process shown in section 7.6 is 









, ψ, Xi)  ≠  f(Ri | Yi
O
, ψ, Xi) 
 
The missing data process carries information about the unobserved values and can no 
longer be ignored when estimating θ or predicting Y
M
. To proceed with the 
estimation task in the presence of a non-ignorable missing data likelihood it is 
therefore necessary to model the full joint likelihood for the responses and the 
missing data indicators: 
 
f(Yi | θ, Xi) f(Ri | Yi, ψ,  Xi). 
 
These functions are often intractable and typically no closed form can be derived, 
although it is possible to fit the likelihood function using numerical optimisation 
algorithms, for example as implemented in WinBUGS. 
 
7.10.1 The missingness process 
A pair of indicator variables was associated with patient i at time point j such that 
{Rij,Mij}={0,0} for scores that were observed, {Rij,Mij}={1,0} for scores that were 
missing due to refusals, and {Rij,Mij}={0,1} for scores that were missing due to other 
reasons. The three events were modelled using two logistic regressions arranged in a 
hierarchical setup: 
 
Mij ~ Bernoulli(πMij) 
 
logit(πMij) = αMj 
 
and conditional on Mij=0 
 
Rij ~ Bernoulli(πRij) 
 





The regression for πRij modelled the conditional probability of an observation being 
missing due to refusal, conditional on the patient having been offered screening. 
Both regressions were parameterised with four separate intercepts to allow for 
varying levels of missingness at the four time points, although βR, the effect of Yij on 
πRij, was assumed constant over time. αRj and αMj reflect the average levels of 
missingness due to refusals and other reasons respectively and were estimated 
directly from the data. What is the likely relationship between the value of the 
response and the probability that the patient refused screening? In the previous 
section we explored the relationship between patients’ available responses and their 
propensity to have refused screening on at least one occasion. In a logistic regression 
we modelled the probability that patients refused screening on at least one occasion 
as a function of their average observed responses: Of patients with some available 
response data, around 7% had refused screening at least once. The estimated gradient 
of the regression (on the log odds scale) was 0.033 (95% CI: -0.005 to 0.071) 
suggesting that patients with average observed scores near the lower end of the 
HADS scale had a probability of around 4% of refusing screening one or more times. 
The equivalent probability near the top end of the HADS scale was around 15% 
(Table 7.7).   
 
We assumed that the effect of Yij on πRij would be in the same direction but of a 
lesser magnitude (bearing in mind that the model was already controlling for the 
effect of being a Refuser). Instead of a single value we assigned a prior distribution 
to βR since this approach allowed us to express the uncertainty about the parameter in 
a quantitative manner. We therefore specified the following prior distribution 
 




which was consistent with an effect half the size, but recognising through the 
variance that it could be as big as 0.033 or it could be non-existent. As a sensitivity 
analysis, the model for the missing data indicators was fitted in WinBUGS jointly 





Table 7.7. Modelled probabilities of patients refusing screening on at least one occasion as a 
function of their average observed distress score 












Based on a logistic regression with intercept: –3.08, and 
regression coefficient: 0.033. 
 
7.11 Modelling informative missingness using offsets 
A large proportion of patients had no observed response data during follow-up. 
Predictions of scores from these patients relied heavily on model assumptions as a 
consequence. Previously we have assumed that such patients were similar to the rest 
of the sample in terms of the levels of distress they experienced. However there was 
the possibility that many of them, particularly the ones who had had no appointments 
during follow-up, were in better health than the rest of the sample and consequently 
less distressed than patients with clinic appointments. Unless known to have been 
treated with palliative intent, or to have died within one year of follow-up, all 
patients without appointments during follow-up were assumed to belong to this 
group of healthier patients (in total 616 patients; 56% of all patients with no follow-
up data).  
 
As a further sensitivity model we therefore included a variable in the linear predictor 
of the response model to indicate whether patients satisfied the hypothesised criteria 
for being healthy and on long-term follow-up. We assessed the model results under a 
variety of values for this regression coefficient ranging from δ = 0 equivalent to no 






Having prepared the data for analysis using the SAS software we used a modified 
version of the publicly available SAS macro by Sparapani (2004) to transform the 
data into a format recognised by WinBUGS. The macro automatically assigns the 
value NA to any missing observations. To speed up convergence with the Gibbs 
sampler, the baseline HADS scores (range 15-42) were mean centred and rescaled to 
have unit variance to lessen the correlations between the intercepts and the regression 
coefficient and to speed up computation time. 
 
Model parameter estimates were based on 5,000 simulated draws from the marginal 
posterior distributions of the parameters, having discarded the first 8000 iterations 
generated by the MCMC algorithm (the burn-in). We sampled from two chains 
simultaneously using over-dispersed initial values and calculating the BGR 
diagnostic (Brooks & Gelman, 1998) to assess convergence, coupled with visual 
inspection of the iteration histories. 
 
7.13 Model estimates 
The parameter estimates resulting from fitting the response model specified in 
sections 7.6 – 7.9 are shown in Table 7.8. There were only small differences between 
the intercepts during follow-up with a small decrease in scores over time. The 
strongest independent predictors of the responses were: time since diagnosis, 
deprivation score and baseline HADS score (range 15 to 42). There was some 
evidence that patients who had refused screening on at least one occasion scored a 
little higher on the HADS, whereas patients who had been excused from screening 
because they had already been screened at a clinic appointment in the preceding four 
weeks scored a little lower. The parameter estimates from the imputation model for 
the four incomplete covariates are shown in Table 7.9. The modelled covariates did 
not effect large variations in the responses although there were strong associations 





Table 7.8. Estimated regression coefficients and variance parameters from fitting the 
response model. 
 Posterior mean  (SD) 
Intercepts   
   1 month 14.32 1.69 
   2 months 13.96 1.67 
   4 months 13.78 1.67 
   7 months 13.50 1.66 
   Auxiliary time point 12.98 1.65 
Gender   
   male 0.36 0.63 
Age   
   50-64 years 0.80 0.46 
   ≥65 years 0.68 0.47 
Time since diagnosis   
   1-5 years 1.26 0.40 
   >5 years 1.65 0.50 
Cancer site   
   breast -0.19 0.96 
   genitourinary 0.46 1.22 
   gynae -0.32 1.00 
   lower gastrointestinal 0.12 1.02 
   other 0.89 1.20 
Treatment intent   
   curative 0.00 0.39 
Two months from start of treatment   
   surgery -0.21 0.54 
   radiotherapy 0.00 1.29 
   chemotherapy -0.35 0.65 
Health board   
   Ayrshire and Arran -1.14 1.57 
   Fife 1.88 1.52 
   Tayside -0.82 1.52 
   Forth Valley 0.43 1.42 
   Lanarkshire 0.72 1.38 
   Argyll and Clyde -0.21 1.37 
   Glasgow 0.97 1.33 
   Lothian -0.11 1.34 
SIMD quintile score   
   2 -1.08 0.49 
   3 -1.09 0.52 
   4 -1.02 0.53 
   5 -1.36 0.50 
Vital status 1 year post follow-up   
   deceased 0.72 0.43 
Standardised baseline HADS score 1.88 0.16 
Screening refused at least once 0.87 0.54 
Screening excused at least once -0.70 0.42 
Variance terms   
   σe
2
 15.49 0.72 
   σs
2
 20.57 1.33 






  36.06 1.27 




 0.57 0.02 
SIMD denotes Scottish Index of Multiple Deprivation. The reference categories were: female 
gender, <50 years of age, <1 year from diagnosis, benign cancer type, palliative treatment 
intent, health board: others, 1st SIMD quintile, alive one year post follow-up. Baseline HADS 









Treatment started in the 2 months preceding 
baseline 
 Surgery Radiotherapy Chemotherapy 
     
Intercept  2.32 (0.20)  0.42 (0.41) -1.32 (0.60) -1.64 (0.45) 
Years since diagnosis  0.18 (0.04) -6.71 (0.60) -1.63 (0.41) -3.28 (0.45) 
Cancer site     
   benign -0.39 (0.45)  0.47 (0.55) -51.24 (62.21) -83.73 (60.77) 
   genitourinary -2.26 (0.21) -63.57 (61.34) -0.59 (0.70) -0.40 (0.72) 
   gynae -0.91 (0.19) -0.50 (0.28) -63.50 (61.09)  1.53 (0.30) 
   lower gastrointestinal -0.72 (0.20)  0.55 (0.25) -0.27 (0.52)  0.44 (0.33) 
   other -1.97 (0.24) -1.43 (0.60)  0.07 (0.63)  0.27 (0.52) 
SIMD quintile score     
   2 -0.23 (0.20) -0.76 (0.30) -2.04 (0.87) -0.04 (0.39) 
   3 -0.16 (0.21) -0.31 (0.30)  -0.08 (0.55)  0.56 (0.38) 
   4 -0.19 (0.21) -0.30 (0.30) -0.92 (0.62)  0.45 (0.37) 
   5  0.16 (0.21) -0.71 (0.28) -1.06 (0.58)  0.45 (0.36) 
Vital status 1 year post 
follow-up 
    
   deceased -1.64 (0.14) -0.16 (0.34)  0.01 (0.58) -0.30 (0.32) 
Treatment intent     
   curative -  1.53 (0.33) -0.52 (0.50) -0.06 (0.31) 
Treatment started in 
past two months 
    
   surgery  0.76 (0.25) - -7.39 (12.82) -0.90 (0.31) 
   radiotherapy -0.64 (0.46) -1.97 (0.94) -  1.06 (0.50) 
   chemotherapy -0.38 (0.29) -0.93 (0.30)  0.98 (0.52) - 
     
Numbers are posterior means (standard deviations). SIMD denotes Scottish Index of 
Multiple Deprivation. The reference categories are: <1 year from diagnosis, breast cancer, 
1st SIMD quintile, alive one year post follow-up. 
 
The estimated intra-patient correlation between the repeated measurements was 0.57. 
This was somewhat lower than the first estimate derived in section 7.5 of around 
0.64. However the estimates of the variance-covariance parameters presented in 
Table 7.8 are conditional on all covariates included in the model. The conditional, 
total variance of the responses, Var(Yij | αj + Xi
T






, is less because 
some of the variability that in section 7.5 was attributed to the inter-patient variance 
term, σs
2
, is now explained by the added covariates. The error term is practically 
unchanged from that estimated in section 7.5 because the covariates are time-
invariant; they explain variation between patients, not between time points.  
 
7.14 Mean profiles and prevalence estimates 
The average distress level in the sample was estimated at each of the four follow-up 




distribution for the missing responses with the means of the observed elements of Y 
at one, two, four and seven months post baseline. We also estimated the prevalence 
of significant psychological distress at each time point. This was done by pooling 
Pr( ijY
~
≥15), the predictive probability that the missing responses were 15 or more, 
with the proportion of observed scores greater than or equal to 15 at each time point 
(Table 7.10). Also shown for comparison are the equivalent estimates from the POD 
Study.  
 
Both mean distress and prevalence estimates were derived at each step of the model 
development described in sections 7.6 – 7.11. The results presented in Table 7.12 are 
from a selection of these models. 
 
7.14.1 Comparison of mean distress and prevalence estimates 
The average distress score as estimated with the screening data dropped considerably 
between baseline and one month followed by a slow decrease over the remainder of 
the follow-up period. The estimated prevalence was halved from baseline to one 
month but reduced only modestly thereafter. The prevalence estimate at seven 
months was 46.4% with a 95% confidence interval from 42.7 to 50.0% derived from 
the multiple imputed data. We found very similar patterns of change over time with 
each of the alternative scenarios, although the absolute values differed somewhat 
depending on the model (Table 7.12). 
 
Compared with the POD Study results, analysis with the screening data resulted in 
larger estimates of the mean distress scores and distress prevalence rates, but the 
patterns of change during follow-up in both mean scores and prevalence estimates 
were similar. There were many potential reasons for the level of distress being higher 
when basing the estimates on the screening data. Because of the large amount of 
missing data, the results obtained with the screening data depended largely on 
modelled data. The results were therefore highly sensitive to modelling assumptions, 
including assumptions about the structure of the relationship between the response 
variable and the covariate data, the validity and type of covariates included, 




responses. However there was also the possibility that the analysis with the screening 
data did not overestimate the parameters of interest. The discrepancies in the distress 
level might have reflected actual differences in the populations being studied. The 
cases included from the screening data were drawn from a geographically much 
wider area than those in the clinical study. There were more men in the screening 
sample (19% versus 14%, p=0.031), the screening sample was slightly older on 
average (62.3 versus 61.0 years, p=0.072) and bowel cancer was more than twice as 
prevalent than in the clinical study (17% versus 8%, p<0.001).  
 
Perhaps the sub-sample of patients in the screening data on whom we had observed 
data during follow-up was not representative of the whole cohort. Perhaps people 
seen in hospital were more distressed on average than those not seen in hospital. We 
addressed this problem in part by allowing for a lower intercept in patients on long-
term follow-up who were not seen in hospital, and assessed the findings under a 
range of plausible values for the intercept offset. 
 
The POD Study collected follow-up data from patients at home over the telephone, 
but the screening data were collected from patients who were waiting for 
appointments in hospital clinics. Perhaps the distress scores collected in the clinic 
area were transiently inflated due to the patient’s anticipation of the upcoming 
appointment, and the hospital surroundings. This would be similar to the so-called 
‘white-coat’ effect where patients exhibit higher blood pressure levels when 
measured in a clinical setting than when measured at home. We investigated this 
possibility in detail in Chapter 4 and found some evidence that patients scored 
around 0.5 units higher on the HADS when measured in the clinic instead of at home 
over the telephone. We also found that patients who refused screening were more 
distressed on average. The analysis of the screening data included all eligible cases 
initially identified with distress, but the POD Study only followed up patients who 
had agreed to take part in a clinical study. It is likely that this self-selected group 





7.15 Multiple imputed datasets 
The second aim of the study was to determine whether early predictors of long-term 
distress existed where long-term distress was defined as significant distress at seven 
months, Yi4 ≥ 15.  
 
The POD Study addressed this research question using a multivariable logistic 
regression to estimate associations with a set of demographic and disease 
characteristics. We wanted to repeat this analysis with the routinely collected 
screening data. However a logistic regression including only patients with complete 
covariate data and available data at one and seven months would limit the analysis to 
include only a fraction of the original sample. 
 
Fortunately the response model that was developed in the previous sections could be 
used to predict the missing response and covariate data. We generated multiple 
imputed datasets in WinBUGS by drawing from the posterior predictive distribution 
for the missing response and covariate data. Consecutive draws obtained using the 
Gibbs sampler are not ordinarily independent. We therefore retained only every 
100th iteration of the sampler to ensure a lag between the predictions large enough 
that no autocorrelation remained in the chain. Using this method we extracted 100 
independent sets of imputations. The imputed data were saved in data files and 
imported into SAS where they were merged with the observed data to create a 
sequence of 100 completed datasets. For each completed dataset the dichotomised 
distress scores at seven months were derived from the continuous Y variables and 
analysed in a logistic regression. Finally the resultant 100 sets of estimates were 
combined into a single set of estimates based on multiple imputation theory. We 
carried out this step in SAS and used the MI procedure to combine the multiple sets 
of estimates. 
 
7.16 Associations with distress at seven months 
The aim as set out in the POD Study was to determine the demographic, cancer and 
distress characteristics at baseline that were predictive of persistent distress defined 




in the logistic regression: gender, age (<50 years/ 50 – 64 years/ ≥65 years), cancer 
site (bowel/ breast/ genitourinary/ gynaecological/ other), disease activity (disease-
free/ active disease), cancer treatments received in the two months preceding 
baseline (no treatment/ chemo or radiotherapy/ surgery only/ hormone treatment 
only), marital status (not married/ married) and baseline distress score (HADS<20/ 
HADS≥20). These were the variables available at baseline. In a subsequent analysis, 
distress status at one month was added to the list of covariates as it was hypothesised 
that a second high distress score one month after the baseline screening would 
predict distress six months later. 
 
Details on disease activity and marital status were not available in the screening data, 
and these covariates were consequently left out of the present predictor analysis. The 
screening data also only contained details on treatment start dates, but not the 
duration of treatments or dates of completion. The covariates from the screening data 
therefore only indicated whether treatments were started in the two months preceding 
baseline which is subtly different from whether treatments were received in that 
same period. For the purpose of comparing results from analysis of the POD Study 
with results from the screening data, we repeated the POD Study predictor analysis, 
but leaving out marital status and disease activity. The focus in the present chapter 
will be on the fully inclusive multivariable analysis which is adjusted for baseline 
covariates as well as distress status at one month. Results from the POD Study are 





Table 7.10. Comparison of mean levels and prevalence of distress during follow-up 
estimated from the screening data and POD Study data. 




mean (SD)  N § Mean (SE) 
      
HADS score (range 0–42)      
   Baseline   2149+     0    18.8 (0.08) #  325+ 0 18.7 (0.20) 
   1 month     226+1923 15.2 (0.34)  325+ 0 13.4 (0.31) 
   2 months     437+1712 14.9 (0.25)  307+18 13.7 (0.35) 
   4 months     499+1650 14.7 (0.22)  296+29 13.6 (0.37) 
   7 months     490+1659 14.4 (0.23)  292+33 12.7 (0.39) 
      
Distress prevalence       
   Baseline   2149+     0 100%  325+ 0 100% 
   1 month     226+1923 51.4% (2.5%)  325+ 0 40.0% (2.7%) 
   2 months     437+1712 49.7% (2.0%)  307+18 43.2% (2.8%) 
   4 months     499+1650 48.4% (1.7%)  296+29 41.6% (2.8%) 
   7 months     490+1659 46.4% (1.8%)  292+33 37.8% (2.8%) 
      
Distress defined as HADS score ≥ 15. Distress prevalence at baseline was 100% by design. 
#
 
The distribution for baseline HADS score was not estimated in the Bayesian analysis since 
this variable entered the model as a fully observed covariate. The reported numbers are the 
sample mean and (frequentist) standard error. Missing data were handled using multiple 





Table 7.11. Comparison of estimated associations of persistent distress based on analysis 
with the screening data and the POD Study data (continued on next page).  
 Screening data POD Study data 
 Adjusted  
log odds ratio  
(standard error) 
Adjusted  
log odds ratio 
(standard error) 
   
Total   
Gender   
   Female 0 0 
   Male 0.24 (0.26) 0.28 (0.81) 
Age (years)   
   < 50 0 0 
   50 to 64 0.23 (0.20) -0.01 (0.35) 
   ≥ 65 0.19 (0.20) -0.21 (0.37) 
Primary cancer   
   Bowel 0 0 
   Breast 0.10 (0.23) -0.36 (0.68) 
   Genitourinary 0.13 (0.33) -0.27 (0.78) 
   Gynaecological 0.02 (0.25) -0.32 (0.71) 
   Other  0.13 (0.28) -0.85 (0.84) 
Cancer treatment  § # 
   Surgery/chemo or  
   radiotherapy 
 
0 0 
   None or hormone 
    therapy only 
0.16 (0.18) 0.70 (0.29) 
Baseline HADS    
   Score < 20 0 0 
   Score ≥ 20 0.62 (0.14) 0.26 (0.29) 
Distress status at 1 month   
   No significant distress 0 0 
   Significant distress 1.80 (0.16) 1.70 (0.28) 









Table 7.11. (Continued). 
 Screening data POD Study data 










     
Total     
Gender  0.353  0.725 
   Female 1  1  
   Male 1.27 (0.77 to 2.09)  1.33 (0.27 to 6.48)  
Age (years)  0.509  0.761 
   < 50 1  1  
   50 to 64 1.25 (0.85 to 1.85)  0.99 (0.50 to 1.99)  
   ≥ 65 1.21 (0.82 to 1.79)  0.81 (0.39 to 1.67)  
Primary cancer  0.974  0.906 
   Bowel 1  1  
   Breast 1.11 (0.70 to 1.75)  0.70 (0.19 to 2.63)  
   Genitourinary 1.14 (0.60 to 2.16)  0.76 (0.17 to 3.51)  
   Gynaecological 1.02 (0.63 to 1.66)  0.73 (0.18 to 2.95)  
   Other  1.13 (0.65 to 1.99)  0.43 (0.08 to 2.21)  
Cancer treatment  § 0.373 # 0.015 
   Surgery/chemo or 




   None or hormone  
   therapy only 
1.17 (0.83 to 1.65)  2.01 (1.15 to 3.54)  
Baseline HADS   <.001  0.361 
   Score < 20 1  1  
   Score ≥ 20 1.87 (1.41 to 2.47)  1.30 (0.74 to 2.29)  
Distress status at 1 month  <.001  <.001 
   No significant distress 1  1  
   Significant distress 6.03 (4.37 to 8.32)  5.45 (3.15 to 9.42)  
     
Parameter estimates are conditional on all other variables in the model. Missing data were 
handled using multiple imputation. § Treatments started in the two months preceding 
baseline. # Treatments received in the two months preceding baseline. 
 
7.16.1 Comparison of results from the predictor analysis 
The two analyses resulting from the screening data and the POD Study data were in 
agreement that there were no significant associations of persistent distress at seven 
months with gender, age and cancer site, and that a strong association existed with 
distress status at one month. The POD Study results suggested that patients not in 
receipt of cancer treatments at baseline were more likely to remain distressed at 
seven months (OR: 2.01, 95% CI: 1.15 to 3.54). The point estimate of the equivalent 
effect in the screening data was smaller and not statistically significant (OR: 1.17, 
p=0.373) but did not contradict the finding and was contained within the 95% 




screening data suggested that the baseline HADS score was a significant predictor, 
but only when distress at one month was left out of the multivariable model did the 
POD Study confirm this finding (OR: 1.89, 95% CI: 1.13 to 3.16; results not shown 
in Table 7.11). 
 
Again there were several possible reasons for these discrepancies. Of the four follow-
up time points, the scores at one month were the least observed in the screening data. 
Estimated associations involving distress status at one month therefore relied heavily 
on model predictions of scores at one month. These in turn were determined by the 
dependencies set out in the model. Via the random intercept the model imposed a 
dependency between the scores at one and seven months while simultaneously 
stipulating a constant effect of the baseline score on the scores at each of one, two, 
four and seven months. Hence, it is not surprising that the modelled screening data 
suggest a statistically significant effect of the baseline distress variable independent 
of distress at one month. The independent effect of having a high baseline distress 
score was estimated in the POD Study to increase the odds of distress at seven 
months by a factor of 1.30 (95% CI, 0.74 to 2.29). The confidence interval for this 
effect comfortably includes 1.87 which is the point estimate of the same effect 
derived with the screening data. There was no evidence therefore that the results 
were contradictory. Lastly, we noted above that the variables available on the cancer 
treatments received by patients in the POD Study and in the screening data were not 
entirely equivalent. This could have explained some of the difference in the 
estimated associations with persistent distress at seven months. In summary, the 
results from the two analyses were rather similar and with no directly contradictory 
results. 
 
The predictor analysis was repeated with data imputed under the models of section 
7.10 and 7.11. Results from analysis under these alternative models were very similar 





Table 7.12. Mean levels and prevalence of distress during follow-up estimated from the 






MNAR offset for patients on  
long-term follow-up 
 δ= -0.5 δ= -1.0 δ= -2.0 
     
HADS score (range 0–42)     
   Baseline   18.8 (0.08)#   18.8 (0.08)#   18.8 (0.08)#   18.8 (0.08)# 
   1 month 15.7 (0.35) 15.1 (0.34) 15.0 (0.34) 14.9 (0.34) 
   2 months 15.3 (0.25) 14.8 (0.25) 14.7 (0.25) 14.5 (0.25) 
   4 months 15.1 (0.23) 14.6 (0.22) 14.5 (0.22) 14.3 (0.22) 
   7 months 15.0 (0.24) 14.3 (0.23) 14.2 (0.23) 14.0 (0.23) 
     
Distress prevalence      
   Baseline 100% 100% 100% 100% 
   1 month 53.8% (2.4%) 50.8% (2.5%) 50.2% (2.5%) 49.0% (2.5%) 
   2 months 51.9% (1.8%) 49.1% (1.9%) 48.5% (1.9%) 47.3% (1.9%) 
   4 months 50.7% (1.7%) 47.7% (1.7%) 47.1% (1.7%) 45.8% (1.7%) 
   7 months 49.5% (1.7%) 45.7% (1.8%) 45.1% (1.7%) 43.8% (1.8%) 
     
Data are posterior means (SD). Distress defined as HADS score ≥ 15. Distress prevalence 
at baseline was 100% by design. #
 
The distribution for baseline HADS score was not 
estimated in the Bayesian analysis since this variable entered the model as a fully observed 








Table 7.13. Analysis of the screening data imputed under the alternative models of sections 
7.10 – 7.11. Prevalence of distress at seven months and associations with patient 
characteristics (Continued on next page). 
 Multivariate analysis 
 
Non-ignorable refusal 
mechanism, βR=0.0164.  
MNAR missingness 
through 
δ =-2 offset for patients on 
long-term follow-up. 
      








      
Total      
Gender  0.463   0.290 
   Female 1   1  
   Male 1.21 (0.73 to 2.02)   1.32 (0.79 to 2.19)  
Age (years)  0.527   0.535 
   < 50 1   1  
   50 to 64 1.24 (0.85 to 1.82)   1.25 (0.84 to 1.86)  
   ≥ 65 1.23 (0.83 to 1.83)   1.20 (0.80 to 1.81)  
Primary cancer  0.951   0.993 
   Bowel 1   1  
   Breast 1.03 (0.68 to 1.58)   1.08 (0.69 to 1.69)  
   Genitourinary 1.26 (0.69 to 2.33)   1.13 (0.60 to 2.14)  
   Gynaecological 0.98 (0.60 to 1.59)   1.07 (0.65 to 1.75)  
   Other  1.08 (0.63 to 1.87)   1.10 (0.62 to 1.95)  
Cancer treatment ¥  0.387   0.567 





   None or hormone 
therapy only 1.16 (0.83 to 1.64) 
  
1.10 (0.79 to 1.55) 
 
Baseline HADS   <.001   <.001 
   Score < 20 1   1  
   Score ≥ 20 1.83 (1.38 to 2.42)   1.86 (1.40 to 2.46)  






   No significant distress 1   1  
   Significant distress 6.39 (4.72 to 8.66)   6.24 (4.51 to 8.65)  






Table 7.14. (Continued). 
  Multivariate analysis 
  Non-ignorable refusal 
mechanism, βR=0.0164, 
and δ =-2 offset for 
patients on long-term 
follow-up. 







    
Total    
Gender   0.413 
   Female  1  
   Male  1.25 (0.73 to 2.14)  
Age (years)   0.572 
   < 50  1  
   50 to 64  1.23 (0.83 to 1.81)  
   ≥ 65  1.22 (0.82 to 1.81)  
Primary cancer   0.980 
   Bowel  1  
   Breast  1.01 (0.64 to 1.58)  
   Genitourinary  1.22 (0.65 to 2.28)  
   Gynaecological  1.02 (0.62 to 1.68)  
   Other   1.06 (0.62 to 1.81)  
Cancer treatment ¥   0.500 





   None or hormone 
therapy only 
 
1.12 (0.80 to 1.58) 
 
Baseline HADS    <.001 
   Score < 20  1  
   Score ≥ 20  1.82 (1.38 to 2.39)  





   No significant distress  1  
   Significant distress  6.57 (4.88 to 8.85)  
    












A main focus throughout this chapter has been the limitations of the screening data 
and the methodological approaches used to analyse these. To provide a repeat 
discussion of these in this section serves little purpose, however the following few 
points have not been made previously.  
 
The linked oncology data provided details related to each primary cancer, but did not 
include information on recurrences. When patients had more than one primary cancer 
recorded, we used information pertaining to the most recent cancer prior to their 
baseline distress measurement. The nature of the clinical data was such that we could 
not reliably assess the effect of time-varying covariates, such as starting treatment, or 
having a second primary cancer diagnosis during follow-up. We were also unable to 
link reasons for patients’ clinic visits, or the content of their consultations, to 
variations in distress profiles because the screening data did not include details about 
the consultations. Furthermore, not all sections of the hospital oncology clinics were 
monitored. There is therefore a possibility that some patients may have had clinic 
appointments that were not recorded in the screening database. 
 
We also found that there were too few observations to estimate reliably the covariate 
effects separately at each time point. The model was therefore restricted to include 
only constant effects of the covariates over time. This was likely to be an 
oversimplification. Particularly the treatment variables and the baseline distress score 
may have had relatively larger effects early on during follow-up. Ideally, with more 
observed data, the model could have accommodated time interactions with some of 
the covariates. Having selected cases for analysis from the irregularly spaced 
screening data we forced the measurements into a regular framework to match the 
structure of the PODS dataset. As a result some data were discarded where multiple 
measurements existed within a time window. As an alternative to this, a more 
efficient approach might have applied an analysis with the screening data that was 
capable of utilising the data in its original irregular form. Finally, the data included in 




have been selected differently, and different estimates might have resulted as a 
consequence. Also, the functional form of the imputation model may not have been 
representative of the true dependencies in the data.  
 
The choice of ‘non-informative’ prior distribution for the subject-level variance 
parameters in longitudinal models is not straightforward. We specified an inverse-
gamma prior distribution for σs
2
. Although this choice of prior has been suggested in 
the past with hierarchical models (Spiegelhalter et al., 2003), Gelman (2006) advises 
against the use of the inverse-gamma prior distribution on variance parameters in 
hierarchical models when the aim is to specify a weak prior relative to the data 
likelihood. The article uses an example to illustrate how the choice of ‘non-
informative’ prior can have a big effect on the posterior distribution. The problem is 
more serious when the group-level variance is close to zero and if the number of 
groups (subjects in our example) is small because the data then contain little 
information about the group-level variance. The article recommends using a non-
informative uniform prior or a half-normal centred at zero for the class-level standard 
deviation in place of the inverse-gamma distribution on the variance. We refitted the 
main model from this chapter using as a prior for σs the half-normal distribution 
centred at zero with variance equal to 100
2
 but found no discernible change in the 
posterior for σs or indeed for any of the other model parameters, perhaps because of 
the large number of subjects and relatively large subject-level variance. 
 
7.17.2 In conclusion 
In this chapter we presented an analysis of routinely collected psychological 
screening data from oncology outpatient clinics. We aimed to determine whether 
analysis of such incomplete data could be used to address research questions by 
comparing the results with those of a purpose-designed clinical study. Overall we 
obtained similar results with the two analyses. We also found that the average level 
of distress and the prevalence of distress cases were somewhat higher in the 
screening data. We gave a number of possible reasons why the results from the two 
analyses might not agree entirely. It was not possible to conclude definitively 




estimates were different as a result of bias in the screening data. The sensitivity 
models yielded largely similar results to the main model; perhaps the model 
assumptions behind these were not extreme enough to capture the actual confounding 
mechanisms at play.  
 
Both the findings from the predictor analysis and the estimated regression 
coefficients of the imputation model suggested that only very few of the covariates 
were associated with the response variable and that none of the associations were 
particularly strong. This is important because the analysis relied on dependencies 
within the observed data to model the incomplete responses. The lack of strong 
associations may have been a consequence both of the design, whereby only patients 
with a high baseline score were followed up resulting in a strong regression-to-mean 
effect, and the choice of a psychological self-report as the response variable, which is 
known to have a large random error. Given the large amount of missingness in the 
screening data it is not surprising then that it proved a challenge to reproduce exactly 






8 FURTHER ANALYSIS WITH THE SCREENING DATA 
In this chapter we will again consider the routine data collected by the screening 
service, but this time for original research purposes addressing questions that have 
not been adequately studied elsewhere. The chapter will focus on the development of 
methods for an analysis of incomplete two-stage screening data. 
 
8.1 Background 
Depression is thought to be a relatively common problem among people who have 
had a cancer diagnosis although exactly how common is unclear. A recent systematic 
review (Walker et al., 2012) found that published prevalence estimates vary wildly 
due to small and poorly executed studies. Consequently there is a need for a good, 
large-scale study of the prevalence of depression in clinically meaningful subgroups 
of people who have had a cancer diagnosis.  
 
The Symptom Monitoring Service routinely screened patients for symptoms of 
depression when they attended appointments in the screened cancer outpatient 
clinics. The service screened more than 20,000 patients using diagnostic interviews 
to assess patients for major depression. There are no other studies of depression in a 
cancer outpatient population that are based on sample sizes of this magnitude. Based 
on analysis with the screening data we therefore aimed to:  
 
(1) estimate the prevalence of depression among patients with a cancer diagnosis 
attending outpatient oncology clinics 
 
(2) identify patient demographic and clinical characteristics associated with 
major depression 
 
8.2 The data 
The Symptom Monitoring Service (further details in Chapters 4, 5 and 7) was a 
depression screening service that operated in a large number of NHS cancer 
outpatient clinics in central Scotland covering a geographically defined area of about 




with the details of patients scheduled to attend for appointment. When attending the 
clinics, patients were approached by the screening service and asked to complete a 
brief questionnaire asking them about physical and psychological symptoms 
common to cancer patients. The questionnaire included the Hospital Anxiety and 
Depression Scale (HADS), the details of which have been described in previous 
chapters. The HADS total scale ranges from zero (no distress) to 42 (maximal 
distress), and a HADS total score of 15 or more has been shown to be a good 
indicator of significant psychological distress warranting further action when 
screening for depression. Patients who scored 15 or more on the HADS in clinic 
were subsequently telephoned at home and asked to complete an interview for 
depression using the major depression component of the Structured Clinical 
Interview for DSM-IV (SCID; First et al., 1999). Patients diagnosed with major 
depression were also asked about any antidepressant medication or psychological 
treatments they were receiving for their depression.  
 
In addition to the screening data we also obtained linked demographic and clinical 
records from the Scottish Cancer Registry (see Chapter 7) on almost all patients in 
the screening database. Over the period during which the screening service operated 
more than 30,000 people were scheduled for appointments in the screened oncology 
outpatient clinics. Over 24,000 patients completed the screening questionnaires and 
most (97%) agreed for their questionnaire data and clinical data to be used for 
research purposes (in anonymised and aggregated form) and were successfully 
matched to their clinical oncology data held by the Scottish Cancer Registry (Figure 
8.1). The final linked research database was prepared in anonymised form by NHS 
Scotland Information Services Division (ISD).  
 
8.3 A layered approach to the analysis 
The screening service operated a two-stage screening service whereby patients were 
screened first using the HADS, and second, if they had scored high on the HADS, 
over the telephone using a clinical interview for depression. The idea behind this 
procedure was that in principle only patients with a high clinic HADS score can be 




would therefore be wasteful. (We will return to this assumption later in section 8.11). 
Yet even of those who had scored high on the HADS, 21% (1276/6108) did not 
complete the clinical interview for depression.  
 
The prevalence estimation problem can be thought of as existing across a number of 
layers. The inner-most layer consists of patients who either scored low on the HADS 
in clinic (score<15), or scored high on the HADS and completed the subsequent 
depression interview. Within this layer we can be very confident about the data, but a 
prevalence estimate based on this subgroup has little external validity.  
 
The second layer consists of all patients who completed the HADS in clinic, some of 
whom scored high but failed to complete the subsequent depression interview. While 
it is clear that the depression diagnosis is not MCAR in this case, it may be 
reasonable to assume that it is MAR conditional on HADS≥15. Within this layer we 
have to make some assumptions about the unobserved data but there is greater 
external validity. 
 
The final layer consists of all patients with at least one scheduled appointment in one 
of the screened clinics. This layer includes patients who completed screening but did 
not want their data used for research, patients who were not matched to their clinical 
records, and nearly 7,000 patients who never completed screening. Clearly, an 
estimate based on such a sample would have good external validity, although one 
would have to make strong assumptions about the unobserved data.  
 
In the following we will approach the analysis within this framework, starting with 







Figure 8.1. Derivation of the analysis sample. 
‡
 Reasons included patients not attending 
appointments, patients missed in the clinic, patients declining screening, clinicians advising 
not to screen, patients too unwell or unable to use screening.
 †
 If patients made multiple 
clinic visits, the first visit on which the HADS was available was used in the analysis. 
Refused interview      483 
Could not be contacted      299 
Other        162 
Hard of hearing/language issues    138 
Clinician advised not to interview      67 
Deceased          53 
Cognitive impairment          47 
Inpatient           27 
Patients completing SCID 
interview for depression  
N=4,832 
High distress score in clinic  
(HADS ≥ 15) 
N=6,108 
Patients scheduled for 
appointments 
12 May 2008 to 24 Aug 2011 
N=31,329 
 
Patients completing the 
HADS  
N=24,423 
Patients consenting to 





(23,573 matched by ISD) 
Declined permission to use data for         163 
research              
Data linkage yielded no matching            687 
 clinical records              
 
Did not complete screening 
‡ 
            6,906  
Low distress score in clinic 
(HADS < 15) 
N=17,465 










8.4 Choosing a single observation from each patient 
More than 24,000 patients completed the HADS questionnaire, but many patients did 
so more than once. Put together, patients completed the questionnaire more than 
50,000 times. When patients completed the questionnaire more than once there was a 
choice therefore as to which questionnaire to include in the analysis. We considered 
three alternatives. 
 
First, the questionnaire to be included in the analysis could be chosen at random from 
the set of available questionnaires from each patient. (This rule could also be based 
on appointments rather than available questionnaires, such that the appointment 
included for analysis is chosen at random from the patient’s history of appointments. 
Missing data arising from appointments with no available questionnaire scores would 
then have to be handled in the analysis.) One potential problem with this approach is 
that many patients came to clinic only once; consequently many of the scores would 
originate from the patients’ first clinic visit. 
 
More straightforward perhaps is the second option whereby the patient’s first 
appointment is always selected for inclusion in the analysis and any subsequent 
appointments are ignored. Again with this approach the sample would be subject to a 
substantial degree of missingness. 
 
The third option is more pragmatic and would base the analysis on the first available 
questionnaire from each patient.  Therefore if a patient attended the clinics twice, but 
only completed the questionnaire on the second occasion (or declined research 
consent on the first occasion), the analysis would be based on data collected at the 
second appointment. 
 
The main analysis presented in this chapter was based on option three above. Figure 
8.1 shows the derivation of the analysis sample. There was a potential risk of bias 
associated with this option because patients’ psychological distress levels might have 




although major depression is more persistent in nature than other types of 
psychological distress. 
 
8.5 The problem with an overall estimate 
A first overall estimate of the depression prevalence was based on the 23,573 
patients with available HADS scores. Of these, 6,108 (26%) scored high (score≥15) 
on the HADS and were shortlisted for further investigation, 4,832 patients actually 
completed the depression interview, and 1,774 (37%) of these were found to have 
major depression. So how can we derive an overall prevalence estimate from these 
figures? 
 
Of the 23,573 patients who completed the HADS, 1,276 patients (6,108 – 4,832) had 
a missing depression diagnosis, all of whom had scored high on the HADS. A naïve 
analysis might derive the number of confirmed depression cases as a proportion of 
the total number of patients, 1774/23573=7.5%. This produces an obvious 
underestimate of the true rate of depression among patients who completed the 
HADS. The analysis assumes that none of the 1,276 patients with a high HADS 
score and a missing depression diagnosis were actually depressed. A more likely 
assumption was that the rate of depression among this group of patients was the same 
as that in the group who did complete the interview. (Assuming that the depression 
diagnosis is missing at random conditional on the clinic HADS score.) 
 
Hence, the overall depression estimate is the product of the rate of depression among 
patients with HADS≥15 and the proportion of patients with a high HADS score: 
 





x  = 0.095. 
 
So, an overall estimate of the prevalence of depression among cancer outpatients 






However it is difficult to know how this estimate generalises to an external, 
meaningful population, the reason being that the depression screening service 
targeted clinics that specialised in cancer types carrying a high risk of major 
depression. For example, the screening service operated in Urology clinics for a 
limited period only because major depression proved not to be very prevalent among 
patients who visited these clinics; as a consequence, to optimise the use of resources, 
the screening service chose to focus on other cancer types. The estimate is therefore 
biased due to an overrepresentation of patients with certain cancer types known to be 
associated with major depression. 
 
Aside from this issue it is also questionable to what extent an overall estimate across 
all cancers is clinically useful. More relevant to clinical practice perhaps are 
prevalence estimates among subgroups of patients, for example as defined by the 
cancer site. 
 
8.6 The patient data 
The most common cancer types represented in the screening database were breast 
cancer (N=8,462), lung cancer (N=4,316), lower gastrointestinal cancers (N=3,356), 
gynaecological cancers (N=3,010), and genitourinary cancer (N=2,009). As these are 
the five most common cancer types the analysis was limited to focus on these. 
 
The patient characteristics collected by the screening service and from the linked 
clinical records are presented in Tables 8.1 and 8.2. Complete data were available on 
most variables. The notable exceptions were clinic appointment type (1% missing), 
the treatment variables (4%, 3% and 6% missing for chemotherapy, radiotherapy and 
surgery respectively), therapeutic objective (12% missing) and prognosis for patients 
with a high clinic HADS score (9% missing). The screening service helped identify 
patients that were eligible for clinical trial participation, and for that purpose the 
service enquired about prognoses for patients with a high HADS score. 
 
There were 46 patients whose date of diagnosis as registered by the Scottish Cancer 




highlight inaccuracies in the cancer registry; however out of more than 20,000 
registrations, this level of inconsistency is hardly alarming. The registered diagnosis 
date for most of the 46 patients was very soon after the clinic appointment. For six 
patients however, the diagnosis date was between one and two years after the first 
clinic appointment perhaps suggesting that the cancer registered in the database 
might not have been the first primary cancer for those patients.  
 
In the analysis that follows we will estimate the prevalence of depression separately 
within each of the five main cancer types listed above. We will also analyse the data 
for associations between patient characteristics and major depressive disorder as this 






Table 8.1. Patients’ demographic and clinic characteristics. 
  
Total 21,153 (100%) 
Gender  
  Female 15113 (71%) 
  Male   6040 (29%) 
Age (years)  
   mean (SD) min – max 64.4 (11.9) 19 – 100 
   median (IQR) 65 (57 – 73) 
Age group  
   < 50 years   2521 (12%) 
   50 to 59 years   4105 (19%) 
   60 to 69 years   6820 (32%) 
   ≥ 70 years   7707 (36%) 
Health board*  
   Lothian   6287 (30%) 
   Glasgow   4320 (20%) 
   Argyll & Clyde   2665 (13%) 
   Lanarkshire   2558 (12%) 
   Forth Valley   1615 (  8%) 
   Fife    1246 (  6%) 
   Tayside   1592 (  8%) 
   Other
†
      868 (  4%) 
Resident setting  
   Urban 16689 (79%) 
   Small town   2001 (  9%) 
   Rural   2461 (12%) 
Deprivation SIMD quintile score**  
   1   4572 (22%) 
   2   4259 (20%) 
   3   3781 (18%) 
   4   3731 (18%) 
   5   4808 (23%) 
Clinic appointment type  
   First appointment    3118 (15%) 
   Return appointment 17761 (84%) 
   Missing data     274 (  1%) 
Clinic HADS score  
   mean (SD) min – max 10.4 (7.5) 0 – 42 
   median (IQR) 9 (5 – 15) 
Clinic distress status  
   HADS<15 15641 (74%) 
   HADS≥15   5512 (26%) 
  
Data are number (%) unless otherwise indicated. 
*
 Health board (HB) where patient was 
resident when cancer was registered. 
†
 Ayrshire and Arran, Borders, Dumfries & Galloway, 
Grampian and Western Isles. 
**
 Scottish Index of Multiple Deprivation quintile score: 1=most 
deprived, 5=least deprived. Note: in addition to other missing data indicated, health board, 




Table 8.2. Patients’ disease and treatment characteristics. 
  
Total 21153 (100%) 
Cancer type  
   Lower gastrointestinal    3356 (16%) 
   Breast   8462 (40%) 
   Genitourinary   2009 (  9%) 
   Gynaecological   3010 (14%) 
   Lung   4316 (20%) 
Time since diagnosis (years)  
   mean (SD) min; max 2.4 (3.3) -2.0 – 31.5 
   median (IQR) 1.0 (0.3 – 3.2) 
Chemotherapy treatment started  
   Yes 11028 (52%) 
   No   9331 (44%) 
   Missing data     794 (  4%) 
If yes, time since treatment started (months)  
   mean (SD) min; max 1.8 (2.5) -1.7 – 14.0 
   median (IQR) 0.7 (0.1 – 2.8) 
Radiotherapy treatment started  
   Yes 11070 (52%) 
   No   8764 (41%) 
   Missing data   1319 (  6%) 
If yes, time since treatment started (months)  
   mean (SD) min; max 1.7 (2.7) -1.7– 13.3 
   median (IQR) 0.4 (0 – 2.8) 
Surgical treatment received  
   Yes 14218 (67%) 
   No   6365 (30%) 
   Missing data     570 (  3%) 
If yes, time since surgery (months)  
   mean (SD) min; max 2.4 (2.8) -2.3 – 14.1 
   median (IQR) 1.2 (0.3 – 3.7) 
Therapy objective  
   Curative 13128 (62%) 
   Palliative   5413 (26%) 
   Missing data   2612 (12%) 
Poor prognosis (patients with HADS≥15 only)
#
  
   Yes   521 (  9%) 
   No 4469 (81%) 
   Missing data   522 (  9%) 
  
Data are number (%) unless otherwise indicated. # Poor prognosis was defined for lung 
(non-lung) cancer patients as a life expectancy of less than three (twelve) months. For 
purposes of clinical trial recruitment the screening service enquired about prognoses for 






8.7 The response model 
The two patients with missing data on health board, resident setting and deprivation 
score were removed from the analysis. However, the incompletely observed 
variables on the remaining 21,151 patients were handled in the analysis. 
 
About one fifth of patients who had scored high on the distress measure in clinic 
failed to complete the clinical interview for depression, and the depression status 
(depressed/not depressed) was consequently missing for these patients. (In section 
8.11 we shall revisit the assumption that only patients with a high distress score can 
be depressed). 
 
Conditional on covariate data it seems reasonable to assume a similar level of 
depression among these patients as was observed among patients who completed the 
depression interview. This corresponds to a MAR assumption conditional on 
covariate data. Therefore in predicting the missing depression diagnoses we 
modelled the dependencies between the covariate data and the response variable, 
depression (yes/no), on the dependencies observed among the high scorers 
(HADS≥15) who had completed the depression interview. 
 
Using Bayesian methods in WinBUGS we fitted the following model to the data 
observed from patients with a clinic HADS of 15 or more. 
 


















Through the log odds link function the logistic regression models the probability πi 





 is a row vector of covariate data belonging to patient i 
and β is the vector of corresponding regression coefficients. We included most of the 




purpose of this model was to impute the missing depression diagnoses. Thus, we 
regressed the outcome on the following variables: gender, age group, health board, 
resident setting, deprivation score, clinic HADS score, cancer type, time since 
diagnosis (<3 months, 3-12 months, 1-3 years, >3 years), recently started on 
treatment (received surgery or started chemotherapy or radiotherapy in preceding six 
months) and therapy objective. We specified a multivariate normal distribution for β 
with mean vector µ=0, and a diagonal precision matrix Σ
-1
 with all entries equal to 
0.001. 
 
8.8 The covariate model 
The relevant four incompletely observed covariates were: therapeutic objective 
[curative/palliative] and the three binary treatment variables, chemotherapy, 
radiotherapy and surgery started in the preceding six months. The variables were 
modelled jointly in a set of linked logistic regressions as in Chapter 7.  
 
Consider the vector of covariates, Xi, as consisting of two parts. The first part, W, 
consists of the completely observed elements of Xi and are thought of as non-
stochastic constants while the second part, Qi, consists of the incompletely observed 
elements of Xi. The elements of Qi are treated in the analysis as random variables.   
 
We also define Wi’ to be a subset of Wi that consists of variables that are predictive 
of the missing Qi. Through exploratory analyses we found the following completely 
observed covariates to be relevant in predicting the four incomplete covariates: 
health board, age category, deprivation score, cancer type and time since diagnosis 
(<3 months, 3-12 months, 1-3 years, >3 years). 
 
Letting Qik denote the kth covariate of the Q vector from patient i we specified the 
joint distribution for the four incomplete binary covariates Q1,…, Q4 through a series 
of chained logistic regressions: 
Qik ~ Bernoulli(πik) ,  k=1,…,4 
(model 8.2) 









Here δk are the intercepts and Wi’
T
γk are the effects of the predictor variables on the 




 ={Qi1, …, Qi4}\{ Qik} 
 
with associated regression coefficients 
 
λk={λk1, …,  λk4}\{ λkk}. 
 
and amounts to the effects of the three elements of Q not being modelled as the 
dependent variable. That is ikQ
~ T
λk =  )( kl ilklQ . 
 
Although the response model was fitted only to data from patients with a high 
distress score, we used data from all the patients to estimate the model for the 
incomplete covariates. This was for two reasons. Firstly, there was no reason only to 
use data from patients with a high distress score to predict the incomplete covariates, 
and it seemed sensible to increase confidence in the estimated parameters by basing 
these on the full sample. Secondly, the predictor analysis described in section 8.10 
necessitated that covariate data be imputed for the full patient sample. 
 
8.9 Results 
Having specified vague normal prior distributions for the regression coefficients of 
the covariate model we used WinBUGS to fit model 8.1 for the responses jointly 
with model 8.2 for the incomplete covariates. 
 
First, we fitted the model exactly as described in section 8.7 where associations with 
depression were assumed to be identical across the five cancer types. However, to 
allow for investigation of interaction effects with cancer type in the subsequent 
predictor analysis we also fitted a second model where the estimated associations 
with depression status were free to vary across cancer types. This was done by fitting 




incomplete covariates was shared across cancer types and therefore unchanged from 
that set out in section 8.8. Cancer type remained an explanatory variable in the model 
for the incomplete covariates but was removed from the linear predictor in the 
response models.   
 
Convergence was assessed using a combination of visual inspection of the iteration 
histories and formal convergence criteria evaluated by running simultaneous chains 
of the Gibbs sampler and monitoring the Gelman-Rubin statistic as described in 
Chapter 7. There were issues with convergence to a stationary distribution in the 
estimated intercept terms and regression coefficients for gender for the two response 
models relating to breast and gynaecological cancer. This is unsurprising since there 
were no males with gynaecological cancer and only very few males with breast 
cancer, none of whom were depressed (i.e. there were no events among males with 
breast cancer). Since the effect of gender was inestimable within those two cancer 
types the associated regression terms were removed from the two relevant models. 
Gender remained in the models for lung, genitourinary and lower gastrointestinal 
cancers. Based on assessment of model convergence we discarded the first 15,000 
iterations from the Gibbs sampler (the burn-in) and based inference on the 
subsequent 10,000 iterations.  
 
The results from fitting the model for the responses and missing covariate data are 
shown in Tables 8.3 and 8.4 respectively. The results in Table 8.3 are of somewhat 
limited clinical interest as the effects were estimated from a sample of patients with a 
clinic HADS score of 15 or more. However, it is reassuring that the results appear to 
be reasonably consistent across cancer types. The results from fitting the common 
model are also given for reference. 
 
The results from fitting the model for the incomplete covariates are presented in 
Table 8.4. In contrast to the response model this model was fitted to the full sample 
of patients. The effect estimates were largely as one would expect. For example, 
patients were more likely to have been treated with curative intent if they had 




had breast cancer, and if they were diagnosed long ago. There was good symmetry in 
the estimated effects among the incomplete covariates themselves. None of the 
patients who were diagnosed more than three years ago had started cancer treatment 
in the past six months, and the associated odds were therefore infinitely smaller 
compared with the reference category. To avoid estimation problems we set these 
undefined odds equal to 0.0001 through the model specification. 
 
Based on the 10,000 draws from the posterior predictive distribution for Y, the mean 
of the observed and predicted Y responses across all 21,151 patients was 0.096. This 
was the case both for the more general model and for the model where estimates 
were restricted to be identical across cancer types. This estimate of an overall 
depression prevalence in the sample of 9.6% was in good agreement with the 




Table 8.3. Estimated parameters for the response model when fitted separately for each 
cancer type and when pooled across all cancer types (Continued on next page). 























      
Intercept -1.04 (0.40) -1.29 (0.35) -2.06 (1.04) -0.38 (0.49) -0.40 (0.51) 
      
Female gender  0.32 (0.14) - -0.77 (0.63) - -0.05 (0.21) 
Age group      
   < 50 years 0 0 0 0 0 
   50 to 59 years -0.22 (0.33) -0.24 (0.16) -0.94 (0.64) -0.02 (0.28) -0.02 (0.37) 
   60 to 69 years -0.57 (0.31) -0.57 (0.17) -0.63 (0.57) -0.67 (0.27) -0.68 (0.35) 
   ≥ 70 years -1.01 (0.32) -1.39 (0.20) -1.36 (0.57) -1.23 (0.30) -1.40 (0.37) 
Health board*      
   Lothian 0 0 0 0 0 
   Glasgow  0.20 (0.20)  0.14 (0.18)  0.58 (0.54) -0.14 (0.32) -0.35 (0.32) 
   Argyll & Clyde -0.29 (0.29)  0.39 (0.18)  0.05 (0.54) -0.63 (0.42) -0.14 (0.41) 
   Lanarkshire  0.15 (0.23)  0.09 (0.20) -0.48 (1.06) -0.46 (0.32) -0.80 (0.34) 
   Forth Valley  0.29 (0.28)  0.26 (0.31)  0.38 (0.55) -0.01 (0.42) -1.08 (0.43) 
   Tayside -0.59 (0.33)  0.05 (0.27)  0.97 (1.12)  0.04 (0.43) -0.60 (0.39) 
   Other
†
  0.01 (0.27)  0.17 (0.25)  0.49 (0.88) -0.76 (0.32) -0.86 (0.47) 
Resident setting      
   Urban 0 0 0 0 0 
   Small town  0.47 (0.26) -0.30 (0.20)  0.08 (0.67) -0.20 (0.37)  0.86 (0.38) 
   Rural -0.07 (0.28) -0.27 (0.21) -0.49 (0.61)  0.06 (0.31)  0.56 (0.44) 
Deprivation SIMD 
quintile score** 
     
   1  0.35 (0.25)  0.39 (0.18)  2.29 (0.66)  0.22 (0.32)  0.65 (0.32) 
   2  0.47 (0.26)  0.31 (0.18)  1.65 (0.66)  0.12 (0.32)  0.23 (0.33) 
   3  0.16 (0.28)  0.49 (0.19)  1.71 (0.71)  0.05 (0.34)  0.34 (0.35) 
   4 -0.14 (0.32)  0.09 (0.19)  1.50 (0.67)  0.38 (0.37) -0.28 (0.39) 
   5 0 0 0 0 0 




 0.13 (0.01)  0.18 (0.01)  0.14 (0.04)  0.19 (0.02)  0.16 (0.02) 





Table 8.3. (Continued on next page). 
 Common multivariate 




Intercept -0.92 (0.18) 
  
Female gender  0.17 (0.11) 
Age group  
   < 50 years 0 
   50 to 59 years -0.23 (0.11) 
   60 to 69 years -0.63 (0.11) 
   ≥ 70 years -1.23 (0.12) 
Health board*  
   Lothian 0 
   Glasgow  0.11 (0.10) 
   Argyll & Clyde  0.04 (0.12) 
   Lanarkshire -0.05 (0.12) 
   Forth Valley  0.06 (0.15) 
   Tayside -0.11 (0.16) 
   Other
†
 -0.17 (0.14) 
Resident setting  
   Urban 0 
   Small town  0.09 (0.13) 




   1  0.46 (0.11) 
   2  0.40 (0.12) 
   3  0.39 (0.13) 
   4  0.15 (0.13) 
   5 0 
  
Clinic HADS score 
(range 15-42) 





Table 8.3. (Continued on next page). 























      
Cancer type      
   Lung - - - - - 
   Breast - - - - - 
   Genitourinary - - - - - 
   Gynaecological - - - - - 
   Lower 
gastrointestinal  
- - - - - 
Time since 
diagnosis 
     
   < 3 months 0 0 0 0 0 
   3 to 12 months  0.32 (0.18)  0.69 (0.24)  0.03 (0.52)  0.70 (0.32)  0.84 (0.30) 
   1 to 3 years  0.60 (0.22)  1.30 (0.25) -0.14 (0.54)  0.37 (0.36)  0.49 (0.33) 
   > 3 years  0.04 (0.30)  0.87 (0.24)  0.19 (0.52)  0.62 (0.37)  0.64 (0.38) 



















0.48 (0.27)  0.15 (0.20)  0.14 (0.61) -0.34 (0.29) -0.12 (0.29) 
      
Curative therapy 
objective 
 0.30 (0.18)  0.25 (0.26)  0.36 (0.37)  0.44 (0.26) -0.07 (0.28) 





Table 8.3. (Continued). 
 Common multivariate model across cancer types 
(N=5,510) 
  
Cancer type  
   Lung 0 
   Breast -0.17 (0.12) 
   Genitourinary -0.13 (0.17) 
   Gynaecological  0.06 (0.13) 
   Lower gastrointestinal  -0.26 (0.13) 
Time since diagnosis  
   < 3 months 0 
   3 to 12 months  0.52 (0.11) 
   1 to 3 years  0.63 (0.12) 




 -0.10 (0.11) 
Started radiotherapy recently
£
  0.24 (0.12) 
Received surgery recently
£
 -0.04 (0.11) 
  
Curative therapy objective  0.31 (0.10) 
  
Data are posterior means (standard deviations) of the log odds ratios. Model fitted with data 
from 1236, 1640, 280, 617, 591 and 4364 patients with observed depression status for each 
of lung, breast, genito-urinary, gynaecological and lower gastrointestinal cancers, and the 
common model respectively. *Health board (HB) where patient was resident when cancer 
was registered.
†
 Ayrshire and Arran, Borders, Dumfries & Galloway, Fife, Grampian and 
Western Isles.
 **
 Scottish Index of Multiple Deprivation quintile score: 1=most deprived, 
5=least deprived. 
£ 


































     
Intercept -0.90 (0.11) -0.58 (0.10) -2.36 (0.15) -3.17 (0.11) 
     
Curative therapy objective - -0.43 (0.07)  0.24 (0.07)  2.00 (0.07) 
Started chemotherapy 
recently -0.46 (0.06) - -0.89 (0.06) -0.19 (0.06) 
Started radiotherapy 
recently  0.47 (0.07) -0.90 (0.06) - -0.69 (0.07) 
Received surgery recently  2.00 (0.07) -0.19 (0.06) -0.62 (0.06) - 
Health board*     
   Lothian 0 0 0 0 
   Glasgow -0.74 (0.06)  0.14 (0.07) -0.36 (0.08) -0.09 (0.07) 
   Argyll & Clyde -0.83 (0.07)  0.31 (0.08) -0.46 (0.09) -0.15 (0.09) 
   Lanarkshire -0.67 (0.07)  0.17 (0.08) -0.68 (0.10) -0.15 (0.08) 
   Forth Valley -0.43 (0.08)  0.45 (0.10) -0.39 (0.11) -0.30 (0.11) 
   Tayside -0.23 (0.09)  0.05 (0.11) -0.09 (0.11) -0.33 (0.11) 
   Other
†
 -0.06 (0.08)  0.07 (0.09) -0.14 (0.09) -0.44 (0.09) 
Age group     
   < 50 years 0 0 0 0 
   50 to 59 years -0.23 (0.09) -0.44 (0.08)  0.02 (0.10)  0.39 (0.08) 
   60 to 69 years -0.46 (0.08) -0.80 (0.08)  0.00 (0.09)  0.58 (0.07) 
   ≥ 70 years -0.74 (0.08) -1.22 (0.08) -0.02 (0.10)  0.44 (0.08) 
Deprivation SIMD quintile 
score**     
   1  0.02 (0.06) -0.15 (0.07)  0.06 (0.08) -0.19 (0.07) 
   2  0.00 (0.06) -0.10 (0.08)  0.18 (0.08) -0.11 (0.07) 
   3  0.03 (0.07) -0.14 (0.08)  0.13 (0.08) -0.03 (0.08) 
   4  0.07 (0.07) -0.12 (0.08)  0.04 (0.08) -0.05 (0.08) 
   5 0 0 0 0 
Cancer type     
   Lung 0 0 0 0 
   Breast  2.68 (0.07) -0.36 (0.08)  0.27 (0.08)  2.58 (0.08) 
   Genitourinary  0.70 (0.07) -1.58 (0.14) -1.25 (0.12)  0.69 (0.12) 
   Gynaecological  1.58 (0.07)  0.42 (0.08) -1.03 (0.09)  1.73 (0.09) 
   Lower gastrointestinal  1.61 (0.06) -0.17 (0.08) -1.71 (0.11)  1.81 (0.08) 
Time since diagnosis     
   < 3 months 0 0 0 0 
   3 to 12 months  0.63 (0.06)  1.42 (0.06)  2.83 (0.08) -0.21 (0.06) 
   1 to 3 years  1.52 (0.06) -3.06 (0.17) -0.65 (0.12) -5.42 (0.16) 
   > 3 years  2.30 (0.08) -812 (590.3) -800 (602) -793 (587) 
     
Data are posterior means (standard deviations) of the log odds ratios. Parameter estimates 
are conditional on all other variables in the model. Model fitted with data from all 21,151 
patients. 
£ 
Treatment started in preceding six months. *Health board (HB) where patient was 
resident when cancer was registered.
†
 Ayrshire and Arran, Borders, Dumfries & Galloway, 
Fife, Grampian and Western Isles.
 **
 Scottish Index of Multiple Deprivation quintile score: 
1=most deprived, 5=least deprived. 
£ 





8.10 The predictor analysis 
Having fitted the prediction model for the incomplete data as described, we were 
now in a position to address the clinical research questions. We wanted to estimate 
the depression prevalence within each of the five cancer types along with 
associations with patients’ demographic and cancer characteristics. We did this by 
storing multiple independent imputed datasets from the Bayesian posterior predictive 
distribution for the missing data and analysing these using the SAS software.  
 
The investigation of predictors was carried out using logistic regression to model 
associations with major depression. Could this not have been modelled jointly with 
the imputation models for the responses and incomplete covariates? The fact that the 
imputation model (model 8.1 - 8.2) was rather different from the substantive model 
(that used for the predictor analysis) made it technically challenging to fit these 
jointly since we would have had contradictory expressions for the expected value of 
Yi within the same model specification. Besides, it seemed conceptually appealing to 
have disjoint models for the imputation and analysis stages of the problem. 
 
As described in detail in Chapter 7 we generated 100 independent imputed datasets 
from the Bayesian model by storing the predicted values for the missing variables 
from every 100
th
 iteration of the Gibbs sampler. (In fact we stored 50 datasets from 
each of two simultaneously run chains and found no systematic differences in the 
scores generated by each chain.) The predicted data were combined with the 
observed data to form 100 complete datasets. Each of these datasets were analysed 
separately and the resultant estimates combined using multiple imputation rules.  
 
From conversations with the clinical investigators we decided to include the 
following demographic and cancer characteristics in the logistic regression: gender, 
age group (<50 years; 50-59 years; 60-69 years; ≥70 years), time since diagnosis 
(<1 year; ≥1 year), recent cancer treatment (any of chemotherapy, radiotherapy or 
surgery started in the preceding six months [yes;no]), therapeutic objective (curative; 
palliative), resident setting (urban; small town; rural) and Scottish Index of Multiple 





Rather uniquely, due to the large sample size it was possible to analyse the data for 
differential subgroup effects across the five cancer types. We therefore extended the 
model to allow for interaction effects between cancer type and each of the remaining 
variables in the model (except for the effect of gender within gynaecological 
cancers). Ordinarily it would then be straightforward to assess the fit of the more 
general model over the reduced model through the likelihood ratio. However with 
multiple imputed data each dataset is different and it is not immediately obvious how 
evidence from each of the 100 likelihood ratio statistics should be combined. 
Alternatively the models can be contrasted using the Wald test to test the 
multidimensional hypothesis that the interaction terms are all equal to zero. This can 
be done by setting up Lβ=0 where L is a matrix of linear contrasts designed to pick 
out the relevant elements of β, the vector of regression coefficients. The test statistic 
is then tested against a chi-square distribution with degrees of freedom equal to the 
number of rows in L. Technically the degrees of freedom for the reference 
distribution are also dependable on m, the number of imputed datasets used, although 
with m=100 we can rely on the asymptotic properties and resort to the usual chi-
square reference distribution. 
 
The evidence from the tests for differential subgroup effects are presented in table 
8.5. Interestingly, the likelihood ratios of the general to the reduced model when 
derived for each of the imputed datasets separately were mostly significantly 
different from unity, but as is clear from table 8.5, when combining the evidence in 
the appropriate manner as described above there is no statistical evidence that such 
interaction effects exist. A single, common model across all five cancer types was 
consequently fitted. The model was estimated for each of the m=100 datasets and the 
results combined using Rubin’s rules along with their multivariate generalisation for 
group tests of multidimensional parameter vectors. The results are shown in Table 
8.6. (Despite the lack of statistical evidence for differential subgroup effects it might 
still be of clinical interest to have the analysis of associations available within each 




levels of the other covariates. The results from the analysis with the effects fitted 
separately for each cancer type are provided in Appendix A.) 
 
The prevalence of depression was highest among patients with a lung cancer 
diagnosis (13.1%; 95% CI: 11.9 to 14.2%), followed by the almost exclusively 
female patient groups with gynaecological (10.9%; 95% CI: 9.8 to 12.1%) and breast 
cancer (9.3%; 95% CI: 8.7 to 10.0%). On the other hand, the almost exclusively male 
group of patients with genitourinary cancer had the lowest depression prevalence 
(5.6%; 95% CI: 4.5 to 6.7%) followed by the more mixed gender group of patients 
with lower gastrointestinal cancer (7.0%; 95% CI: 6.1 to 8.0%). These point and 
interval estimates were derived using multiple imputation rules. 
 
Besides cancer type there were three other factors found to be predictive of major 
depression in the multivariate analysis. Female gender was predictive of major 
depression (OR: 1.49; 95% CI: 1.27 to 1.76). Younger age was a strong predictor 
with odds of depression 3.70 times higher (95% CI: 3.13 to 4.35) in the under 50s 
compared with those aged 70 years or more. Deprivation score was also a strong 
predictor with prevalence estimates ranging from 15% among those most deprived to 
5% among the least deprived (OR: 2.91; 95% CI: 2.47 to 3.44). 
 










    
Gender 
#
 3   0.36 0.948 
Age group 12 11.88 0.455 
Time since diagnosis 4   6.44 0.169 
Recent cancer treatment 4   5.04 0.283 
Therapeutic objective 4   2.44 0.655 
Resident setting 8 10.88 0.209 
Deprivation SIMD quintile score 16 20.80 0.186 
    
Global test of all interaction terms 51 56.10 0.290 
    
Based on m=100 imputed datasets. Reference distribution used is chi-square. 
# 
Interaction 




Table 8.6. Prevalence and associations of major depression in outpatients with a cancer 
diagnosis. 












Total 21151 (100) 2031 (10) 19120 (90)   
Cancer type     <.001 
   Lower GI   3355 (16) 236 (  7)   3119 (93) 1  
   Breast   8461 (40) 788 (  9)   7673 (91) 0.95 (0.79 to 1.14)  
   Genitourinary   2009 (  9) 113 (  6)   1896 (94) 1.03 (0.79 to 1.35)  
   Gynaecological   3010 (14) 329 (11)   2681 (89) 1.11 (0.90 to 1.36)  
   Lung   4316 (20) 564 (13)   3752 (87) 1.81 (1.49 to 2.20)  
Gender     <.001 
   Male   6039 (29)   456 (  8)   5583 (92) 1  
   Female 15112 (71) 1575 (10) 13537 (90) 1.49 (1.27 to 1.76)  
Age group     <.001 
   <50 years   2521 (12)   400 (16)   2121 (84) 1  
   50-59 years   4104 (19)   587 (14)   3517 (86) 0.88 (0.76 to 1.02)  
   60-69 years   6820 (32)   626 (  9)   6194 (91) 0.51 (0.44 to 0.59)  
   ≥70 years   7706 (36)   417 (  5)   7289 (95) 0.27 (0.23 to 0.32)  
Time since 
diagnosis 
    
0.670 
   <1 year 10694 (51) 1110 (10)   9584 (90) 1.03 (0.89 to 1.21)  
   ≥1 year 10457 (49)   921 (  9)   9536 (91) 1  
Recent cancer 
treatment* 
    
0.257 
   No 13642 (64) 1272 (  9) 12370 (91) 1  
   Yes   7509 (36)   759 (10)   6751 (90) 0.92 (0.79 to 1.07)  
Therapeutic 
objective 
    
0.586 
   Palliative   5892 (28)   631 (11)   5261 (89) 1  
   Curative 15259 (72) 1400 (  9) 13860 (91) 0.96 (0.83 to 1.11)  
Resident setting     0.103 
   Urban 16689 (79) 1687 (10) 15002 (90) 1  
   Small town   2001 (  9)   169 (  8)   1832 (92) 0.92 (0.76 to 1.10)  




    
<.001 
   1   4572 (22)   701 (15)   3871 (85) 2.91 (2.47 to 3.44)  
   2   4259 (20)   482 (11)   3777 (89) 2.15 (1.80 to 2.55)  
   3   3781 (18)   341 (  9)   3440 (91) 1.73 (1.44 to 2.08)  
   4   3731 (18)   254 (  7)   3477 (93) 1.30 (1.07 to 1.59)  
   5   4808 (23)   253 (  5)   4555 (95) 1  
Missing data for the depression response, recent treatment and therapeutic objective were 
handled using multiple imputation with the reported frequencies averaged over the m=100 
imputed datasets. Lower GI = lower gastrointestinal. *Any of chemotherapy, radiotherapy or 
surgery started in the preceding six months. **Scottish Index of Multiple Deprivation quintile 
score: 1=most deprived, 5=least deprived. Odds ratios are conditional on all other variables 





8.11 Revisiting HADS<15 to indicate absence of depression 
The above analysis took account of the many patients with a HADS score of 15 or 
more who failed to complete the subsequent interview for depression. However it 
was assumed that not a single one of the nearly 16,000 patients who scored less than 
15 were depressed. The threshold of 15 was chosen because it was clinically 
convenient, not because of a natural divide reflecting fundamental qualities of the 
HADS. In fact, based on a previous study (Walker et al., 2007) we anticipated that 
approximately 1% of patients who scored low on the HADS were in fact depressed.  
 
Figure 8.2 presents the distribution of HADS scores collected from the 21,151 
patients who were included in the analysis sample, and for each HADS score, the 
number of patients who were actually diagnosed with major depression. Again, the 
numbers with actual diagnoses underestimate the true number with major depression 
because not all high scorers completed the depression interview. 
 
 
Figure 8.2. Distribution of HADS scores in the analysis sample (n=21,151) and number 
with a depression diagnosis (dark grey). 
 
From looking at the distribution it is apparent that the majority of patients with a 




depressed patients decreases with lower HADS scores. It also seems reasonable to 
suppose that this gradual trend would have continued into the lower range of HADS 
scores had the screening service also interviewed patients with HADS scores in this 
range.  
 
When fitting the response model (model 8.1) to the high scorers we obtained 
estimates of the effect of the HADS score on the probability of depression. We found 
that the odds of depression were increased by a factor of 1.16 for each unit increase 
in the HADS. It is possible that this relationship between HADS score and 
depression applies to the lower end of the HADS scale as well. If so, we can use this 
to estimate the number of depressed patients who scored below 15 on the HADS. In 
fact we can improve on this even further by also taking into account the other 
covariate effects estimated in model 8.1.  
 
We used the posterior distributions for the parameters estimated in model 8.1 to 
define the predictive distribution for the missing depression responses among 
patients with HADS scores less than 15. Overall, the model predicted that 
approximately 7.3% (95% CI: 5.9 to 8.7%) of those who scored low on the HADS 
were in fact depressed (Figure 8.3). If this were the case, the resultant overall 
prevalence estimate would be around 15.0% (95% CI: 13.9 to 16.2%). 
 
The model prediction of the number of low scorers who were depressed was 
considerably higher than the 1% estimate from our previous study. Compared with 
other relevant studies included in our recent systematic review of the prevalence of 
depression in cancer patients, the overall estimate of 15% is also rather high. 
Together this suggests that the covariate effects that apply to the high HADS scorers 
cannot be applied to the whole population, and perhaps in particular that the 
relationship between HADS score and the log odds of depression cannot be 
extrapolated linearly in the way presumed.  
 
Finally we note that there are alternative ways of modelling the depression scores at 




1% of low scorers were depressed. One way to do so would be to fix the intercept of 
the prediction model to ensure a common probability of 1%. Alternatively we could 
use the prior distribution on the intercept to restrict departure from a common 
probability of 1% in a way that accommodates our confidence in this previous 
finding. However we will not pursue this any further here. 
 
 
Figure 8.3. Distribution of HADS scores in the analysis sample (n=21,151) and number 
with observed and predicted depression. 
 
8.12 Further sensitivity analysis 
The results presented in section 8.10 were derived under a MAR assumption. But 
perhaps it was unreasonable to assume that the levels of depression among patients 
who failed to complete the depression interview were similar to those observed 
among people who completed the interview. 
 
Modelling the refusal mechanism 
Approximately one third of patients who scored high on the HADS and who were 
not interviewed for depression had refused the offer of an interview. It seemed 
reasonable to suppose that suffering from a major depressive episode would increase 




twice as high in patients with depression, and that it would be no more than four 
times as high. 
 
To assess the sensitivity of the findings to these altered assumptions we modelled the 
missingness mechanism jointly with the model for the responses and missing 
covariates (model 8.1-8.2) in patients with HADS≥15. We took a similar approach as 
that outlined in section 7.10 by specifying a model for the probability of patient i 
refusing interview conditional on that patient having been offered an interview for 
depression: 
 
Ri ~ Bernoulli(πRi) 
 
logit(πRi) = αR + βRYi 
  
Here Ri =1 if the patient refused and Ri =0 if the patient accepted the offer of 
interview. πRi is the conditional probability of refusal given the patient did not fail to 
interview for other reasons. αR, the log odds of refusal in patients who were not 
depressed, was estimated from the data once βR, the increase in log odds of refusal 
among patients who were depressed, was fixed. The model was fitted jointly with 
model 8.1-8.2 first setting βR=log(2) and secondly with βR=log(4). 
 
The first scenario under which the odds of refusal were assumed twice as high in 
patients with depression yielded a value for αR = -2.61. Under this model, conditional 
on the patients having been offered an interview, the probability of refusal in patients 
who were depressed was therefore e
(-2.61+log(2))
=0.148 compared with e
(-2.61)
=0.074 in 
those who were not depressed. Under the second scenario where the odds of refusal 
were assumed four times as high in patients with depression, we found that 
αR = -3.03, and the corresponding probabilities of refusal were 0.193 and 0.048 in 
patients who were depressed and not depressed respectively. 
 
As expected the two models resulted in depression prevalence estimates that were 




section 8.10 using multiple imputed datasets from these two selection models;  the 
estimated associations were very similar indeed to the estimated associations under 
the main model.  
 
Table 8.7. Depression prevalence estimates (95% CIs) under the two alternative MNAR 
assumptions for the refusal mechanism. 
Cancer type  βR=log(2) βR=log(4) 
    
Lung  14.1% (13.0% to 15.3%) 15.0% (13.8% to 16.2%) 
Breast    9.5% (  8.8% to 10.1%)   9.7% (  9.0% to 10.4%) 
Genitourinary    5.9% (  4.7% to   7.0%)   6.1% (  5.0% to   7.2%) 
Gynaecological  11.1% (  9.9% to 12.3%) 11.3% (10.1% to 12.5%) 
Lower gastro-intestinal    7.3% (  6.4% to   8.3%)   7.6% (  6.6% to   8.6%) 
    
 
MNAR offset 
In a second sensitivity analysis we considered two scenarios again concerning 
patients who had scored high on the HADS without completing the depression 
interview. We repeated the main analysis under the assumption that (a) these patients 
had half the odds of being depressed and (b) that they had twice the odds of being 
depressed compared with patients who had completed the interview. 
 
We incorporated these assumptions by adding the term δMi to model 8.1, where 
Mi=1 (0) when Yi was missing (observed). Scenarios (a) and (b) corresponded to 
offset values of δ=log(0.5) and δ=log(2) respectively. 
 
Approximately one fifth of patients who had scored high on the HADS did not 
complete the depression interview. Under scenario (a), the prevalence in this group 
was estimated to be 26.5%, somewhat less than the 36.6% observed among those 
who completed the interview. Under scenario (b) however, the equivalent estimated 
prevalence among the unobserved group was 51.0%.  
 
The prevalence estimates under these two scenarios are shown in Table 8.8 for each 
of the five cancer types. As expected, the prevalence estimates were somewhat lower 
under scenario (a) and higher under scenario (b) compared with the main analysis, 




Again, the predictor analysis was repeated; there were no substantial differences in 
the estimated associations with major depression. 
 
Table 8.8. Depression prevalence estimates (95% CIs) under two alternative MNAR 
assumptions for the δ-offset. 
Cancer type  δ=log(0.5) δ=log(2) 
    
Lung  11.9% (10.8% to 13.0%) 14.6%  (13.4% to 15.8%) 
Breast    8.8% (  8.2% to   9.5%)   9.8%  (  9.1% to 10.5%) 
Genitourinary    5.2% (  4.2% to   6.3%)   6.2%  (  5.0% to   7.3%) 
Gynaecological  10.5% (  9.3% to 11.6%) 11.5%  (10.3% to 12.7%) 
Lower gastro-intestinal    6.6% (  5.7% to   7.5%)   7.6%  (  6.6% to   8.6%) 
    
 
8.13 Discussion 
The study aimed to determine the prevalence of depression in patients with a cancer 
diagnosis attending outpatient oncology clinics, and to identify demographic and 
clinical characteristics that were predictive of depression.  
 
We found that the depression prevalence differed markedly between cancer types, 
although some of the differential effects were attributable, at least in part, to gender 
differences. Depression tended to be more prevalent in female dominated cancers 
(breast: 9%; gynaecological: 11%) and less so in more male dominated cancers 
(genitourinary: 6%; lower gastrointestinal: 7%). But it was the mixed gender lung 
cancer group who were most likely to suffer from major depression (13%). Common 
to all cancer types, the study found that female gender, younger age and greater 
deprivation were highly associated with an increased risk of depression. The time 
since diagnosis and treatment, and the therapeutic objective, were not predictive of 
depression. 
 
In addition to the fully adjusted odds ratios we reported prevalence estimates for 
subgroups of patients defined by their gender, age, time since diagnosis and 
treatment, therapeutic objective, resident setting and level of deprivation. Because of 
the unusually large dataset it was also possible to present this information separately 
within each of the five common cancer types (presented in Appendix A). To our 
knowledge, the prevalence and associations of depression in cancer patients have not 






Because of the two-stage screening procedure and missingness both in the response 
and covariate data this was not a straightforward prevalence estimation problem, and 
the analysis consequently rested on a number of assumptions. 
 
However, we took a principled approach to the analysis. The main analysis was 
conducted under a MAR assumption: we estimated the posterior predictive 
distribution for the missing data in WinBUGS and used this to generate multiple 
independent imputed datasets for subsequent analysis in SAS. Secondly in a number 
of sensitivity analyses we used the same approach to generate multiple imputed data 
under various MNAR scenarios re-estimating the model under two different types of 
informative missingness, and choosing values to quantify the departure from MAR 
that spanned the set of plausible values.  
 
Compared with the main analysis, the results from the sensitivity analysis yielded 
prevalence estimates that were a few percentage points higher or lower depending on 
the direction and size of the departure from MAR. However, the finding that 
depression was most prevalent in lung cancer patients followed by gynaecological, 
breast, lower gastrointestinal and genitourinary cancer patients, in that order, 
remained unchanged in the sensitivity analysis. Female gender, younger age and 
greater deprivation were strongly associated with increased risk of depression under 
all scenarios. The consistency in these results provided added confidence in the 
validity of the study findings.  
 
8.13.2 Other directions 
With more time we would have liked to have carried out further analyses: some to 
investigate in more detail the robustness of the findings from the main analysis, and 
others to widen the external validity of the study. 
 
For example, to improve prediction of the missing depression responses it would 




patients’ HADS scores from subsequent clinic visits. Alternatively we could have 
modelled subsequent depression responses jointly with the depression response of 
interest to improve the predictions. This would be similar to the use of auxiliary data 
points in Chapter 7. In addition to symptoms of psychological distress, the screening 
service also asked about symptoms of pain, fatigue, disturbed sleep and nausea/ 
vomiting. It is possible that these could have been used to improve predictions of the 
missing depression responses too, although the explanatory power of these would 
presumably be limited after adjusting for a patient’s HADS score. 
 
It would also have been interesting to have repeated the analysis using data collected 
from patients’ first clinic appointment only, ignoring any subsequent appointments. 
This is the second of the three options that are listed in section 8.3 for selecting the 
analysis sample. Clearly this selection strategy would have resulted in a substantial 
degree of missing HADS and depression responses which would have had to have 
been handled in the analysis.  
 
To broaden the external validity of the analysis we could have widened the analysis 
sample to include all 31,329 patients with appointments, including those who never 
completed the HADS. However, predictions from these patients would have been 
particularly unreliable because the linked research database prepared by NHS 
Scotland Information Services Division contained no information on these patients.  
 
In a final extension, one could consider all patients living in Scotland with a cancer 
diagnosis, including those who did not have any recorded clinic appointments. Such 
an extrapolation would rely mostly on untestable assumptions but is worth a thought 
nonetheless since it is likely that the findings from this study will be interpreted in 








9.1 Summary of findings 
The observational symptoms data routinely collected by the oncology outpatient 
depression screening service in Scotland are possibly the most extensive collection of 
such data in the world. As is generally the case with routinely observed healthcare 
data, the limitations to these data were many. Nonetheless, we wondered whether 
with the right analysis approach these data might offer a unique opportunity for 
observational study on an unprecedented scale into this population.  
 
Meanwhile the POD Study was conducted to investigate the progression of distress 
symptoms over time in patients who had presented at a screened clinic with signs of 
significant distress but without meeting criteria for major depression. The study was 
undertaken in part to inform the design of a potential trial in this population. It was 
unknown to what extent such distress symptoms were likely to persist over time and 
to require treatment. The study showed that the distress prevalence dropped quickly 
following enrolment into the study, but remained rather constant thereafter and that 
around 38% of patients were still suffering from significant distress seven months 
after their clinic appointment. Distress status at one month follow-up was a strong 
predictor of persistent distress at seven months. There was also evidence that patients 
recently treated with radio or chemotherapy were less likely to remain distressed at 
seven months. A potential trial should aim to enrol patients who exhibit symptoms of 
significant distress at clinic appointment and again one month later. 
 
Having identified a subsample of patients in the screening database that satisfied the 
POD Study inclusion criteria we used the observational symptom data from this 
sample to construct a dataset which matched the structure of the POD Study. Most 
patients represented in the screening data attended appointments at a frequency that 
was much less than the frequency with which follow-up data were accrued in the 
POD Study. As a consequence, there was a substantial amount of missing data. We 
developed a model to predict the incomplete longitudinal responses (along with the 
limited incomplete covariates) under both MAR and MNAR mechanisms using 




in SAS. We found as with the POD Study that distress levels dropped initially and 
remained moderately constant with around 46% still distressed at seven months. 
Likewise, distress status at one month follow-up was seen to be a strong predictor of 
persistent distress also in this analysis. But there were also systematic departures 
from the POD Study findings. The mean distress and prevalence estimates were 
consistently higher in the screening data, and there were some differences in the 
results from the predictor analysis as well. Lastly, we used the observational 
symptom data from the screening service to conduct a comprehensive analysis to 
estimate the prevalence and associations of depression in this population. We 
estimated the depression prevalence in the five most common types of cancer and 
found that this varied from 13.1% in lung cancer patients to 5.6% in patients with 
genitourinary cancer. Female gender, deprivation and younger age were found to be 
strongly associated with depression. This will likely be the largest study in world to 
answer these questions. 
 
A recent systematic review of the prevalence of depression in cancer patients found 
that estimates vary widely due to small and poorly executed studies and depending 
on the clinical setting and diagnostic criteria used to identify patients who are 
depressed (Walker et al., 2012). The review, which included only studies that met 
basic quality criteria and used diagnostic interviews to determine caseness, found 
prevalence estimates in mixed cancer outpatients ranging from 5% to 16% and 
reported generally higher prevalence estimates from studies in palliative care 
settings. A separate review of major depression in breast cancer patients (Fann et al., 
2008) found rates of depression from about 10% to 25%. This report found higher 
rates in studies that based findings on screening instruments rather than diagnostic 
interviews. 
  
Two US studies included in a review by Mitchell et al. (2001) and which were rated 
as low quality reported depression prevalence rates among patients with 
gynaecological cancers around 23% (Evans et al., 1986; Golden et al., 1991). Two 
other small studies from the review also rated as low quality found very different 




patients (20%) in Canada and Australia respectively (Ginsburg et al., 1995; Kangas 
et al., 2005) 
 
The review also reported a pooled depression prevalence in mixed cancer in- and 
outpatients from non-palliative-care settings of 16.3% (95% CI: 13.4 to 19.5). This 
was markedly higher than the prevalence estimates derived in Chapter 8. However 
the review reported large heterogeneity in the estimates and found strong evidence of 
publication bias with few small studies reporting a low prevalence. Finally this 
review found many studies reporting the prevalence of depression individually for 
breast cancer patients and for mixed cancer groups, but found few that reported 
individually on other cancer groups as is done in Chapter 8.  
 
9.2 Context 
Where purpose-designed, prospective studies are not feasible, observational 
healthcare data can be used to study safety and effectiveness outcomes from medical 
interventions and for epidemiological research to study associations between 
exposures and outcomes. Furthermore, with the right analysis approach and a good 
background understanding we believe that pilot work with observational healthcare 
data could be used to inform future trial designs. In Chapter 7 the POD Study 
eligibility criteria were applied to the observational data to identify an analysis 
sample from the screening data that mirrored the POD Study sample at the time of 
enrolment. In a similar manner, Danaei et al. (2013) use observational data to 
emulate a randomised controlled trial to estimate the effect on coronary heart disease 
of initiating treatment with statins. The authors achieve surprisingly sound results 
and conclude that meaningful analysis of observational healthcare data requires 
background knowledge, high quality information and appropriate analytical methods. 
Equally, Overhage & Overhage (2013) write that analysis with observational data 
can produce valuable insight if careful attention is given to the limitations and the 
particular characteristics of the data. Ryan (2013) concludes that inter-disciplinary 
collaboration is key to advancing clinical research with observational healthcare data 
and that statisticians should play an integral role in ensuring the sound use and 





9.3 Limitations and other directions 
The present project is entitled Analysis of routinely collected repeated patient 
outcomes. Although we chose to study this in the context of missing data there are 
clearly many other ways that the topic can be approached. In the central analysis of 
Chapter 7 we forced an artificial temporal structure onto the irregularly observed 
data and regarded the discrete time points as either observed or missing. The chapter 
offers just this one strategy for handling the irregular spacing of the measurements. 
Other analysis approaches might have resulted in a more efficient use of the data. As 
an alternative to this setup we could have analysed the data in continuous time by 
fitting parametric curves to the available data, thus avoiding discarding data where 
multiple measurements existed within a single time window. Instrumental variables 
methods are often used for causal effects estimation in econometrics in attempts to 
control for unmeasured confounding. We did not find these methods directly relevant 
to the present research since the concern is not one of estimation of central causal 
effects. Moreover, these methods rely on the presence of instruments that are 
associated with the explanatory variable of interest but not with the outcome 
modelled. These are strong assumptions that cannot be empirically verified.  
 
The work described in this thesis is the result of a dynamic process. The project has 
evolved along with my understanding of the topic. Inevitably some chapters were 
written earlier on in the process; given the chance again there are a number of things 
that I would do differently. The review of missing data methodology in Chapter 3 
puts disproportionate emphasis on multiple imputation. However much of the content 
placed under this heading is generic to analysis with missing data. I would also have 
liked to have included a detailed account of the EM algorithm and its applications, a 
section on the special cases when closed-form derivation of incomplete data-
likelihoods is possible, and a more thorough treatment of methods for analysis with 
non-ignorable missing data. I would also have provided a review of MCMC methods 
and given an account of Gibbs sampling. In Chapter 7 and 8 the likelihood for the 
four incomplete covariates was specified in terms of a chain of fully conditional 




A less complicated alternative to this specification as suggested by Ibrahim et al. 
(2005) would be to model the joint distribution of the incomplete covariates Q using 
the following hierarchical factorisation:  
f(Q1, Q2, Q3, Q4) = f(Q4|Q3, Q2, Q1) f(Q3|Q2, Q1) f(Q2|Q1) f(Q1) 
For comparison, the main model in Chapter 7 was refitted using this alternative 
model specification; the results of this preliminary analysis suggested that 
computation time was reduced by about one sixth. The resulting posterior mean 
parameter estimates and standard deviations were practically identical to those from 
the original model with the exception of the covariate model parameters belonging to 
the three logistic regressions where the linear predictors had been reduced. 
 
The work presented in chapter 7 would have benefitted from reanalysis under 
alternative model formulations. We modelled the responses in a hierarchical model 
using univariate normal distributions at each time point that were linked via a 
random intercept. We could instead have specified the joint multivariate normal 
distribution explicitly. Alternatively the flexibility offered by WinBUGS could have 
been exploited to condition the outcome at any one time point on a function of the 
adjoining outcomes, for example in a way that would take into account their relative 
proximity in time. Future research could also explore the role of prior distributions in 
order to take full advantage of the Bayesian approach. The model presented could 
have been supplemented with assessments of model diagnostics at various stages of 
the development. Furthermore, the analysis with the screening data in Chapter 7 
could have been extended to also include estimation of the distress trajectories and 
the comparative utility of confirmatory distress measurements at one, two and four 
months follow-up as was done with the POD Study sample (sections 5.7.5 to 5.7.7). 
 
For the prediction of depression outcomes in Chapter 8 it would have been fitting to 
have modelled outcomes from other time points jointly with the outcome of interest 
in the prediction model to make full use of the longitudinal nature of the data in a 
way similar to the use of auxiliary time points in Chapter 7. Finally the screening 




received by patients identified with major depression; the inclusion of these data will 
enrich the research presented in Chapter 8.  
 
9.4 Implications 
The question that motivated this project was whether, and if so how, meaningful 
analysis using observational healthcare data can be achieved. Clearly there is no 
answer in general to this question since no analysis will suit all problems, and no 
amount of statistical ingenuity can compensate for poor data. However, of course 
there are strategies and methodological approaches that are better suited to such 
analysis than others depending on the context and data.  
 
We studied the question within the confines of the observational symptom screening 
data and the POD Study research aims and asked whether, through analysis with the 
screening data, we could reproduce the clinical study findings. It now seems that this 
was rather a tough test because the temporal structure of the screening data was not 
ideally suited to address the aims of the POD Study. As a consequence the analysis 
rested to a large degree on model predictions. In spite of this the overall findings 
from the two analyses were much the same, and there were no directly contradicting 
results. Still, there were systematic differences in the results as described above and 
one would probably not ordinarily have recommended using these observational data 
for the research aims pursued in the POD Study. On the other hand the mismatch 
between the screening data and the POD Study research aims served to illustrate 
some of the central challenges that arise when using observational data for research.  
 
So, were we able to reproduce the POD Study findings from analysis with the 
observational screening data? Mostly, but not excellently. In contrast, the cross-
sectional design of the study presented in Chapter 8 was probably better suited to 
analysis with the screening data. Setting out the motivation for the present project in 
section 1.2 we wondered about the comparative advantages of a vast but unstructured 
set of observational data versus a much smaller but deliberately designed clinical 
study. At least here the answer was clear: Thanks to the routinely collected symptom 




which we could not have achieved in a prospective clinical study. In conclusion, 
while it is not possible to provide a general answer to the question can observational 
healthcare data be used for research, the work presented in this thesis demonstrates 
that analysis with such data can potentially be advanced considerably with the use of 
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APPENDIX A: SUPPLEMENT TO CHAPTER 8  
 
Table A.1. Prevalence and associations of major depression in outpatients with a cancer 
diagnosis presented separately for five common cancer types. 
 
Lung cancer 












Total 4316 (100%) 564 (13%) 3752 (87%)   
Gender     <.001 
   Male 2216 (51%) 238 (11%) 1978 (89%) 1  
   Female 2100 (49%) 327 (16%) 1773 (84%) 1.52 (1.24 to 1.87)  
Age group     <.001 
   <50 years   150 (  3%)   39 (26%)   111 (74%) 1  
   50-59 years   591 (14%) 119 (20%)   472 (80%) 0.76 (0.48 to 1.21)  
   60-69 years 1473 (34%) 212 (14%) 1261 (86%) 0.51 (0.33 to 0.79)  
   ≥70 years 2102 (49%) 194 (  9%) 1908 (91%) 0.31 (0.20 to 0.48)  
Time since 
diagnosis 
    
0.599 
   <1 year 3362 (78%) 447 (13%) 2915 (87%) 1.08 (0.81 to 1.43)  
   ≥1 year   954 (22%) 117 (12%)   837 (88%) 1  
Recent cancer 
treatment* 
    
0.740 
   No 2613 (61%) 327 (13%) 2286 (87%) 1  
   Yes 1703 (39%) 237 (14%) 1466 (86%) 1.04 (0.83 to 1.30)  
Therapeutic 
objective 
    
0.430 
   Palliative 3105 (72%) 401 (13%) 2705 (87%) 1  
   Curative 1211 (28%) 163 (13%) 1047 (87%) 1.10 (0.87 to 1.37)  
Resident setting     0.627 
   Urban 3598 (83%) 481 (13%) 3117 (87%) 1  
   Small town 374 (  9%)   50 (13%)   324 (87%) 1.13 (0.78 to 1.64)  




    
<.001 
   1 1481 (34%) 243 (16%) 1238 (84%) 2.20 (1.50 to 3.21)  
   2 1047 (24%) 154 (15%)   893 (85%) 1.95 (1.31 to 2.91)  
   3   693 (16%)   81 (12%)   612 (88%) 1.50 (0.97 to 2.33)  
   4   536 (12%)   43 (  8%)   493 (92%) 0.98 (0.59 to 1.62)  

















Total 8461 (100%) 788 (  9%) 7673 (91%)   
Gender     0.980 
   Male     28 (    0%)     1 (  5%)     27 (95%) 1  
   Female 8433 (100%) 787 (  9%) 7646 (91%) 6.22 (0.00 to 1e64)  
Age group     <.001 
   <50 years 1413 (17%) 205 (14%) 1208 (86%) 1  
   50-59 years 2161 (26%) 277 (13%) 1884 (87%) 0.90 (0.73 to 1.11)  
   60-69 years 2698 (32%) 223 (  8%) 2475 (92%) 0.54 (0.44 to 0.67)  
   ≥70 years 2189 (26%)   84 (  4%) 2104 (96%) 0.24 (0.18 to 0.31)  
Time since 
diagnosis 
    
0.145 
   <1 year 3467 (41%) 317 (9%) 3150 (91%) 0.77 (0.55 to 1.09)  
   ≥1 year 4994 (59%) 472 (9%) 4522 (91%) 1  
Recent cancer 
treatment* 
    
0.608 
   No 5251 (62%) 491 (  9%) 4760 (91%) 1  
   Yes 3210 (38%) 297 (  9%) 2913 (91%) 1.10 (0.77 to 1.57)  
Therapeutic 
objective 
    
0.209 
   Palliative   553 (  7%)   60 (11%)   493 (89%) 1  
   Curative 7908 (93%) 728 (  9%) 7180 (91%) 0.80 (0.57 to 1.13)  
Resident setting     0.225 
   Urban 6603 (78%) 648 (10%) 5955 (90%) 1  
   Small town   820 (10%)   63 (  8%)   757 (92%) 0.84 (0.63 to 1.12)  




    
<.001 
   1 1458 (17%) 218 (15%) 1240 (85%) 2.89 (2.26 to 3.68)  
   2 1559 (18%) 176 (11%) 1383 (89%) 2.18 (1.70 to 2.80)  
   3 1553 (18%) 152 (10%) 1401 (90%) 1.84 (1.41 to 2.39)  
   4 1627 (19%) 116 (  7%) 1511 (93%) 1.34 (1.00 to 1.78)  


















Total 2009 (100%) 113 (6%) 1896 (94%)   
Gender     0.252 
   Male 1926 (96%) 105 ( 5%) 1821 (95%) 1  
   Female     83 (  4%)    8 (10%)     75 (90%) 1.68 (0.69 to 4.07)  
Age group     0.004 
   <50 years 164 (  8%) 15 (  9%) 149 (91%) 1  
   50-59 years 200 (10%) 18 (  9%) 182 (91%) 0.97 (0.43 to 2.22)  
   60-69 years 659 (33%) 47 (  7%) 612 (93%) 0.77 (0.38 to 1.55)  
   ≥70 years 986 (49%) 34 (  3%) 952 (97%) 0.36 (0.17 to 0.77)  
Time since 
diagnosis 
    
0.672 
   <1 year   657 (33%) 44 (  7%)   613 (93%) 1.12 (0.66 to 1.92)  
   ≥1 year 1352 (67%) 69 (  5%) 1283 (95%) 1  
Recent cancer 
treatment* 
    
0.701 
   No 1719 (86%) 92 (  5%) 1627 (95%) 1  
   Yes   290 (14%) 21 (  7%)   269 (93%) 1.14 (0.59 to 2.20)  
Therapeutic 
objective 
    
0.687 
   Palliative   812 (40%) 46 (  6%)   766 (94%) 1  
   Curative 1197 (60%) 67 (  6%) 1130 (94%) 0.90 (0.54 to 1.51)  
Resident setting     0.150 
   Urban 1505 (75%) 98 (  6%) 1407 (94%) 1  
   Small town   202 (10%)   8 (  4%)   194 (96%) 0.75 (0.31 to 1.78)  




    
<.001 
   1 352 (18%) 43 (12%) 309 (88%) 10.99 (3.89 to 31.1)  
   2 342 (17%) 30 (  9%) 312 (91%)   7.69 (2.69 to 22.0)  
   3 358 (18%) 16 (  4%) 342 (96%)   4.18 (1.37 to 12.8)  
   4 415 (21%) 18 (  4%) 397 (96%)   4.33 (1.45 to 12.9)  

















Total 3010 (100%) 329 (11%) 2681 (89%)   
Age group     <.001 
   <50 years 550 (18%) 105 (19%) 445 (81%) 1  
   50-59 years 607 (20%)   98 (16%) 509 (84%) 0.88 (0.64 to 1.21)  
   60-69 years 892 (30%)   74 (  8%) 818 (92%) 0.41 (0.29 to 0.57)  
   ≥70 years 961 (32%)   51 (  5%) 910 (95%) 0.25 (0.17 to 0.36)  
Time since 
diagnosis 
    
0.036 
   <1 year 1529 (51%) 179 (12%) 1350 (88%) 1.47 (1.03 to 2.11)  
   ≥1 year 1481 (49%) 151 (10%) 1330 (90%) 1  
Recent cancer 
treatment* 
    
0.052 
   No 1842 (61%) 204 (11%) 1638 (89%) 1  
   Yes 1168 (39%) 126 (11%) 1043 (89%) 0.70 (0.48 to 1.00)  
Therapeutic 
objective 
    
0.984 
   Palliative   653 (22%)   66 (10%)   587 (90%) 1  
   Curative 2357 (78%) 263 (11%) 2094 (89%) 1.00 (0.72 to 1.41)  
Resident setting     0.180 
   Urban 2275 (76%) 265 (12%) 2010 (88%) 1  
   Small town   330 (11%)   24 (  7%)   306 (93%) 0.64 (0.39 to 1.05)  




    
<.001 
   1 633 (21%) 115 (18%) 518 (82%) 2.63 (1.77 to 3.92)  
   2 649 (22%)   71 (11%) 578 (89%) 1.44 (0.94 to 2.20)  
   3 572 (19%)   50 (  9%) 522 (91%) 1.19 (0.76 to 1.87)  
   4 566 (19%)   52 (  9%) 514 (91%) 1.20 (0.76 to 1.90)  




Lower gastrointestinal cancer 












Total 3355 (100%) 236 ( 7%) 3119 (93%)   
Gender     0.031 
   Male 1869 (56%) 112 (6%) 1757 (94%) 1  
   Female 1486 (44%) 124 (8%) 1362 (92%) 1.38 (1.03 to 1.86)  
Age group     <.001 
   <50 years   244 (  7%) 37 (15%)   207 (85%) 1  
   50-59 years   545 (16%) 75 (14%)   470 (86%) 0.97 (0.61 to 1.53)  
   60-69 years 1098 (33%) 70 (  6%) 1028 (94%) 0.43 (0.27 to 0.68)  
   ≥70 years 1468 (44%) 54 (  4%) 1414 (96%) 0.24 (0.14 to 0.39)  
Time since 
diagnosis 
    
0.395 
   <1 year 1679 (50%) 124 ( 7%) 1555 (93%) 1.19 (0.80 to 1.76)  
   ≥1 year 1676 (50%) 112 ( 7%) 1564 (93%) 1  
Recent cancer 
treatment* 
    
0.241 
   No 2217 (66%) 158 ( 7%) 2059 (93%) 1  
   Yes 1138 (34%)   78 ( 7%) 1060 (93%) 0.78 (0.52 to 1.18)  
Therapeutic 
objective 
    
0.645 
   Palliative   768 (23%)   58 ( 7%)   710 (93%) 1  
   Curative 2587 (77%) 178 ( 7%) 2409 (93%) 0.92 (0.64 to 1.32)  
Resident setting     0.163 
   Urban 2708 (81%) 196 ( 7%) 2512 (93%) 1  
   Small town   275 (  8%)   24 ( 9%)   251 (91%) 1.45 (0.89 to 2.35)  




    
<.001 
   1 648 (19%) 82 (13%) 566 (87%) 3.21 (2.02 to 5.08)  
   2 662 (20%) 51 (  8%) 611 (92%) 1.90 (1.17 to 3.10)  
   3 605 (18%) 43 (  7%) 562 (93%) 1.82 (1.08 to 3.05)  
   4 587 (17%) 26 (  4%) 561 (96%) 1.09 (0.61 to 1.95)  
   5 853 (25%) 33 (  4%) 820 (96%) 1  
 
Notes: Missing data for the depression response, recent treatment and therapeutic objective 
were handled using multiple imputation with the reported frequencies averaged over the 
m=100 imputed datasets. *Any of chemotherapy, radiotherapy or surgery started in the 
preceding six months. **Scottish Index of Multiple Deprivation quintile score: 1=most 
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Screening medical patients for distress and
depression: does measurement in the clinic
prior to the consultation overestimate distress
measured at home?
C. H. Hansen1, J. Walker2, P. Thekkumpurath1, A. Kleiboer1, C. Beale1, A. Sawhney1, G. Murray3
and M. Sharpe2*
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Background. Medical patients are often screened for distress in the clinic using a questionnaire such as the Hospital
Anxiety and Depression Scale (HADS) while awaiting their consultation. However, might the context of the clinic
artificially inflate the distress score? To address this question we aimed to determine whether those who scored high
on the HADS in the clinic remained high scorers when reassessed later at home.
Method. We analysed data collected by a distress and depression screening service for cancer out-patients. All
patients had completed the HADS in the clinic (on computer or on paper) prior to their consultation. For a period,
patients with a high score (total of o15) also completed the HADS again at home (over the telephone) 1 week later.
We used these data to determine what proportion remained high scorers and the mean change in their scores. We
estimated the effect of ‘ regression to the mean ’ on the observed change.
Results. Of the 218 high scorers in the clinic, most [158 (72.5%), 95% confidence interval (CI) 66.6–78.4] scored high
at reassessment. The mean fall in the HADS total score was 1.74 (95% CI 1.09–2.39), much of which could be
attributed to the estimated change over time (regression to the mean) rather than the context.
Conclusions. Pre-consultation distress screening in clinic is widely used. Reassuringly, it only modestly over-
estimates distress measured later at home and consequently would result in a small proportion of unnecessary
further assessments. We conclude it is a reasonable and convenient strategy.
Received 21 April 2012 ; Revised 20 September 2012 ; Accepted 23 November 2012
Key words : Cancer, depression, distress, screening, test–retest.
Introduction
There is increasing awareness of the importance
of subjective measures including quality of life in
medical care. Such measure are often referred to
as patient-reported outcomes or ‘PROs’ (Greenhalgh,
2009). Emotional distress and depression are im-
portant PROs that have a major effect on quality of
life (Moussavi et al. 2007). Consequently, it has been
recommended that medical patients, such as those
with cancer (Carlson et al. 2012), are screened for
emotional distress and depression (Pignone et al. 2002;
NICE, 2009), but only if there are facilities to provide
treatment for identified cases (USPSTF, 2009). Despite
an extensive literature on such screening (Carlson et al.
2012), there is limited information on the practicalities
of carrying it out, an important aspect of which is when
and where to administer the screening measures.
The most convenient and widely used strategy is to
administer a questionnaire, such as the Hospital
Anxiety and Depression Scale (HADS; Zigmond &
Snaith, 1983), in the medical clinic, taking advantage
of the time patients spend waiting to go into their
consultation. The patient’s questionnaire score is then
used to determine whether they have a significant
level of distress that requires attention and whether
they need a further assessment to determine whether
they have a depressive disorder.
However, there is a potential problem with this
strategy ; measuring distress in the clinic prior to the
consultation might result in a transient inflation
* Address for correspondence : Professor M. Sharpe, Psychological
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of the score because of the clinical context and the an-
ticipation of the consultation. This phenomenon
would be similar to that referred to as the ‘white-coat
effect ’ in the measurement of blood pressure (Gerin
et al. 2006). If such inflation were to occur it would
result in false positives in the identification of patients
suffering from significant distress and would lead to
more patients than necessary being given assessment
interviews for depression. Such an effect would
therefore be important in increasing both incon-
venience to patients and the costs to clinical services.
As far as we are aware, although there are studies of
the test–retest reliability of measures of quality of life
and distress (Hjermstad et al. 1995; Bakker et al. 2009),
the course of distress over a series of cancer consulta-
tions (van Dooren et al. 2005) and of the influence
of the content of the consultation on distress (van
Dulmen et al. 1995), this particular question has not
been specifically addressed in the published literature.
We therefore aimed to find out whether oncology
patients who were high scorers on the HADS ques-
tionnaire, completed while waiting for their cancer
consultation in clinic, remained high scorers when
completing a repeat HADS questionnaire a week later
at home. Specifically, we aimed to determine : (a) what
proportion of the patients who scored high (total score
of o15) on the HADS prior to their consultation still
had a high score when reassessed at home 1 week
later ; and (b) how much the mean HADS score had
changed between these two occasions and how much
any fall could be accounted for by regression to the
mean.
Method
To address the research question we analysed data
that had been routinely collected by an established
distress and depression screening service operating in
multiple cancer out-patient clinics in Scotland, UK.
Routine screening procedure
The screening service was in operation in numerous
clinics, each specializing in one of a variety of cancer
types including breast, colorectal, gynaecological, lung
and genito-urinary. All patients attending the clinics
were asked to complete the HADS on touch-screen
computers (or, where computers were not available,
on paper) prior to their medical consultation. The
results of screening were given to their cancer clinician
at the time of the consultation. In addition, all patients
who had scored high on the HADS in clinic were
telephoned at home, approximately 1 week later, and
assessed for depression using the major depression
component of the Structured Clinical Interview for
DSM-IV (SCID; First et al. 1999).
Collection of repeat HADS scores
As part of routine clinical service data collection dur-
ing March and April 2009, patients who had scored
o15 on the HADS in the clinic were asked to complete
the HADS again at home over the telephone, im-
mediately before they were given the routine inter-
view to assess them for depression. We analysed these
clinical data to address the research question.
Ethical approval
We obtained ethical approval from the local Research
Ethics Committee to use the data in this way and also
obtained each patient’s permission to use their an-
onymized clinical data for research.
Measure
The HADS is the most extensively studied distress
scale in cancer patients and is very widely used as a
first stage in screening medical patients for depression
(Vodermaier et al. 2009). The HADS asks patients how
they have been feeling over the past 2 weeks. It has
14 items : seven on each of the anxiety and depression
subscales. Each item is rated from 0 to 3, resulting in a
total HADS score between 0 and 42, with higher scores
indicating more severe symptoms (Zigmond & Snaith,
1983) A recent review concluded that the HADS was
an effective measure of emotional distress but that
the subscales were unable to differentiate consistently
between anxiety and depression (Cosco et al. 2012).
A total HADS score of o15 has been reported to be
optimal to identify cancer patients likely to have major
depression on further assessment (Walker et al. 2007).
Analysis
We analysed these data to determine whether patients
with high HADS scores measured in the clinic prior to
their consultation still had high scores when measured
later at home. We therefore calculated the proportion
of patients who still had a high score (o15) when the
HADS was repeated at home. We also determined the
mean change in the total HADS score between clinic
and home.
Individual patient distress scores vary over time.
Patients scoring high or low are likely to score closer
to the mean score of all assessed patients on later re-
assessment, a phenomenon known as ‘regression to
the mean’. If all patients who completed a first HADS
also completed a second HADS, we would expect the
effect of these variations on the mean score of the
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whole group to even out. However, as we only had
follow-up data the subsample of initial high scorers
we would expect the average of the reassessed scores
in this subsample to be lower because of this ‘ re-
gression to the mean’ effect (Barnett et al. 2005).
Therefore, to isolate the effect of the clinic from this
phenomenon we estimated the size of the anticipated
regression to the mean. This involved using more than
5000 HADS scores that had been collected by the
screening service in similar clinics from 2007 to 2010 to
obtain details of the overall distribution of HADS
scores in this population. These details included the
variance and covariance of repeated scores. The tech-
nical details of this approach are provided in the
Appendix and described elsewhere (Das & Mulder,
1983). Finally, we conducted an exploratory analysis
describing and comparing the changes in the HADS
anxiety and depression subscales to determine
whether these differed in the amount they changed.
Results
The service had offered screening to all patients at-
tending the cancer clinics except for a small number
(<5%) who were unable to complete questionnaires
because they were too unwell or had severe cognitive
or communication problems. A further 10% of
patients were missed by the service, mainly because
they were taken straight to their consultation before
being screened, and an additional 7% refused to par-
ticipate in screening.
A total of 1691 patients were screened in clinic
during the period from which the data analysed were
derived. Of these, 395 scored high on the HADS in
clinic and 329 were listed for further assessment at
home (the remainder were not listed for a variety of
reasons including a recent depression assessment,
cognitive or communication problems or exclusion by
their clinician, usually because they were considered
to be too ill). Repeat HADS were not available on 111
of these patients for several reasons, but mainly
because they were not contacted by the screening
service within the 1-month time window used for the
analysis. The final patient sample is shown in Fig. 1.
A total of 218 patients were given a repeat HADS
at home by the screening service during the data
collection period. This is the sample analysed.
In the analysed sample, 159 (73%) patients were
female and the median age was 61 years [interquartile
range (IQR) 53–70 years]. Almost all of the patients
were attending follow-up appointments. The median
interval between the clinic and repeat HADS assess-
ments was 6 days (IQR 5–8 days). The 111 patients
who did not have a repeat HADS at home had similar
C ognitive impairment (n = 4)
Exclusion by clinician (n = 8)
Hearing or language difficulties (n = 13)
R ecent interview for depression (n = 41)
Patients reassessed for 
distress and included for 
analysis
(n = 218)
Patients identified with 
distress (HADS ≥ 15) during 
data collection period
(n = 395)
In-patient (n = 1)
Deceased (n = 1)
Refused interview (n = 21)
Could not be contacted within (n = 87)
data collection period
Unknown (n = 1)
Patients eligible for analysis
(n = 329)
Fig. 1. Derivation of patient sample. The patients initially identified with distress (HADS o15) were screened during
the period from 25 February 2009 to 31 March 2009.
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distributions of sex, age and clinic HADS scores and
attended similar types of cancer clinics. However,
there were more new and good prognosis patients
included in the sample reassessed. The patients’
characteristics and the comparison of those with
and without a HADS rated at home are shown in
Table 1.
Figure 2 shows the distributions of HADS scores
when patients were (a) assessed in clinic and (b) re-
assessed at home. Fig. 3 shows the change in HADS
scores for each individual patient. As a result of the
large variance in the HADS scores, there was also
considerable variability in the change scores between
the two assessments despite a high intra-class corre-
lation between repeated measurements (ICC=0.83).
Almost three-quarters (72.5%; 158/218) of the in-
itial high-scoring patients were still high scorers at
reassessment [95% confidence interval (CI) 66.6–78.4].
The mean change in total HADS score was a reduction
of 1.74 points (95% CI 1.09–2.39).








Mean (S.D.) 61.4 (11.5) 61.3 (12.2)
Median (range) 61.4 (25.3–87.7) 62.5 (28.7 to 89.8)
Age categories, n (%) 0.736
f50 years 38 (17) 23 (21)
51–60 years 67 (31) 28 (25)
61–70 years 66 (30) 35 (32)
o71 years 47 (22) 25 (23)
Gender, n (%) 0.396
Male 59 (27) 35 (32)
Female 159 (73) 76 (68)
Cancer clinic type, n (%) 0.383
Breast 83 (38) 39 (35)
Gynaecology 33 (15) 15 (14)
Lung 47 (22) 24 (22)
Colorectal 18 (8) 8 (7)
Urology 14 (6) 12 (11)
Gastrointestinal 15 (7) 4 (4)
Other 8 (4) 9 (8)
Appointment typeb, n (%) 0.025
First appointment 30 (14) 6 (6)
Return appointment 183 (86) 100 (94)
Poor prognosisc, n (%) <0.001
Yes 19 (9) 25 (23)
No 195 (91) 84 (77)
HADS scores 0.356
Mean (S.D.) 20.1 (4.7) 20.6 (4.8)
Median (range) 19 (15–37) 19 (15–34)
HADS score categories, n (%) 0.604
15–19 115 (53) 59 (53)
20–24 66 (30) 29 (26)
o 25 37 (17) 23 (21)
HADS, Hospital Anxiety and Depression Scale ; S.D., standard deviation.
a Age in years and HADS scores were compared using the Wilcoxon rank sum test. All other p values were from x2 tests.
b Appointment type was unknown for 10 patients.
c Poor prognosis was defined for lung (non-lung) cancer patients as a life expectancy of <3 (12) months. Prognosis was
unknown for six patients.
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Our estimate of the regression-to-mean effect was
an average reduction of 1.21 points (95% CI 1.02–1.43).
Hence regression to the mean potentially accounts
for the majority of this observed fall in mean score,
meaning that the effect of measuring in clinic was very
small. The exploratory analysis of changes in HADS
subscales found a mean reduction in the anxiety
subscale of 1.26 points (95% CI 0.84–1.67) and in the
depression subscale of 0.48 points (95% CI 0.12–0.85).
The difference between the scales in the reduction in
scores was statistically significant (p<0.001).
Discussion
We had hypothesized that patients’ HADS scores
might be transiently inflated when measured in the
clinic prior to the consultation because of the poten-
tially stressful clinical surroundings and anticipation
of the upcoming appointment. If that were the case it
would question the utility of this widely used strategy
for screening for distress and depression in medical
clinics. We found that the majority of the patients who
scored high on the HADS in clinic prior to their cancer
consultation (72.5%) were still high scorers when re-
assessed at home a week later. That also means that
27.5% of patients who had scored high in the clinic
were no longer high scorers when reassessed later at
home. However, further analysis indicates that despite
large variability at the individual patient level, the
mean HADS total score in the sample fell by only 1.74
points between the two assessments, most of which
could reasonably be attributed to the natural tendency
for individuals who score high on an initial measure-
ment to score lower on later reassessment (regression
to the mean), independent of the setting in which the
measurement was made. Our hypothesis was there-
fore not supported and measuring distress in the clinic
prior to the consultation is a reasonable strategy to
adopt.
There was considerable individual variability in the
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(b)
Fig. 2. Hospital Anxiety and Depression Scale (HADS) scores of patients (n=218) in the study sample (a) when assessed
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Fig. 3. Change in Hospital Anxiety and Depression Scale
(HADS) total score from clinic to follow-up at home plotted
against initial HADS score in clinic. Circles indicate patients
whose reassessment score fell below 15. Patients plotted
above the dashed line had a higher HADS score on
reassessment whereas those below the line had a lower score.
A degree of ‘ jitter ’ was applied to separate out overlapping
data points.
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despite a high intra-class correlation between repeated
measurements from the same patient. This was due
to large overall variance in the scores, a property
common to measures of psychological distress. It is
unclear whether this variation is due to a large
random error in the measurements or a reflection
of actual fluctuations in the severity of distress over
time. Nonetheless, our sample of 218 patients was
sufficiently large to estimate the mean change for the
sample with reasonable accuracy.
It is notable that, whereas the screening service used
the total score in the HADS to define significant dis-
tress, the fall in score was slightly larger on the anxiety
subscale. This may be because the consultation has a
greater transient effect on anxiety than on depression.
It may also imply that scales that measure only de-
pressive symptoms are even less subject to a clinic
effect.
We are not aware of any studies that have directly
addressed the question we have posed. We identified
a test–retest reliability study of the European
Organization for Research and Treatment of Cancer
(EORTC) quality of life measures, which include
emotional functioning, that compared questionnaire
scores administered to 270 patients attending routine
post-treatment follow-up visits to cancer clinics with
their score at home 4 days later and found generally
good agreement (Hjermstad et al. 1995). Other studies
that have administered repeated psychological as-
sessment have examined distress trajectories over
longer periods of time (Hinnen et al. 2008) or before
and after consultations (van Dooren et al. 2005) but we
found none that directly addressed the possible effect
of the clinical context on the measurement score.
There were limitations to this study. First, we ana-
lysed data collected by a routine screening service
operating in cancer clinics ; the findings may not
therefore generalize to other clinical settings. Second,
the service administered a second HADS only to
patients who had scored high in clinic. This meant
that our observed HADS scores obtained at home
underestimated the true proportion of patients who
would have scored high had all patients been re-
assessed, as it would be likely that some of the patients
who scored low in clinic would have scored high on
the second occasion. This limitation was addressed
by estimating the regression to the mean. Third, there
were missing data from patients who could not be
contacted during the limited time window in which
repeat HADS were administered. However, the
characteristics of patients on whom we had analy-
sable data and those on whomwe did not were mostly
similar ; systematic bias is therefore unlikely. Fourth,
there may be limits to the intrinsic test–retest re-
liability of the HADS (as opposed to real changes in
symptoms) but this is unlikely to be large over this
time period, or to represent a systematic bias. Fifth,
patients completed the HADS on a touch-screen com-
puter or on paper in the clinic, but the follow-up
assessment was carried out by reading out the scale
over the telephone. It is possible that administering
the HADS over the telephone causes patients to score
differently. Previous studies have found good agree-
ment between self-completed and verbally completed
distress screening questionnaires, with a tendency for
the latter to record a lower score (Pinto-Meza et al.
2005; Cheung et al. 2006). Such a bias, if present, would
reduce further the observed fall in HADS score at-
tributable to the effect of measurement in the clinic.
Future studies could use the same mode of adminis-
tration to avoid this issue. Sixth, the content of the
consultation and its meaning for the patient, whether
positive or negative, might have accounted for some
of the changes in scores and we were not able to assess
this. However, most of the consultations were for
follow-up and not for the communication of new
diagnoses. The effect of consultation type could be
addressed in future studies. Seventh, because the
results of the screening were given to the clinician be-
fore the consultation, it is possible that they might
have taken action to address the distress, for example
by referring the patient for psychological treatment.
This is, however, very unlikely to have occurred
within 1 week. Finally, although the average change
in scores was small, the intra-patient variability was
high, with some patients scoring very differently on
reassessment. It is possible, therefore, that a minority
of patients are affected considerably by the clinic set-
ting. Consequently, we cannot rule out the possibility
of an important ‘clinic effect ’ for some individuals.
Conclusions
In conclusion, most patients who scored high on the
HADS administered in clinic prior to their medical
consultation remained high scorers when reassessed
at home a week later. There was only a small reduction
in mean score, most of which could be attributed to
regression to the mean. Therefore, the widely used
strategy of asking patients to complete a screening
questionnaire for distress while they wait for their
clinic appointment is a reasonable method of identi-
fying those who have significant distress and also a
useful first step in identifying those who require an
interview for the assessment of possible depressive
disorder. The increasing use of telephones and the in-
ternet provides opportunities to screen patients away
from the clinic, thereby potentially avoiding the
issue of clinic context. However, the pre-consultation
waiting time has long provided an opportunity to
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undertake such clinic-based screening, and is likely
to continue to do so in the future.
Appendix
Estimating the regression-to-the-mean effect
As only patients with an initial high score were
followed up, the scores on reassessment were subject
to regression to the mean. We estimated the average
drop in scores caused by this effect as follows.
Suppose that a patient’s HADS score, H, is the sum
of their (constant) true underlying score, S, and an
independent error term, e, where S is distributed
according to some arbitrary density function with
variance ss
2 and the errors are normally distributed
with mean 0 and variance se
2. The total variance is
then Var(H)=st2=ss2+se2 and r=ss2/st2 is the intra-
patient correlation between repeated scores from the
same individual.
We wanted to estimate the expected difference
between a pair of repeated HADS scores, H1 and H2,
conditional on H1 being o15. That is, we wanted to
estimate E[H1 – H2jH1 o15].
For a continuous H it can be shown that




where g(hc) is the probability density function for
H evaluated at hc, and G(hc) is the corresponding
cumulative distribution function (Das & Mulder,
1983). From the large sample of scores collected by the
screening service in similar clinics from 2007 to 2010,
we obtained empirical estimates of g(hc) and G(hc).
Using data from the 5215 patients who had HADS
scores measured in subsequent clinic visits during
this period, we estimated st
2 and r as the correlation of
scores obtained 1 week apart. We did this by model-
ling the covariance matrix of repeated scores in a lin-
ear regression with random intercept and exponential
covariance structure to account for a decreasing cor-
relation over time. A 95% quantile-based CI for the
regression-to-mean estimate was derived through
bootstrapping.
Although technically a discrete scale, we applied
the HADS (range 0–42) with the above result, in-
troducing a continuity correction by evaluating g(.)
and G(.) at hc=14.5 by approximating a theoretical
continuous curve. The approach was verified through
simulation studies and sensitivity analysis.
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